

UNIVERSITY OF OKLAHOMA
COLLEGE OF MEDICINE

CURRICULUM VITAE

Doris Mangiaracina Benbrook, BA, PhD

Professor, Department of Obstetrics & Gynecology
Section of Gynecologic Oncology
Presbyterian Health Foundation Presidential Professor
Biomedical Research Center 1217A
975 NE 10th St.
Oklahoma City, OK 73104
Phone: (405) 271-5523
Email: doris-benbrook@ouhsc.edu

Appointment Type: Tenured

EDUCATION AND TRAINING

Postgraduate Education and Training

- 1988 - 1991 Research Fellow, Integration of CREB and AP1 Transcription Factors in Cancer, Imperial Cancer Research Fund (Cancer Research UK), London, UK
Mentor: Nicholas C Jones, PhD
- 1985 - 1988 Postdoctoral Fellow, Nuclear Receptor Transcription Factors in Cancer, La Jolla Cancer Research Institute (Burnham Institute), La Jolla, CA, USA
Mentor: Magnus Pfahl, PhD.

Education

- 1981 - 1985 Doctor of Philosophy, Biochemistry
Loyola University Medical Center, Maywood, IL, USA
"Effects of Norfloxacin on Pseudomonas aeruginosa and its DNA Gyrase"
Advisor: Robert V. Miller, PhD
- 1977 - 1981 Bachelor of Arts, Biology and Chemistry Majors, German Minor
North Central College, Naperville, IL, USA

PROFESSIONAL EXPERIENCE

Academic

- 2018 - Present Adjunct Professor, Pathology, Medicine, University of Oklahoma Health Sciences Center, Oklahoma City
- 2013 - Present Adjunct Professor, Pharmaceutical Sciences, Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, OK
- 2011 - Present Adjunct Professor, Genetic Counseling, College of Medicine, University of Oklahoma, Oklahoma City, OK
- 2010 - Present Adjunct Professor, Clinical and Translational Sciences, Graduate College, University of Oklahoma Health Sciences Center, Oklahoma City, OK

- 2004 - Present Tenured Full Professor, Gynecologic Oncology, Obstetrics and Gynecology, College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK
- 1993 - Present Graduate Faculty, OUHSC Graduate College, University of Oklahoma Health Sciences Center, Oklahoma City, OK
- 2005 - 2013 Adjunct Professor, Biochemistry and Molecular Biology, College of Medicine, University of Oklahoma, Oklahoma City
- 1997 - 2005 Adjunct Associate Professor, Biochemistry and Molecular Biology, College of Medicine, University of Oklahoma, Oklahoma City, OK
- 1997 - 2004 Associate Professor, Gynecologic Oncology, Obstetrics and Gynecology, College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK
- 1993 - 1997 Adjunct Assistant Professor, Biochemistry and Molecular Biology, College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK
- 1991 - 1996 Assistant Professor, Gynecologic Oncology, Obstetrics and Gynecology, College of Medicine, University of Oklahoma, Oklahoma City, OK

Administrative

- 2019 - Present Gynecologic Cancers Group, Stephenson Cancer Center, University of Oklahoma
- 1993 - Present Director of Research, Gynecologic Oncology, Obstetrics and Gynecology, College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, USA
- 2016 - 2019 Co-Leader Gynecologic Cancers Program, Stephenson Cancer Center, University of Oklahoma
- 2014 - 2019 Co-Principal Investigator Center for Cancer Prevention and Drug Development, Center for Chemoprevention and Drug Development, Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City
- 2011 - 2014 Co-Director, Women's Cancer Program, Stephenson Cancer Center
- 2007 - 2009 Director, Women's Cancer Program, University of Oklahoma Cancer Institute
- 2006 - 2009 Co-Chair, Scientific Advisory Committee, Stephenson Cancer Center
- 2002 - 2009 Co-Director, Gynecologic Cancer Program, Stephenson Cancer Center
- 1996 - 2003 Research Tuberculosis Coordinator, Obstetrics and Gynecology, University of Oklahoma
- 1995 - 2003 Environmental Health & Safety Coordinator, Obstetrics and Gynecology, University of Oklahoma
- 1994 - 2003 Administration Liaison, Obstetrics and Gynecology, University of Oklahoma
- 2002 Faculty Affair Liaison, University of Oklahoma

HONORS AND AWARDS

National/International

Second Place for best business plan, W. Reynolds Tri-State Collegiate Business Plan competition, 2009

Local/Regional

Health Care Hero, The Journal Record, 2023 - Present

Woman of the Year - 50 Making a Difference, the Journal Record, 2016

First Place for best business plan, Oklahoma Governors Cup Competition, 2009

Innovator of the Year on the Brink Award, the Journal Record, 2005

Oklahoma Scientist of the Year, the Oklahoma Academy of Science, 2004

Woman of the Year - 50 Making a Difference, the Journal Record, 2004

Institutional

Educators for Excellence, Member, University of Oklahoma, May 3, 2022 - Present

Presbyterian Health Foundation Presidential Professorship, Presbyterian Health Foundation Presidential Professor, Presbyterian Health Foundation, 2019 - Present

Master Mentor, Oklahoma Shared Clinical and Translational Resources, 2018 - Present

North Central College Sequicentennial Medal, North Central College, 2011

Innovator of the Year, the Journal Record, 2010

Endowed Chair in Gynecologic Oncology, University of Oklahoma Health Sciences Center, 2009

SCHOLARSHIP

Contracts, Grants, and Other Research

* indicates mentee

Current

Grants

Mutch, D. (Principal Investigator), **Benbrook, D. M.** (Co-Principal Investigator), 20% Effort, Leslie, K. K. (Co-Principal Investigator), "Route 66 Endometrial Cancer SPORE," Sponsored by National Cancer Institute, Federal

Grant/Contract Number: P50 CA265793

Total Direct Costs: \$1,851,611.00

August 8, 2023 - July 31, 2028

Benbrook, D. M. (Master Mentor), 10% Effort, James, J. (Principal Investigator), "Oklahoma Shared Clinical and Translational Resources," Sponsored by NIGMS, Federal

Grant/Contract Number: U54GM104938
September 2013 - June 2028

Benbrook, D. M. (Principal Investigator), 12% Effort, Burgett, A. (Co-Principal Investigator), "Taking Ovarian Cancer Maintenance Therapy to the Next Level," Sponsored by DOD CDMRP, Federal

Grant/Contract Number: OC220161
Total Direct Costs: \$533,046.00
April 1, 2023 - March 31, 2027

Csiszar, A. (Principal Investigator), **Benbrook, D. M.**, 1.5% Effort, Hannafon, B. N. (Co-Investigator), "Chemotherapy-induced vascular cognitive impairment: role of endothelial senescence," Sponsored by NIH National Cancer Institute, Federal

Grant/Contract Number: R01 CA255840
January 1, 2021 - December 31, 2026

Csiszar, A. (Principal Investigator), **Benbrook, D. M.**, 1.5% Effort, Hannafon, B. N. (Co-Investigator), "Age-related vascular cognitive impairment: Role of endothelial senescence," Sponsored by NIH National Institute on Aging, Federal

Grant/Contract Number: R01AG068295
August 1, 2020 - July 31, 2025

Benbrook, D. M. (Co-Lead Gyn Prevention Group), "The MW Cancer Prevention Clinical Trials Network," Sponsored by National Cancer Institute PREVENT Clinical Trial Network, Federal

Grant/Contract Number: UG1CA242635-01A1
April 1, 2020 - March 31, 2025

Benbrook, D. M. (Co-Investigator), Sorokin, A. (Principal Investigator), "Role of p66Shc in Regulation of Microvascular Reactivity of Renal Blood Vessels," Research, Sponsored by NHLBI, Federal

Grant/Contract Number: R01HL147976
July 1, 2019 - June 30, 2024

Stoner, J. (Co-Principal Investigator), Houchen, C. (Co-Principal Investigator), **Benbrook, D. M.** (Course Director), "Addressing Health Disparities among Oklahoma Minority and Rural Communities through Clinical Research Education and Career Development"

Grant/Contract Number: NIH/NIMHD 1R25MD011564-01

Additional Information: The overall goal is to enhance clinical research methods expertise and research careers among underrepresented researchers focused on health disparities and minority health.

September 9, 2017 - May 31, 2022

Professional Service Agreements

Rao, C. (Principal Investigator), 5% Effort, **Benbrook, D. M.** (Co-Principal Investigator), 5% Effort, "PREVENT Preclinical Drug Development Program," PREVENT Cancer Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Endpoint Biomarkers, Sponsored by NIH National Cancer Institute, Federal

Grant/Contract Number: N01CN77019-18/75N91019D00020

Additional Information: This is a Prime Contract, indefinite delivery/indefinite quantity (IDIQ) agreement which allows us to compete for government contracts called "Task Orders" to conduct preclinical cancer research.

January 25, 2019 - January 24, 2024

Completed

Clinical Trial Agreements

Benbrook, D. M. (Study Co-Chair), Gold, M. A. (Study Chair), Cummings, R. (Study Co-Chair), Rodgers, W. (Study Co-Chair), "Comparison of Glycoprotein Expression and T-Synthase Function in Primary versus Metastatic Tumors," Sponsored by Gynecologic Oncology Group, Foundation Grant/Contract Number: COG - 0221
April 13, 2007 - August 24, 2017

Benbrook, D. M. (Collaborator), Powell, M. (Study Chair), "A Phase II evaluation of Brivanib (BMS582664), an oral, multitargeted growth factor tyrosine kinase inhibitor in the treatment of recurrent or persistent endometrial carcinoma," Sponsored by Gynecologic Oncology Group (GOG) Protocol #02291, Foundation Grant/Contract Number: GOG-02291
July 6, 2009 - July 16, 2016

Benbrook, D. M. (Translational Research Chair), McMeekin, S. (Study Chair), "A Phase II evaluation of thalidomide in the treatment of recurrent or persistent carcinosarcoma of the uterus," Sponsored by Gynecologic Oncology Group, Foundation Grant/Contract Number: NCT00025506
January 27, 2003 - May 27, 2015

Benbrook, D. M. (Scientific Collaborator), Usha, L. (Study Chair), "A Phase II Evaluation of Enzastaurin in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma," Sponsored by Gynecologic Oncology Group, Foundation Grant/Contract Number: NCT00420381
January 11, 2007 - March 30, 2015

Benbrook, D. M. (Collaborator), Copeland, L. (Study Chair), "A randomized Phase III trial of maintenance chemotherapy comparing 12 monthly cycles of single agent paclitaxel or CT-2103 (IND#70177) versus no treatment until documented relapse in women with advanced ovarian, primary peritoneal or fallopian tube cancer who achieve a complete clinical response to primary platinum/taxane chemotherapy," Sponsored by Gynecologic Oncology Group (GOG) Protocol #0212, Foundation Grant/Contract Number: NCT00108745
April 19, 2005 - January 13, 2014

Benbrook, D. M. (Translational Research Chair), Hurteau, J. A. (Study Chair), "A randomized study of tamoxifen versus thalidomide in patients with biochemical-recurrence-only epithelial ovarian cancer, cancer of the fallopian tube, and primary peritoneal cancer after first line chemotherapy," Sponsored by Gynecologic Oncology Group, Foundation Grant/Contract Number: NCT00041080
January 27, 2003 - September 16, 2013

Benbrook, D. M. (Translational Research Chair), Rader, J. (Study Chair), "A randomized Double-Blind Phase II Trial of Celecoxib, a Cox 2 Inhibitor, in the Treatment of Patients with Cervical Intraepithelial Neoplasia 3 (CIN3)," Sponsored by Gynecologic Oncology Group (GOG) Protocol #0207, Foundation Grant/Contract Number: NCT00041080
June 2005 - September 2012

Benbrook, D. M. (Collaborating Scientist), Method, M. (Study Chair), "A Randomized, Controlled Phase II Evaluation of Megestrol in Different Dose and Sequence in the Treatment of Endometrial Intraepithelial Neoplasia (EIN) From a Referred Cohort of Atypical Endometrial Hyperplasia (AEH) or EIN," Sponsored by Gynecologic Oncology Group, Protocol #0224, Foundation

Grant/Contract Number: NCT00503581
July 2007 - July 2012

Benbrook, D. M. (Translational Research Chair), McMeekin, S. (Study Chair), "A Phase II evaluation of thalidomide in the treatment of recurrent or persistent leiomyosarcoma of the uterus," Sponsored by Gynecologic Oncology Group, Foundation
Grant/Contract Number: GOG Protocol 231-B
2007

Benbrook, D. M. (Research Scientist), McMeekin, S. (Principal Investigator), "Phase II Trial of Gleevec (Imatinib Mesylate formerly known as STI571) in Patients with CD1q17(+) Gynecologic Malignancies," Sponsored by Novartis Pharmaceutical through PRA International, Private
Total Direct Costs: \$65,882.00
November 1, 2002 - October 31, 2004

Benbrook, D. M. (Scientific Collaborator), Markman, M. (Study Chair), "A Randomized Phase III trial of maintenance chemotherapy comparing 12 monthly cycles of single agent paclitaxel or Xyotax (CT-2103) (IND#70177) versus no treatment until documented relapse in women with advanced ovarian or primary peritoneal cancer who achieve a complete clinical response to primary platinum/Taxane chemotherapy," Sponsored by Gynecologic Oncology Group, Foundation
2001 - 2003

Benbrook, D. M. (Translational Research Chair), McMeekin, S. (Study Chair), "A Phase II evaluation of thalidomide in the treatment of recurrent or persistent endometrial carcinoma," Sponsored by Gynecologic Oncology Group, Foundation
August 2001 - July 2002

Grants

Benbrook, D. M. (Principal Investigator), "Project 1. Targeting HSPA Proteins in Advanced and Recurrent Endometrial Cancer Therapy within "Washington University/University of Oklahoma/University of Iowa SPORE: Midwest Endometrial Cancer Consortium"," Bridge Grant, Sponsored by Presbyterian Health Foundation, Foundation
Current Funding (Total Cost per Year): \$75,000.00
Total Direct Costs: \$75,000.00
July 1, 2022 - June 30, 2023

Benbrook, D. M. (Principal Investigator), "Increasing sensitivity and feasibility of measuring proteins in small samples," Equipment Grant, Sponsored by Presbyterian Health Foundation, Foundation
Current Funding (Total Cost per Year): \$34,012.00
Total Direct Costs: \$34,012.00
July 1, 2022 - June 1, 2023

Benbrook, D. M. (Co-Investigator), 5% Effort, Mannel, R. S. (Principal Investigator), "Stephenson Cancer Center – Cancer Center Support Grant," National Cancer Institute Designated Cancer Center, Sponsored by National Cancer Institute, Federal
Grant/Contract Number: P30CA225520
May 1, 2018 - April 30, 2023

Benbrook, D. M. (Principal Investigator), 2.5% Effort, "Identification of Targetable Factors for Prevention of Thrombosis in Ovarian Clear Cell Carcinoma Patients," Sponsored by University of Arizona Lauder Alberts Gift Fund, Non-Profit
April 1, 2020 - March 31, 2023

Benbrook, D. M. (Principal Investigator), 30% Effort, Rao, C. (Co-Principal Investigator), Zuna, R. (Co-Investigator), Garcia-Contreras, L. (Co-Principal Investigator), Woo, S. (Co-Principal Investigator), Zhao, D. (Co-Investigator), Frumovitz, M. (Co-Principal Investigator), Coleman, R. (Co-Principal Investigator), "Targeting HPV Consequences in a Cervical Cancer Clinical Trial," Peer-reviewed, federally-funded research grant, Sponsored by NIH/NCI, Federal
Grant/Contract Number: R01 CA200126/C3111201
Total Direct Costs: \$1,426,722.00
June 1, 2016 - May 31, 2022

Csiszar, A. (Principal Investigator), **Benbrook, D. M.** (Co-Investigator), 1% Effort, "Chemotherapy-induced vascular cognitive impairment," Sponsored by American Heart Association, Non-Profit
Grant/Contract Number: 20PRE35211043
January 1, 2020 - December 31, 2021

Benbrook, D. M. (Principal Investigator), "cGMP NSC 721689 Production for IRB-approved and NCI-funded Clinical Trials," Sponsored by NCI PREVENT, Federal
Grant/Contract Number: 721689
February 10, 2015 - 2021

Benbrook, D. M. (Co-Investigator), 1% Effort, Miles, P. (Co-Investigator), Wu, D. (Co-Investigator), "Iron Status at Perimenopause: Effects on Brain and Behavior," Sponsored by NIH, Federal
Grant/Contract Number: R21 ES027909
Total Direct Costs: \$275,000.00
September 1, 2018 - July 31, 2021

Benbrook, D. M. (Principal Investigator), Chandra, V. (Co-Principal Investigator), Rai, R. (Co-Principal Investigator), "Chemoprevention of Endometrial Hyperplasia and Its Transition to Endometrial Cancer with NSC 721689," Sponsored by NCI PREVENT Program, Federal
June 2017 - July 2021

Garcia-Contreras, L. (Principal Investigator), **Benbrook, D. M.** (Co-Investigator), 1% Effort, "OHet72: A Potential New drug in the Armamentarium Against TB and MDR-TB Role: Co-I," Sponsored by NIH GM, Federal
Grant/Contract Number: P20 GM1036487
September 18, 2019 - June 30, 2021

Jackson, C. (Principal Investigator), **Benbrook, D. M.** (Co-Investigator), 1% Effort, "Mebendazole Therapy for Ovarian Cancer," Sponsored by Presbyterian Health Foundation, Foundation
July 1, 2018 - June 30, 2021

Benbrook, D. M. (Principal Investigator), 40% Effort, Rao, C. (Co-Investigator), Janakiram, N. (Co-Investigator), Garcia-Contreras, L. (Co-Investigator), Woo, S. (Co-Investigator), Zuna, R. (Co-Investigator), Crouse, E. (Co-Investigator), "Ovarian Cancer Chemoprevention," Peer-reviewed Nationally-funded Research Grant, Sponsored by National Cancer Institute, Federal
Grant/Contract Number: R01 CA196200/C31042101
Total Direct Costs: \$1,671,157.00
July 1, 2015 - June 30, 2021

Hays, F. A. (Principal Investigator), **Benbrook, D. M.** (Co-Investigator), "Deciphering ShcA-mediated ROS Production as a Novel Intervention Strategy in Diabetes Therapy," Sponsored by NIH/GMI, Federal

Grant/Contract Number: R01 GM118599

Additional Information: The goal is to decipher the mechanism of how Shc proteins regulate reactive oxygenation species in cells and apply the results toward developing novel therapies for treatment of diabetes

July 1, 2016 - June 30, 2020

Benbrook, D. M. (Co-Investigator), 3% Effort, Woo, S. (Principal Investigator), "Overcoming resistance to anti-VEGF therapy with predictive modeling," Peer-reviewed, federally-funded research grant, Sponsored by American Cancer Society, Federal

Grant/Contract Number: C5092601

July 1, 2016 - June 30, 2020

Benbrook, D. M. (Co-Investigator), 3% Effort, You, Y. (Principal Investigator), "NIR-activatable Prodrugs for treating peritoneally metastasized ovarian cancers," Peer-reviewed, federally-funded research grant, Sponsored by National Cancer Institute, Federal

Grant/Contract Number: 1R01GM113940/C3101802

March 1, 2015 - April 28, 2020

Benbrook, D. M. (Principal Investigator), "Ovarian Cancer Chemoprevention," Sponsored by NCI PREVENT Program, Federal

2015 - 2019

Garcia-Contreras, L. (Principal Investigator), **Benbrook, D. M.** (Co-Investigator), 2% Effort, "OHet72: A Potential New Drug in the Armamentarium against TB and MDR-TB," Sponsored by Oklahoma Center for Respiratory & Infectious Diseases, Other Academic Institution

Current Funding (Total Cost per Year): \$35,000.00

October 26, 2018 - June 30, 2019

Mannel, R. S. (Principal Investigator), **Benbrook, D. M.** (Co-Investigator), "Oklahoma Tobacco Settlement Endowment Trust (TSET)," Sponsored by State of Oklahoma, State

Current Funding (Total Cost per Year): \$5,500,000.00

Additional Information: The purpose of this project is to establish the TSET Cancer Research Program to advance translational, clinical and population-based cancer research and serve to enhance efforts to prevent and combat cancer.

July 1, 2013 - 2018

Wenger, M. (Principal Investigator), **Benbrook, D. M.** (Co-Investigator), "Memory Consolidation and Cerebral Oxygenation in Elders with Mild Cognitive Impairment," Sponsored by Norman Faculty Investment Program, Norman Research Council, The University of Oklahoma (Institutional)

Total Direct Costs: \$15,000.00

2014 - 2017

Garcia-Contreras (Principal Investigator), **Benbrook, D. M.** (Co-Investigator), "Inhalable Microparticle SHetA2 Nanocrystals for Lung Cancer Treatment," Sponsored by Presbyterian Health Foundation, Foundation

Total Direct Costs: \$100,000.00

July 1, 2016 - August 30, 2017

Benbrook, D. M. (Co-Principal Investigator), Garcia-Contreras (Co-Principal Investigator), "Development of SHetA2 vaginal suppositories for treatment of cervical dysplasia," Sponsored by MD Anderson Moonshot Program, Non-Profit

Total Direct Costs: \$30,000.00

May 15, 2015 - August 1, 2017

Summers (Principal Investigator)*, **Benbrook, D. M.** (co-Mentor), "Retinoic Acid Synthesis in Visually Guided Eye Growth," Sponsored by NIH/EY, Federal
Grant/Contract Number: 1 F31 eY 025168-01A1
July 1, 2015 - June 30, 2017

Benbrook, D. M. (Principal Investigator), "Optimizing targeting strategy for delivering NIR-activatable prodrugs to peritoneally metastasized ovarian cancers," Sponsored by Presbyterian Health Foundation/OUHSC Bridge Grant, Foundation
Total Direct Costs: \$75,000.00
March 1, 2015 - January 31, 2016

Garcia-Contreras (Principal Investigator), **Benbrook, D. M.** (Co-Investigator), "Inhaled SHetA2 dry powder aerosols as novel treatment for tuberculosis," Sponsored by Presbyterian Health Foundation/OUHSC Seed Grant, Foundation
Total Direct Costs: \$45,000.00
October 1, 2014 - September 30, 2015

Benbrook, D. M. (Principal Investigator), "Sensitization of Ovarian Cancer to DR5 Agonists," Sponsored by Presbyterian Health Foundation/OUHSC Bridge Grant, Foundation
Total Direct Costs: \$75,000.00
October 1, 2014 - September 30, 2015

Guaderes (Principal Investigator), **Benbrook, D. M.** (Co-Investigator), "Correlates of Quality of Life, Biomarkers, and Physical Activity in Older Women with Ovarian Cancer who Experience Chemotherapy-Induced Peripheral Neuropathy Pain (CIPN)," Sponsored by Reynold Center of Geriatric Nursing Excellence Interdisciplinary Seed Grants, Foundation
Total Direct Costs: \$30,000.00
September 1, 2014 - August 31, 2015

Craft (Principal Investigator), **Benbrook, D. M.** (Co-Investigator), "Descriptive Study of Cognitive Disturbances in Older Breast Cancer Survivors," Sponsored by Reynold Center of Geriatric Nursing Excellence Interdisciplinary Seed Grants, Foundation
Total Direct Costs: \$30,000.00
September 1, 2014 - August 31, 2015

Benbrook, D. M. (Co-Principal Investigator), Ozpolant (Co-Principal Investigator), "Autophagy in Ovarian Cancer Therapeutics and Tumor Microenvironment," Sponsored by MD Anderson Cancer Center/Stephenson Cancer Center, Non-Profit
Total Direct Costs: \$45,000.00
2013 - 2014

Akins, D. (), **Benbrook, D. M.** (Mentor of Wei-Qun Ding's Faculty Award), "Oklahoma INBRE (IDeA Network of Biomedical Research Excellence)," Sponsored by NIH/NCRR, Federal
Grant/Contract Number: P20RR016478
Total Direct Costs: \$13,312,160.00
Additional Information: \$20,000 for percent effort over 4 years
2009 - 2014

Benbrook, D. M. (Principal Investigator), "A Phase II Evaluation of Enzastaurin in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma," Sponsored by Gynecologic Oncology Group (GOG), Foundation
Total Direct Costs: \$17,279.00
2007 - 2014

Benbrook, D. M. (Co-Principal Investigator), Hays, F. A. (Co-Principal Investigator), "Therapeutic Targeting of HSP70 Chaperones in Cancer Drug Discovery," Sponsored by Stephenson Cancer Center Experimental Therapeutics Program Grant
Total Direct Costs: \$25,000.00
2013

Benbrook, D. M. (Principal Investigator), "Heat Shock Proteins and Stress in Cancer Prevention," Sponsored by OUHSC Vice President of Research (VPR) Bridge Grant Program, The University of Oklahoma (Institutional)
Total Direct Costs: \$60,000.00
July 1, 2012 - June 30, 2013

Benbrook, D. M. (Principal Investigator), "Translational Research of GOG2291 Phase II trial of Brivnab for Persistent or Recurrent Endometrial Cancer," Sponsored by Gynecologic Oncology Group (GOG) NIH/NCI, Federal
Total Direct Costs: \$20,000.00
July 1, 2012 - June 30, 2013

Benbrook, D. M. (Co-Investigator), Kelly (Principal Investigator), "Probing the Interactions of SHetA2 and Hsp70 Mortalin: A new route for Flex-Het Anticancer Activity?," Sponsored by Oklahoma IDeA Network of Biomedical Research Excellence (INBRE) NIH/NCRR, Federal
Grant/Contract Number: P20RR016478
Total Direct Costs: \$50,000.00
April 1, 2012 - March 31, 2013

Benbrook, D. M. (Co-Investigator), Rundle (Principal Investigator), "Structure Activity Relationship Studies to Develop Improved Cancer Drugs," Sponsored by Oklahoma IDeA Network of Biomedical Research Excellence Collaborative Grant, Federal
Total Direct Costs: \$49,919.00
April 1, 2012 - March 31, 2013

Benbrook, D. M. (Principal Investigator), "Flex-Het Treatment for Polycystic Kidney Disease," Sponsored by University of Oklahoma Growth Fund, The University of Oklahoma (Institutional)
Total Direct Costs: \$50,000.00
2009 - 2011

Benbrook, D. M. (Principal Investigator), "Flexible Heteroarotinoids for Chemoprevention," Sponsored by Rapid Access to Preventative Intervention Development (RAPID)/NCI, Federal
2007 - 2011

Benbrook, D. M. (Principal Investigator), "Mechanism of SHetA2 in Ovarian Cancer," Sponsored by NCI/NIH (R01), Federal
Total Direct Costs: \$987,500.00
June 1, 2005 - May 31, 2010

Benbrook, D. M. (Principal Investigator), "Bringing OU Research to New Dimensions with Multiplex Technologies," Sponsored by Presbyterian Health Foundation - Equipment Grant, Federal
Total Direct Costs: \$50,000.00
September 1, 2008 - August 31, 2009

Benbrook, D. M. (Collaborator), Hanigan, M. H. (Parent Grant), Dozmorov, I. (Principal Investigator), "Search for the Potential Targets for the Prevention of Carcinogenesis," Sponsored by American Cancer Society, Non-Profit

Total Direct Costs: \$25,000.00
July 1, 2008 - June 30, 2009

Benbrook, D. M. (Co-Investigator), Moore, K. (Principal Investigator), "The Role of Ribonucleotide Reductase Regulatory Subunit 1 (RRM1) and Excision Repair Cross Complementation Group 1 (ERCC1) in Determining Chemosensitivity for Advanced Ovarian Cancer," Sponsored by Gynecologic Cancer Foundation, Foundation
Total Direct Costs: \$50,000.00
2007 - 2008

Benbrook, D. M. (Co-Director of Women's Cancer Program), Ozer, H. (Principal Investigator), "Cancer Center Planning Grant (P20)," Sponsored by NCI Program Planning Grant for NCI Cancer Research Centers, Federal
Total Direct Costs: \$925,084.00
July 1, 2002 - June 30, 2008

Benbrook, D. M. (Collaborator), Rundle, D. (Principal Investigator), "Effects of heteroarotinoids on PKC activation and apoptosis in ovarian carcinoma organotypic cultures," Sponsored by University of Central Oklahoma Basic Research Grant to Faculty, State
Total Direct Costs: \$10,000.00
June 1, 2007 - May 31, 2008

Benbrook, D. M. (Collaborator), Kelly, W. (Principal Investigator), "Investigations of SHetA2 mediated Mitochondrial changes," Sponsored by Oklahoma IDeA Network of Biomedical Research Excellence (INBRE) NIH/NCRR, Federal
Total Direct Costs: \$50,000.00
Additional Information: \$15,383 to Dr. Benbrook
May 1, 2007 - April 30, 2008

Benbrook, D. M. (Collaborator), Cummings, R. (Principal Investigator), "Gene Regulation of Glycan Antigen in Cancer Cells," Sponsored by NCI/NIH, Federal
Total Direct Costs: \$200,000.00
April 1, 2005 - March 31, 2007

Benbrook, D. M. (Principal Investigator), "Lab Analysis for GOG0207 Phase II Trial of Celecoxib for CINIII," Sponsored by Gynecologic Oncology Group, Foundation
Total Direct Costs: \$64,028.00
April 1, 2005 - March 31, 2007

Benbrook, D. M. (Co-Investigator), Goodfellow, P. (Principal Investigator), "A Murine Model of Endometrial Tumorigenesis," Sponsored by National Cancer Institute/National Institutes of Health (R01), Federal
Total Direct Costs: \$74,996.00
April 1, 2004 - March 31, 2007

Benbrook, D. M. (Collaborator), Kelly, W. (Principal Investigator), "Investigations of SHetA2 mediated Mitochondrial changes," Sponsored by Oklahoma IDeA Network of Biomedical Research Excellence (INBRE) NIH/NCRR, Federal
Total Direct Costs: \$50,000.00
Additional Information: \$15,383 to Dr. Benbrook
June 1, 2006 - December 31, 2006

Benbrook, D. M. (Principal Investigator), "SHetA2 will Inhibit Cancer Recurrence Without Retinoid-Associated Toxicities," Sponsored by Rapid Access to Intervention Development (RAID), Federal

Total Direct Costs: \$2,083,000.00
2003 - 2006

Benbrook, D. M. (Principal Investigator), "Steroids and Stem Cells in Carcinogenesis," Sponsored by NCI/NIH (R03), Federal
Total Direct Costs: \$100,000.00
September 30, 2004 - June 30, 2006

Benbrook, D. M. (Principal Investigator), "Mechanism of ER Activation in Thyroid Hormone Administration in Breast Cancer Survivors," Sponsored by Mary Kay Ash Charitable Foundation, Foundation
Total Direct Costs: \$100,000.00
July 1, 2004 - June 30, 2006

Benbrook, D. M. (Collaborator), Kelly, W. (Principal Investigator), "Investigations of SHetA2 mediated Mitochondrial changes in Human Cancer Organotypic Cultures," Sponsored by Oklahoma INBRE (IDeA Network of Biomedical Research Excellence), State
Total Direct Costs: \$50,000.00
Additional Information: \$15,383 to Dr. Benbrook
June 1, 2005 - December 31, 2005

Benbrook, D. M. (Co-Investigator), Ceresa, B. (Principal Investigator), "Does HPV16 E5 affect EGF Receptor Endocytosis and Signaling?," Sponsored by Oklahoma Center for the Advancement of Science and Technology (OCAST), State
Total Direct Costs: \$100,000.00
July 1, 2003 - June 30, 2005

Benbrook, D. M. (Principal Investigator), "Agreement Using Proxima Technology to Screen Libraries of Recombinant Probes," Sponsored by Proxima Concepts, LTD, London, England, UK, Private
Total Direct Costs: \$6,078.00
December 22, 2004 - May 31, 2005

Benbrook, D. M. (Co-Investigator), McMeekin, S. (Principal Investigator), "Phase II Trial of Gleevec (Imatinib Mesylate Formerly Known as STI571) in Patients with CD1q17(+) Gynecologic Malignancies," Sponsored by Novartis Pharmaceutical through PRA International, Private
Total Direct Costs: \$65,882.00
November 1, 2002 - October 31, 2004

Benbrook, D. M. (Collaborator), Kelly, W. (Principal Investigator), "Is Retinoid Induced Cell Apoptosis Mediated by Superoxide Radical Anion Production," Sponsored by Oklahoma Biomedical Research Infrastructure Network (BRIN) Collaborative Grant, State
Total Direct Costs: \$50,000.00
Additional Information: \$15,383 to Dr. Benbrook
February 1, 2004 - June 30, 2004

Benbrook, D. M. (Principal Investigator), "Analysis for GOG229-B, GOG230-B, GOG-231-B Stage I," Sponsored by Gynecologic Oncology Group, Foundation
Total Direct Costs: \$25,290.00
July 1, 2002 - June 30, 2004

Benbrook, D. M. (Principal Investigator), "Mechanism & Potential of Retinoid & DNA Damage Therapy," Sponsored by NCI/NIH (R01), Federal
Total Direct Costs: \$310,555.00
July 1, 1999 - June 30, 2004

Benbrook, D. M. (Principal Investigator), Lu, S. (Postdoctoral Fellow), "Human Papillomavirus and Epidermal Growth Factor Receptor as Biomarkers of Retinoid Cervix Cancer Chemoprevention," Sponsored by Cancer Research Foundation of America (CRFA) Fellowship, Foundation
Total Direct Costs: \$60,000.00
January 15, 2000 - January 4, 2003

Benbrook, D. M. (Principal Investigator), "Develop and Perform ELISA's for Neo-MS-02 Clinical Trial," Sponsored by NeoPharm, Private
Total Direct Costs: \$72,000.00
May 1, 2000 - June 30, 2002

Benbrook, D. M. (Principal Investigator), "Determination of Retinoid X Receptor Ligand Structure-Function Properties," Sponsored by Procter & Gamble, Private
Total Direct Costs: \$48,000.00
February 1, 2002 - June 15, 2002

Benbrook, D. M. (Collaborator), Glore, S. (Principal Investigator), "Ligand Activation of Peroxisome Proliferator-Activated Receptors in Rodent Mammary Tumor Models," Sponsored by American Institute for Cancer Research (AICR), Non-Profit
Total Direct Costs: \$100,000.00
January 1, 1998 - December 1, 2000

Benbrook, D. M. (Principal Investigator), "Development of Retinoids and Response Biomarkers for Ovarian Cancer," Sponsored by Mary Kay Ash Charitable Foundation
Total Direct Costs: \$90,864.00
Additional Information: \$9,136 Indirect
July 1, 1998 - June 30, 2000

Benbrook, D. M. (Co-Investigator), Nelson, E. C. (Principal Investigator), "Biological Activity of Heteroarotinoids," Sponsored by NCI/NIH (R01), Federal
Total Direct Costs: \$269,761.00
Additional Information: \$124,190 indirect
August 1, 1996 - December 1, 1999

Benbrook, D. M. (Principal Investigator), "Determination of Retinoid Receptor Transactivation Properties," Sponsored by Procter & Gamble, Private
Total Direct Costs: \$8,890.00
July 1, 1999 - September 1, 1999

Benbrook, D. M. (Principal Investigator), "Carotenoid Effects on Transcription and Growth in Tumors," Sponsored by American Institute of Cancer Research, 94A63, Non-Profit
Total Direct Costs: \$10,000.00
Additional Information: \$10,000 Indirect
July 1, 1994 - June 30, 1996

Benbrook, D. M. (Principal Investigator), "Radiation and Retinoid Effects on Cervical Cancer," Sponsored by Presbyterian Health Foundation, Foundation
Total Direct Costs: \$25,000.00
January 1, 1994 - January 1, 1995

Benbrook, D. M. (Principal Investigator), "DNA Binding Specificities of cJun Dimers," Sponsored by National Science Foundation, MCB-9209479, Foundation
Grant/Contract Number: MCB-9209479
Total Direct Costs: \$16,200.00

Additional Information: \$1,800 Indirect
August 1, 1992 - January 31, 1994

Benbrook, D. M. (Principal Investigator), "Retinoids, cJun and Cervical Cancer," Sponsored by Oklahoma Medical Alumni Association, Foundation
Total Direct Costs: \$20,000.00
Additional Information: \$20,000 awarded, \$11,000 accepted due to overlap with other funding
September 1, 1992 - August 31, 1993

Benbrook, D. M. (Principal Investigator), "Retinoids, cJun and Cervical Cancer," Sponsored by Milheim Foundation for Cancer Research, 92-14, Foundation
Grant/Contract Number: 92-14
Total Direct Costs: \$14,000.00
July 1, 1992 - June 30, 1993

Benbrook, D. M. (Principal Investigator), "Repair of an Ultracentrifuge," Sponsored by Presbyterian Health Foundation, Research Equipment Fund, Foundation
Total Direct Costs: \$5,000.00
1992

Professional Service Agreements

Benbrook, D. M. (Project Director), Chandra, V. (Co-Project Director), Rai, R. (Co-Project Director), Rao, C. (Principal Investigator), "Chemoprevention of Endometrial Hyperplasia and Its Transition to Endometrial Cancer with NSC 721689," Sponsored by NCI PREVENT Program, Federal
Grant/Contract Number: HHSN261201500038I
Current Funding (Total Cost per Year): \$713,988.00
June 16, 2017 - June 14, 2021

Benbrook, D. M. (Principal Investigator), 7.2% Effort, Janakiram, N. (Co-Principal Investigator), "Ovarian Cancer Chemoprevention," Research Contract, Sponsored by NIH/NCI/PREVENT Program, Federal
Grant/Contract Number: HHSN261201500038I
Total Direct Costs: \$599,353.00
September 24, 2015 - February 23, 2019

Publications - Peer-Reviewed/Refereed

* indicates Mentee
+ indicates Co-First Author
indicates Contributing Author/Corresponding Author

Scientific/Scholarly Journals

1. Sharma, A.*, Liu, X., Chandra, V., Rai, R., **Benbrook, D. M.**, Woo, S.# (2023). Pharmacodynamics of Cyclin D1 Degradation in Ovarian Cancer Xenografts with Repeated Oral SHetA2 Dosing. *The AAPS Journal*(26), 5. PMID: 38087107. DOI: 10.1208/s12248-023-00874-7
2. Rai, R., Lightfoot, S., **Benbrook, D. M.**# (2023). Manipulation of metabolic responses enhances SHetA2 efficacy without toxicity in cervical cancer cell lines and xenografts. *Gynecologic Oncology*, 180, 44-54. PMID: 38052108. DOI: 10.1016/j.ygyno.2023.11.013
3. Rai, R., Dey, D. K., **Benbrook, D. M.**, Chandra, V. (2023). Niclosamide causes lysosome-dependent cell death in endometrial cancer cells and tumors. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie*, 161, 114422. PMID: 36841028. DOI: 10.1016/j.biopha.2023.114422

4. **Benbrook, D. M.**, Deng, W., Gold, M. A., Rai, R., Conrad, R. D., van der Wel, H., Husain, S., Moore, K., Spirtos, N., Jackson, A. L., Zakhour, M., Mathews, C. A., West, C. M. (2023). Association of Sialyl Tn antigen with cervical cancer lymph node status: An NRG oncology/GOG study. *Gynecologic oncology*, 171, 67-75. PMID: 36827840. DOI: 10.1016/j.ygyno.2023.02.001
5. **Benbrook, D. M.** (2022). SHetA2 Attack on Mortalin and Colleagues in Cancer Therapy and Prevention. *Frontiers in Cell and Developmental Biology*. PMID: 35281109. DOI: 10.3389/fcell.2022.848682
6. Ade, C. J., Dockery, L. E., Walter, A. C., **Benbrook, D. M.**, Vesely, S. K., Hammond, S. T., Moore, K., Holman, L. L. (2022). Association between Serum Biomarkers with Postoperative Complications and Delay of Adjuvant Chemotherapy Initiation in Ovarian Cancer Patients Undergoing Primary Cytoreductive Surgery: A Pilot Study. *Nutrition and cancer*, 10, 1-8. PMID: 36495155. DOI: 10.1080/01635581.2022.2152060
7. Rai, R.* , Chandra, V., Kennedy, A. L.* , Zuna, R. E., **Benbrook, D. M.**# (2022). Distinct mechanism of cervical cancer cell death caused by the investigational new drug SHetA2. *Frontiers in Oncology*, 12. PMID: 36203464. DOI: 10.3389/fonc.2022.958536
8. Javadian, P., Cai, X., Sjoelund, V., Borden, L. E., Garland, J., **Benbrook, D. M.**# (2022). Identification of Candidate Biomarker and Drug Targets for Improving Endometrial Cancer Racial Disparities. *International Journal of Molecular Sciences*, 23(a4), 779. PMID: 35887124. DOI: 10.3390/ijms23147779
9. **Benbrook, D. M.**, Hocker JRS, Moxley, K. M., Hanas, J. S. (2022). Sera Protein Signatures of Endometrial Cancer Lymph Node Metastases. *International journal of molecular sciences*, 23(6). PMID: 35328698. DOI: 10.3390/ijms23063277
10. Cybula, M., Wang, L., Moxley, K. M., Drumond-Bock, A. L., **Benbrook, D. M.**, Jackson, C. C., Ruiz Echevarria, M. J., Bhattacharya, R., Mukherjee, P., Bieniasz, M.# (2021). Patient-Derived Xenografts of High-Grade Serous Ovarian Cancer Subtype as a Powerful Tool in Pre-Clinical Research. *Cancers*, 13(24), 6288. DOI: doi.org/10.3390/cancers13246288
11. Rai, R.** , Kennedy, A. L.** , Isingizwe, Z. R.* , Javadian, P.* , **Benbrook, D. M.**# (2021). Similarities and Differences of Hsp70, hsc70, Grp78 and Mortalin as Cancer Biomarkers and Drug Targets. *Cells*, 10(11), 2996-3015. PMID: 34831218. DOI: 10.3390/cells10112996
12. Chandra, V., Rai, R., **Benbrook, D. M.**# (2021). Utility and Mechanism of SHetA2 and Paclitaxel for Treatment of Endometrial Cancer. *Cancers*, 13, 2322-2341. PMID: 34066052. DOI: 10.3390/cancers13102322
13. Javadian, P.* , Washington, C.* , Mukasa, S.* , **Benbrook, D. M.**# (2021). Histopathologic, Genetic and Molecular Characterization of Endometrial Cancer Racial Disparity. *Cancers(The Current and Future Status of Personalized Medicine for Gynecologic Cancers)*, 1900. DOI: doi.org/10.3390/cancers13081900
14. Elayapillai, S.** , Ramraj, S. K.** , **Benbrook, D. M.*** , Bieniasz, M., Wang, L., Pathuri, G., Isingizwe, Z.* , Kennedy, A. L.* , Zhao, Y. D., Lightfoot, S., Hunsucker, L. A., Gunderson, C. C.** (2021). Potential and mechanism of mebendazole for treatment and maintenance of ovarian cancer. *Gynecologic Oncology*, 160(1), 302-311. PMID: 33131904. DOI: 10.1016/j.ygyno.2020.10.010
15. Klionsky, D. J., et. al., **Benbrook, D. M.**, et. al. (2021). Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition). *Autophagy*, 17, 1-382. PMID: 33634751. DOI: 10.1080/15548627.2020.1797280.

16. Rai, R.**, Essel, K. G.**, **Benbrook, D. M.**, Garland, J., Zhao, Y. D., Chandra, V.# (2020). Preclinical Efficacy and Involvement of AKT, mTOR, and ERK Kinases in the Mechanism of Sulforaphane Against Endometrial Cancer. *Cancers*, 12(5), E1273. PMID: 32443471. DOI: 10.3390/cancers12051273
17. Kennedy, A. L.* , Rai, R.* , Isingizwe, Z. R.* , Zhao, Y. D., Lightfoot, S. A., **Benbrook, D. M.**# (2020). Complementary Targeting of Rb Phosphorylation and Growth in Cervical Cancer Cell Cultures and a Xenograft Mouse Model by SHetA2 and Palbociclib. *Cancers*, 12(5), E1269. PMID: 32429557. DOI: 10.3390/cancers12051269
18. Sharma, A.* , Li, M., Thavathiru, E.* , Ibrahim, M.* , Garcia-Contreras, L., **Benbrook, D. M.**, Woo, S.*# (2020). Physiologically Based Pharmacokinetic Modeling and Tissue Distribution Characteristics of SHetA2 in Tumor-Bearing Mice. *The AAPS Journal*, 22, 51. PMID: 32086622. DOI: 10.1208/s12248-020-0421-z
19. Mahjabeen, S.* , Hatipoglu, M. K., Kosanke, S. D., Garcia-Contreras, D., **Benbrook, D. M.**# , Garcia-Contreras, L.# (2020). Vaginal Suppositories Containing Sheta2 To Treat Cervical Dysplasia:Pharmacokinetics Of Daily Doses And Preliminary Safety Profile. *Journal of Pharmaceutical Sciences*. PMID: 32113976. DOI: 10.1016/j.xphs.2020.02.016
20. Ramraj, S. K.* , Elayapillai, S.P.* , Pelikan, R. C., Zhao, Y.D., Isingizwe, Z.R.* , Kennedy, A. L.* , Lightfoot, S. A., **Benbrook, D. M.** (2019). Novel ovarian cancer maintenance therapy targeted at mortalin and mutant p53. *International Journal of Cancer*, 147, 1086-1097. PMID: 31845320. DOI: 10.1002/ijc.32830
21. Gnanasekaran, K. K., Pouland, T.* , Bunce, R. A., Berlin, K. D., Abuskhuna, /., Mashayekh, M., Zhou, D. H., **Benbrook, D. M.** (2019). Tetrahydroquinoline units in flexible heteroarotinoids (Flex-Hets) convey anti-cancer properties in A2780 ovarian cancer cells. *Bioorganic and Medicinal Chemistry*. PMID: 31831296. DOI: 10.1016/j.bmc.2019.115244
22. Csiszar, A., Balasubramanian, P., Tarantini, S., Yabluchanskiy, A., Zhang, X. A., Springo, Z., **Benbrook, D. M.**, Sonntag, W. E., Ungvari, Z. (2019). Chemically induced carcinogenesis in rodent models of aging: assessing organismal resilience to genotoxic stressors in geroscience research. *Geroscience*, 41(2), 209-227. PMID: 31037472. DOI: 10.1007/s11357-019-00064-4
23. Nammalwar, B., Bunce, R. A., Berlin, K. D., **Benbrook, D. M.**, Toal, C.* (2019). Synthesis and biological evaluation of SHetA2 (NSC-721689) analogs against the ovarian cancer cell line A2780. *European Journal of Medicinal Chemistry*, 170, 16-27. PMID: 30878829. DOI: 10.1016/j.ejmech.2019.03.010
24. Mahjabeen, S., Hatipoglu, M. K., **Benbrook, D. M.**, Garcia-Contreras, L. (2018). Pharmacokinetics and Pharmacodynamics of Escalating Doses of SHetA2 After Vaginal Administration to Mice. *Journal of Pharmaceutical Sciences*, 107(12), 3179-3186. PMID: 30196041. DOI: 10.1016/j.xphs.2018.08.024
25. **Watts, F. M.**, Pouland, T.* , Bunce, R. A., Berlin, K. D., Benbrook, D. M., Mashayekhi, M., D. B., Zhou, D. (2018). Activity of oxygen-versus sulfur-containing analogs of the Flex-Het anticancer agent SHetA2. *European Journal of Medicinal Chemistry*, 158, 720-732. PMID: 30245396.
26. Virani, N. A., Thavathiru, E.* , McKernan, P., Moore, K., **Benbrook, D. M.**, Harrison, R. G. (2018). Anti-CD73 and anti-OX40 immunotherapy coupled with a novel biocompatible enzyme prodrug system for the treatment of recurrent, metastatic ovarian cancer. *Cancer Letters*, 425, 174-182. PMID: 29574275. DOI: 10.1016/j.canlet.2018.03.027

27. Carlson, B. W., Craft, M. A., Carlson, J. R., Deardeuff, K., **Benbrook, D. M.** (2018). Accelerated vascular aging and persistent cognitive impairment in older female breast cancer survivors. *Geroscience*, 40(3), 325-336. PMID: 29804200. DOI: 10.1007/s11357-018-0025-z
28. Mahjabeen, S., Hatipoglu, M. K., **Benbrook, D. M.**, Kosanke, S. D., Garcia-Contreras, D., Garcia-Contreras, L. (2018). Influence of the estrus cycle of the mouse on the disposition of SHetA2 after vaginal administration. *European Journal of Pharmaceutics and Biopharmaceutics: Official Journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.*, 130, 272-280. PMID: 30064701. DOI: 10.1016/j.ejpb.2018.07.004
29. **Benbrook, D. M.**[#], Janakiram, N. B., Chandra, V.^{*}, Pathurib, G., Madk, V., Stratton, N. C., Masamha, C. P.^{*}, Farnsworth, C. N.^{*}, Garcia-Contreras, L., Hatipoglu, M. K., Lightfoot, S., Rao, C. V. (2018). Development of a dietary formulation of the SHetA2 chemoprevention drug for mice. *Investigational New Drugs*, 36(4), 561-570. PMID: 29273857. DOI: 10.1007/s10637-017-0550-0
30. Ramraj, S. K., Smith, K. M., Janakiram, N. B., Toal, C., Raman, A., **Benbrook, D. M.** (2018). Correlation of clinical data with fallopian tube specimen immune cells and tissue culture capacity. *Tissue & cell*, 52, 57-64. PMID: 29857829. DOI: 10.1016/j.tice.2018.04.001
31. Sharma, A., **Benbrook, D. M.**, Woo, S. (2018). Pharmacokinetics and interspecies scaling of a novel, orally-bioavailable anti-cancer drug, SHetA2. *PloS one*, 13(4), e0194046. PMID: 29634717. DOI: 10.1371/journal.pone.0194046
32. Rader, J., Sill, M. W., Beumer, J. H., Lankes, H. A., **Benbrook, D. M.**, Garcia, F., Trimble, C., Thigpen, T., Lieberman, R., Zuna, R. E., Leath, C. A., Spirtos, N. M., Byron, J., Thaker, P. H., Lele, S., Alberts, D. (2017). A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: an NRG Oncology/Gynecologic Oncology Group study. *Gynecologic Oncology*(145), 291-297. PMID: 28285845. DOI: 10.1016/j.ygyno.2017.02.040
33. Sharma, A., Thavathiru, E., **Benbrook, D. M.**, Woo, S. (2017). Bioanalytical Method Development and Validation of HPLC-UV Assay for the Quantification of SHetA2 in Mouse and Human Plasma: Application of Pharmacokinetics Study. *Journal of Pharmaceutical Technology & Drug Research*, 6(2). PMID: 29708233. DOI: 10.7243/2050-120X-6-2
34. **Janakiram, N. B.**, Mohammed, A., Briant, T., Ritchie, R., Stratton, N., Jackson, L., Lightfoot, S., Benbrook, D. M., Ash, A. S., Lang, M. L., Rao, C. (2017). Loss of natural killer T cells promotes pancreatic cancer in LSL-Kras(G12D/+) mice. *Immunology*, 152, 36-51.
35. Muhjabeen, S., Hatipoglu, M. K., Chandra, V.^{*}, **Benbrook, D. M.**, Garcia-Contreras, L. (2017). Optimization of a vaginal suppository formulation to deliver SHetA2 as a novel treatment for cervical dysplasia. *Journal of Pharmaceutical Sciences*, 107(2), 638-646. PMID: 28989018. DOI: 10.1016/j.xphs.2017.09.018
36. Griffith, J., Andrade, D., Mehta, M., Berry, W., **Benbrook, D. M.**, Aravindan, N., Tanaka, T., Herman, T. S., Ramesh, R., Munshi, A. (2017). Silencing BMI1 radiosensitizes human breast cancer cells by inducing DNA damage and autophagy. *Oncology Reports*, 37(4), 2382-2390. PMID: 28260023. DOI: 10.3892/or.2017.5478
37. Jackson, C. C., Ding, K., Dvorak, J., Moore, K., McMeekin, D. S., **Benbrook, D. M.** (2016). The pro-inflammatory effect of obesity on high grade serous ovarian cancer. *Gynecologic Oncology*. PMID: 27423378. DOI: 10.1016/j.ygyno.2016.07.103
38. Walgama, C., Al Mubarak, Z. H., Zhang, B., Akinwale, M., Pathiranage, A., Deng, J., Berlin, K. D.,

- Benbrook, D. M.**, Krishnan, S. (2016). Label-free real-time microarray imaging of cancer protein-protein interactions and their inhibition by small molecules. *Analytical Chemistry*, 88(6), 3130-5. PMID: 26886845. DOI: 10.1021/acs.analchem.5b04234
39. Okon, I. S.* , Ding, Y., Coughlan, K. A., Wang, Q., Song, P., **Benbrook, D. M.**, Zou, M.-H. (2016). Aberrant NRP-1 expression serves as predictor of metastatic endometrial and lung cancers. *Oncotarget*, 7(7), 7970-8. PMID: 26701889. DOI: 10.18632/oncotarget.6699
40. Chandra, V.* , Kim, J. J., **Benbrook, D. M.**, Dwivedi, A., Rai, R.* (2016). Therapeutic options for management of endometrial hyperplasia. *Journal of Gynecologic Oncology*, 27(1), e8. PMID: 26463434. DOI: 10.3802/jgo.2016.27.e8
41. Gnanasekaran, K. K., **Benbrook, D. M.**, Nammalwar, B., Thavathiru, E.* , Bunce, R. A., Berlin, K. D. (2015). Synthesis and evaluation of second generation Flex-Het scaffolds against the human ovarian cancer A2780 cell line. *European Journal of Medicinal Chemistry*, 96, 209-17. PMID: 25880346. DOI: 10.1016/j.ejmech.2015.03.070
42. Powell, M. A., Sill, M. W., Goodfellow, P. J., **Benbrook, D. M.**, Lankes, H. A., Leslie, K. K., Jeske, Y., Mannel, R. S., Spillman, M. A., Lee, P. S., Hoffman, J. S., McMeekin, D. S., Pollock, P. M. (2014). A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study. *Gynecologic Oncology*, 135(1), 38-43. PMID: 25019571. DOI: 10.1016/j.ygyno.2014.07.083
43. Ozpolat, B., **Benbrook, D. M.** (2014). Targeting autophagy in cancer management – strategies and developments. *Cancer Management and Research*. DOI: <https://doi.org/10.2147/CMAR.S34859>
44. **Benbrook, D. M.**, Nammalwar, B., Long, A.* , Matsumoto, H., Singh, A., Bunce, R. A., Berlin, K. D. (2014). SHetA2 interference with mortalin binding to p66shc and p53 identified using drug-conjugated magnetic microspheres. *Investigational New Drugs*, 32(3), 412-23. PMID: 24254390. DOI: 10.1007/s10637-013-0041-x
45. Slaughter, K. N.* , Thai, T. C., Penarozza, S., **Benbrook, D. M.**, Thavathiru, E.* , Ding, K., Nelson, T., McMeekin, D. S., Moore, K. (2014). Measurements of adiposity as clinical biomarkers for first-line bevacizumab-based chemotherapy in epithelial ovarian cancer. *Gynecologic Oncology*, 133(1), 11-5. PMID: 24680585. DOI: 10.1016/j.ygyno.2014.01.031
46. Bishop, E. A.* , Lightfoot, S., Thavathiru, E.* , **Benbrook, D. M.** (2014). Insulin exerts direct effects on carcinogenic transformation of human endometrial organotypic cultures. *Cancer Investigation*, 32(3), 63-70. PMID: 24499106. DOI: 10.3109/07357907.2013.877479
47. **Benbrook, D. M.**, Guruswamy, S., Wang, Y., Sun, Z., Mohammed, A., Zhang, Y., Li, Q., Rao, C. (2013). Chemoprevention of colon and small intestinal tumorigenesis in APC(min/+) mice by SHetA2 (NSC721689) without toxicity. *Cancer Prevention Research (Philadelphia, Pa.)*, 6(9), 908-16. PMID: 23852423. DOI: 10.1158/1940-6207.CAPR-13-0171
48. Moxley, K. M.* , **Benbrook, D. M.**, Queimado, L., Zuna, R. E., Thompson, D., McCumber, M., Premkumar, P.* , Thavathiru, E.* , Hines, L., Moore, K.* (2013). The role of single nucleotide polymorphisms of the ERCC1 and MMS19 genes in predicting platinum-sensitivity, progression-free and overall survival in advanced epithelial ovarian cancer. *Gynecologic Oncology*, 130(2), 377-82. PMID: 23632208. DOI: 10.1016/j.ygyno.2013.04.054
49. Naylor, M. F., Thompson, D. M., Lightfoot, S., **Benbrook, D. M.** (2013). Anti-Cancer Activities and Interaction of Imiquimod and Flex-Het, SHetA2. *Journal of Cancer Therapy*, 4(6A), 7-19. DOI: 10.4236/jct.2013.46A1002

50. Kabirov, K. K., Kapetanovic, I. M., **Benbrook, D. M.**, Dinger, N., Mankovskaya, I., Zakharov, A., Detrisac, C., Pereira, M., Martín-Jiménez, T., Onua, E., Banerjee, A., van Breemen, R. B., Nikolić, D., Chen, L., Lyubimov, A. V. (2013). Oral toxicity and pharmacokinetic studies of SHetA2, a new chemopreventive agent, in rats and dogs. *Drug and Chemical Toxicology*, 36(3), 284-95. PMID: 22947079. DOI: 10.3109/01480545.2012.710632
51. McMeekin, D. S., Sill, M. W., Darcy, K. M., Abulafia, O., Hanjani, P., Pearl, M. L., Rubin, S. C., Rose, P. G., Small, L., **Benbrook, D. M.** (2012). A phase II trial of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis: a Gynecologic Oncology Group study. *Gynecologic Oncology*, 127(2), 356-61. PMID: 22796461. DOI: 10.1016/j.ygyno.2012.07.095
52. **Benbrook, D. M.**, Long, A.* (2012). Integration of autophagy, proteasomal degradation, unfolded protein response and apoptosis. *Experimental Oncology*, 34(3), 286-97. PMID: 23070014.
53. Doppalapudi, R. S., Riccio, E. S., Davis, Z., Menda, S., Wang, A., Du, N., Green, C., Kopelovich, L., Rao, C., **Benbrook, D. M.**, Kapetanovic, I. M. (2012). Genotoxicity of the cancer chemopreventive drug candidates CP-31398, SHetA2, and phospho-ibuprofen. *Mutation Research*, 746(1), 78-88. PMID: 22498038. DOI: 10.1016/j.mrgentox.2012.03.009
54. Ramachandran, I., Thavathiru, E.*, Ramalingam, S., Natarajan, G., Mills, W. K., **Benbrook, D. M.**, Zuna, R. E., Lightfoot, S., Reis, A., Anant, S., Queimado, L. (2012). Wnt inhibitory factor 1 induces apoptosis and inhibits cervical cancer growth, invasion and angiogenesis in vivo. *Oncogene*, 31(22), 2725-37. PMID: 22002305. DOI: 10.1038/onc.2011.455
55. **Benbrook, D. M.**, Masamha, C. P.** (2011). The Pro-Survival Function of Akt Kinase can be Overridden or Altered to Contribute to Induction of Apoptosis. *Current Cancer Drug Targets*, 11(5), 586-599. PMID: 21486222. DOI: <https://doi.org/10.2174/156800911795655994>
56. Jiang, H., Taggart, J. E., Zhang, X., **Benbrook, D. M.**, Lind, S. E., Ding, W.-Q. (2011). Nitroxoline (8-hydroxy-5-nitroquinoline) is more a potent anti-cancer agent than clioquinol (5-chloro-7-iodo-8-quinoline). *Cancer Letters*, 312(1), 11-7. PMID: 21899946. DOI: 10.1016/j.canlet.2011.06.032
57. Dozmorov, I. M., Jarvis, J., Saban, R., **Benbrook, D. M.**, Wakeland, E., Aksentijevich, I., Ryan, J., Chiorazzi, N., Guthridge, J. M., Drewe, E., Tighe, P. J., Centola, M., Lefkovits, I. (2011). Internal standard-based analysis of microarray data analysis of functional associations between HVE-genes. *Nucleic Acids Research*, 39(18), 7881-99. PMID: 21715372. DOI: 10.1093/nar/gkr503
58. Zheng, J., **Benbrook, D. M.**, Yu, H., Ding, W.-Q. (2011). Clioquinol suppresses cyclin D1 gene expression through transcriptional and post-transcriptional mechanisms. *Anticancer Research*, 31(9), 2739-47. PMID: 21868515.
59. Usha, L., Sill, M. W., Darcy, K. M., **Benbrook, D. M.**, Hurteau, J. A., Michelin, D. P., Mannel, R. S., Hanjani, P., De Geest, K., Godwin, A. K. (2011). A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies. *Gynecologic Oncology*, 121(3), 455-61. PMID: 21414654. DOI: 10.1016/j.ygyno.2011.02.013
60. Nammalwar, B., Bunce, R. A., **Benbrook, D. M.**, Lu, T., Li, H.-F., Chen, Y.-D., Berlin, K. D. (2011). Synthesis of N-[3,4-Dihydro-4-(acetoxymethyl)-2,2,4-trimethyl-2H-1-benzothiopyran-6-yl]-N'-(4-nitrophenyl)thiourea and

N-[3,4-dihydro-4-(hydroxymethyl)-2,2,4-trimethyl-2H-1-benzothiopyran-6-yl]N'-(4-nitrophenyl)thiourea, a Major Metabolite of N-(3,4-Dihydro-2,2,4,4-tetramethyl-2H-1benzothiopyran-6-YL)-N'-(4-nitrophenyl)thiourea. *Phosphorus, Sulfur, and Silicon and the Related Elements*, 186(1), 189-204. DOI: 10.1080/10426507.2010.534521

61. Zheng, J., Lou, J. R., Zhang, X., **Benbrook, D. M.**, Hanigan, M. H., Lind, S. E., Ding, W.-Q. (2010). N-Acetylcysteine interacts with copper to generate hydrogen peroxide and selectively induce cancer cell death. *Cancer Letters*, 298(2), 186-94. PMID: 20667650. DOI: 10.1016/j.canlet.2010.07.003
62. Hurteau, J. A., Brady, M. F., Darcy, K. M., McGuire, W. P., Edmonds, P., Pearl, M. L., Ivanov, I., Tewari, K. S., Mannel, R. S., Zanotti, K., **Benbrook, D. M.** (2010). Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study. *Gynecologic Oncology*, 119(3), 444-50. PMID: 20846715. DOI: 10.1016/j.ygyno.2010.08.002
63. Chenedza, S.*, **Benbrook, D. M.** (2010). NF-kappaB is involved in SHetA2 circumvention of TNF-alpha resistance, but not induction of intrinsic apoptosis. *Anti-Cancer Drugs*, 21(3), 297-305. PMID: 20032777. DOI: 10.1097/CAD.0b013e3283350e43
64. Moxley, K. M.*, Chenedza, S.*, **Benbrook, D. M.** (2009). Induction of death receptor ligand-mediated apoptosis in epithelial ovarian carcinoma: The search for sensitizing agents. *Gynecologic Oncology*, 115(3), 438-42. PMID: 19804900. DOI: 10.1016/j.ygyno.2009.09.007
65. Tuller, E. R.*, Beavers, C. T., Lou, J. R., Ihnat, M. A., **Benbrook, D. M.**, Ding, W.-Q. (2009). Docosahexaenoic acid inhibits superoxide dismutase 1 gene transcription in human cancer cells: the involvement of peroxisome proliferator-activated receptor alpha and hypoxia-inducible factor-2alpha signaling. *Molecular Pharmacology*, 76(3), 588-95. PMID: 19528198. DOI: 10.1124/mol.109.057430
66. Masamha, C. P.*, **Benbrook, D. M.** (2009). Cyclin D1 degradation is sufficient to induce G1 cell cycle arrest despite constitutive expression of cyclin E2 in ovarian cancer cells. *Cancer Research*, 69(16), 6565-72. PMID: 19638577. DOI: 10.1158/0008-5472.CAN-09-0913
67. Myers, T.*, Chenedza, S.*, Lightfoot, S., Pan, Y., Dedmond, D.*, Cole, L., Tang, Y., **Benbrook, D. M.** (2009). Flexible heteroarotinoid (Flex-Het) SHetA2 inhibits angiogenesis in vitro and in vivo. *Investigational New Drugs*, 27(4), 304-18. PMID: 18802666. DOI: 10.1007/s10637-008-9175-7
68. Liu, T.*, Masamha, C. P.*, Chenedza, S.*, Berlin, K. D., Lightfoot, S., He, F.*, **Benbrook, D. M.** (2009). Development of flexible-heteroarotinoids for kidney cancer. *Molecular Cancer Therapeutics*, 8(5), 1227-38. PMID: 19417155. DOI: 10.1158/1535-7163.MCT-08-1069
69. Tuller, E. R.*, Brock, A. L., Yu, H., Lou, J. R., **Benbrook, D. M.**, Ding, W.-Q. (2009). PPARalpha signaling mediates the synergistic cytotoxicity of clioquinol and docosahexaenoic acid in human cancer cells. *Biochemical Pharmacology*, 77(9), 1480-6. PMID: 19426685. DOI: 10.1016/j.bcp.2009.02.002
70. Lin, Y., Liu, X., Yue, P., **Benbrook, D. M.**, Berlin, K. D., Khuri, F. R., Sun, S. Y. (2008). Involvement of c-FLIP and survivin down-regulation in flexible heteroarotinoid-induced apoptosis and enhancement of TRAIL-initiated apoptosis in lung cancer cells. *Molecular Cancer Therapeutics*, 7(11), 3556-65. PMID: 19001438. DOI: 10.1158/1535-7163.MCT-08-0648

71. Liu, Z., Zhang, Y., Hua, Y. F., Covey, J. M., **Benbrook, D. M.**, Chan, K. K. (2008). Metabolism of a sulfur-containing heteroarotinoid antitumor agent, SHetA2, using liquid chromatography/tandem mass spectrometry. *Rapid Communications in Mass Spectrometry : RCM*, 22(21), 3371-81. PMID: 18837006. DOI: 10.1002/rcm.3744
72. Lin, Y., Chen, S., Yue, P., Zou, W., **Benbrook, D. M.**, Liu, S., Le, T. C., Berlin, K. D., Khuri, F. R., Sun, S. Y. (2008). CAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction is a major component of SHetA2-induced apoptosis in lung cancer cells. *Cancer Research*, 68(13), 5335-44. PMID: 18593935. DOI: 10.1158/0008-5472.CAN-07-6209
73. Ju, T., Lanneau, G. S., Gautam, T., Wang, Y., Xia, B., Stowell, S. R., Willard, M. T., Wang, W., Xia, J. Y., Zuna, R. E., Laszik, Z., **Benbrook, D. M.**, Hanigan, M. H., Cummings, R. D. (2008). Human tumor antigens Tn and sialyl Tn arise from mutations in Cosmc. *Cancer Research*, 68(6), 1636-46. PMID: 18339842. DOI: 10.1158/0008-5472.CAN-07-2345
74. **Benbrook, D. M.**, Lightfoot, S., Ranger-Moore, J., Liu, T. *, Chenedza, S. *, Berry, W. L. *, Dozmorov, I. (2008). Gene expression analysis of biological systems driving an organotypic model of endometrial carcinogenesis and chemoprevention. *Gene Regulation and Systems Biology*, 2, 21-42. PMID: 19784388.
75. **Liu, T. ***, Hannafon, B., Gill, L. *, Kelly, W., Benbrook, D. M. # (2007). Flex-Hets differentially induce apoptosis in cancer over normal cells by directly targeting mitochondria. *Molecular Cancer Therapeutics*, 6, 1814-1822. PMID: 17575110.
76. Le, T. C., Berlin, K. D., **Benbrook, D. M.** (2007). Modified heteroarotinoids as potential anticancer agents-improved syntheses of 2-nitrotetralin and 2-aminotetralin. *Journal of the Saudi Chemical Society*, 11, 351-360.
77. Le, T. C., Berlin, K. D., Benson, S. D., Eastman, M. A., Bell-Eunice, G., Nelson, A. C., **Benbrook, D. M.** (2007). Heteroarotinoids with anti-cancer activity against ovarian cancer cells. *The Open Medicinal Chemistry Journal*, 1, 11-23. PMID: 19662136. DOI: 10.2174/1874104500701010011
78. **McMeekin, D. S.**, Sill, M. W., Darcy, K. M., Stearns-Kurosawa, D. J., Webster, K., Waggoner, S., Benbrook, D. M. (2007). A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: A Gynecologic Oncology Group study. *Gynecologic Oncology*, 106(3), 596-603. PMID: 17597196. DOI: 10.1016/j.ygyno.2007.05.013
79. **McMeekin, D. S.**, Sill, M. S., Benbrook, D. M., Darcy, K. M., Stearns-Kurosawa, D. J., Eaton, L., Yamada, S. D. (2007). A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study. *Gynecologic Oncology*, 105(2), 508-516. PMID: 17306350. DOI: 10.1016/j.ygyno.2007.01.019
80. Guruswamy, S. *, **Benbrook, D. M.** (2006). Retinoids chemosensitize ovarian cancer cell lines to cisplatin independent of nuclear receptors and p53. *American Journal of Pharmacology and Toxicology*, 1(4), 87-93. DOI: 10.3844/ajptsp.2006.87.93
81. Lu, S. *, **Benbrook, D. M.** (2006). Role of AP-1 antagonism in growth inhibition of cervical cancer cell lines by retinoids. *American Journal of Pharmacology and Toxicology*, 1(3), 40-47. DOI: 10.3844/ajptsp.2006.40.47
82. Zhang, Y., Hua, Y., **Benbrook, D. M.**, Covey, J. M., Dai, G., Liu, Z., Chan, K. K. (2006). High performance liquid chromatographic analysis and preclinical pharmacokinetics of the heteroarotinoid antitumor agent, SHetA2. *Cancer Chemotherapy and Pharmacology*, 58(5), 561-9.

PMID: 16534614. DOI: 10.1007/s00280-006-0211-z

83. **Benbrook, D. M.** (2006). Promise and problems of translational research. *Gynecologic Oncology*, 103(2 Suppl 1), S14-7. PMID: 17027066. DOI: 10.1016/j.ygyno.2006.08.019
84. Matsuzaki, S., Hayes, J. M., **Benbrook, D. M.**, Jankowiak, R. (2006). Nonphotochemical hole-burning study of selectively stained normal and cancerous human ovarian tissues. *The Journal of Physical Chemistry. B*, 110(32), 16124-30. PMID: 16898770. DOI: 10.1021/jp060114i
85. Chiu, P. M., Feng, H. C., **Benbrook, D. M.**, Ngan, H. Y., Khoo, U. S., Xue, W. C., Tsao, S. W., Chan, K. W., Cheung, A. N. (2006). Effect of all-trans retinoic acid on tissue dynamics of choriocarcinoma cell lines: an organotypic model. *Journal of Clinical Pathology*, 59(8), 845-50. PMID: 16461808. DOI: 10.1136/jcp.2005.025833
86. Hyde, J.* , **Benbrook, D. M.** (2006). Sensitivities of uterine adenocarcinoma, mixed mullerian tumor (MMT) and sarcoma cell lines to chemotherapeutic agents and a Flex-Het drug. *American Journal of Pharmacology and Toxicology*, 1(4), 83-86. PMID: 19890461. DOI: 10.3844/ajptsp.2006.83.86
87. **Benbrook, D. M.**, Kamelle, S. A., Guruswamy, S. B.* , Lightfoot, S. A., Rutledge, T. L.* , Gould, N. S.* , Hannafon, B. N.* , Dunn, S. T., Berlin, K. D. (2005). Flexible heteroarotinoids (Flex-Hets) exhibit improved therapeutic ratios as anti-cancer agents over retinoic acid receptor agonists. *Investigational New Drugs*, 23(5), 417-28. PMID: 16133793. DOI: 10.1007/s10637-005-2901-5
88. Tillmanns, T. D.* , Kamelle, S. A.* , Guruswamy, S.* , Gould, N. S.* , Rutledge, T. L.* , **Benbrook, D. M.** (2005). Sensitization of cervical cancer cell lines to low-dose radiation by retinoic acid does not require functional p53. *Gynecologic Oncology*, 97(1), 142-50. PMID: 15790450. DOI: 10.1016/j.ygyno.2004.12.034
89. Berlin, K. D., Subramanian, S., Smith, C. M., Tabatabai, A., Bryan, C. D., Buettner, B., Hale, S., Wakefield, C. A., **Benbrook, D. M.** (2005). Synthesis of novel heteroarotinoids with receptor activation capabilities and TGase activity. Single crystal analysis of (E)-4-[(2,3-dihydro-2,2,4,4-tetramethyl-2H-1-benzo- [b]thiopyran-6-Yl)- 1-propenyl]-2-methylbenzoic acid. *Phosphorus, Sulfur, and Silicon and the Related Elements*, 180(1), 67-77. DOI: 10.1080/104265090507678
90. Brown, C. W., Liu, S., Klucik, J., Berlin, K. D., Brennan, P. J., Kaur, D., **Benbrook, D. M.** (2004). Novel heteroarotinoids as potential antagonists of Mycobacterium bovis BCG. *Journal of Medicinal Chemistry*, 47(4), 1008-17. PMID: 14761203. DOI: 10.1021/jm0303453
91. Liu, S., Brown, C. W., Berlin, K. D., Dhar, A.* , Guruswamy, S.* , Brown, D., Gardner, G. J., Birrer, M. J., **Benbrook, D. M.** (2004). Synthesis of flexible sulfur-containing heteroarotinoids that induce apoptosis and reactive oxygen species with discrimination between malignant and benign cells. *Journal of Medicinal Chemistry*, 47(4), 999-1007. PMID: 14761202. DOI: 10.1021/jm030346v
92. Chun, K. H., **Benbrook, D. M.**, Berlin, K. D., Hong, W. K., Lotan, R. (2003). The synthetic heteroarotinoid SHetA2 induces apoptosis in squamous carcinoma cells through a receptor-independent and mitochondria-dependent pathway. *Cancer Research*, 63(13), 3826-32. PMID: 12839980.
93. Mic, F. A., Molotkov, A., **Benbrook, D. M.**, Duester, G. (2003). Retinoid activation of retinoic acid receptor but not retinoid X receptor is sufficient to rescue lethal defect in retinoic acid synthesis. *Proceedings of the National Academy of Sciences of the United States of America*, 100(12), 7135-40. PMID: 12782789. DOI: 10.1073/pnas.1231422100

94. **Hassan, R.***, Lerner, M. R., **Benbrook, D. M.**, Lightfoot, S. A., Bracket, D. J., Wang, Q.-C., Pastan, I. (2002). Anti-tumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant anti-mesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro. *Clinical Cancer Research*, 8, 3520-3526. PMID: 12429643.
95. Kamelle, S.* , Sienko, A., **Benbrook, D. M.** (2002). Retinoids and steroids regulate menstrual phase histological features in human endometrial organotypic cultures. *Fertility and Sterility*, 78(3), 596-602. PMID: 12215339.
96. **Benbrook, D. M.** (2002). Refining retinoids with heteroatoms. *Mini Reviews in Medicinal Chemistry*, 2(3), 277-83. PMID: 12370069.
97. **Benbrook, D. M.** (2002). An ELISA method for detection of human antibodies to an immunotoxin. *Journal of Pharmacological and Toxicological Methods*, 47(3), 169-75. PMID: 12628308. DOI: 10.1016/S1056-8719(02)00232-0
98. Scribner, Jr, D. R.* , **Benbrook, D. M.** (2002). Retinoids enhance cisplatin-based chemoradiation in cervical cancer cells in vitro. *Gynecologic Oncology*, 85(1), 223-5. PMID: 11925151. DOI: 10.1006/gyno.2002.6590
99. Simoni, D., Roberti, M., Invidiata, F. P., Rondanin, R., Baruchello, R., Malagutti, C., Mazzali, A., Rossi, M., Grimaudo, S., Capone, F., Dusonchet, L., Meli, M., Raimondi, M. V., Landino, M., D'Alessandro, N., Tolomeo, M., Arindam, D., Lu, S., **Benbrook, D. M.** (2001). Heterocycle-containing retinoids. Discovery of a novel isoxazole arotinoid possessing potent apoptotic activity in multidrug and drug-induced apoptosis-resistant cells. *Journal of Medicinal Chemistry*, 44(14), 2308-18. PMID: 11428925.
100. Guruswamy, S.* , Lightfoot, S., Gold, M. A.* , Hassan, R.* , Berlin, K. D., Ivey, R. T.* , **Benbrook, D. M.** (2001). Effects of retinoids on cancerous phenotype and apoptosis in organotypic cultures of ovarian carcinoma. *Journal of the National Cancer Institute*, 93(7), 516-25. PMID: 11287445.
101. Dhar, A.* , Liu, S., Klucik, J., Berlin, K. D., Madler, M. M., Lu, S.* , Ivey, R. T.* , Zacheis, D.* , Brown, C. W., Nelson, E. C., Birckbichler, P. J., **Benbrook, D. M.** (2000). Synthesis, structure-activity relationships, and RARgamma-ligand interactions of nitrogen heteroarotinoids. *Journal of Medicinal Chemistry*, 43(2), 303. PMID: 10650065.
102. Zacheis, D.* , Dhar, A.* , Lu, S.* , Madler, M. M., Klucik, J., Brown, C. W., Liu, S., Clement, F., Subramanian, S., Weerasekare, G. M., Berlin, K. D., Gold, M. A.* , Houck, Jr, J. R., Fountain, K. R., **Benbrook, D. M.** (1999). Heteroarotinoids inhibit head and neck cancer cell lines in vitro and in vivo through both RAR and RXR retinoic acid receptors. *Journal of Medicinal Chemistry*, 42(21), 4434-45. PMID: 10543887.
103. Liu, S., Berlin, K. D., Simms-Kelley, M. D., **Benbrook, D. M.** (1999). Optimization and synthesis of (E)-4-[2-(3,4-Dihydro-4,4-dimethyl-2h-1-benzopyran-6-yl)-1-propenyl]benzoic Acid-11[14C]. *Journal of Labelled Compounds and Radiopharmaceuticals*, 42(8), 789-796. DOI: 10.1002/(SICI)1099-1344(199908)42:83.O.CO;2-#
104. Salsman, S.* , Lu, S.* , **Benbrook, D. M.** (1999). The mechanism of retinoic acid radiosensitization is independent of AP-1 repression in a cervical carcinoma cell line. *Gynecologic Oncology*, 73(2), 253-6. PMID: 10329043. DOI: 10.1006/gyno.1999.5352
105. DiSilvestro, P. A.* , Lightfoot, S. A., **Benbrook, D. M.** (1999). Ki-67 expression in a cervical cancer organotypic model correlates with growth and EGF-R expression. *Journal of Lower Genital Tract Disease*, 3(2), 111-5. PMID: 25950557.

106. Waliszewski, P., Waliszewska, M., Gordon, N., Hurst, R. E., **Benbrook, D. M.**, Dhar, A., Hemstreet, 3rd, G. P. (1999). Retinoid signaling in immortalized and carcinoma-derived human uroepithelial cells. *Molecular and Cellular Endocrinology*, 148(1-2), 55-65. PMID: 10221771.
107. Hurst, R. E., Waliszewski, P., Waliszewska, M., Bonner, R. B., **Benbrook, D. M.**, Dar, A., Hemstreet, 3rd, G. P. (1999). Complexity, retinoid-responsive gene networks, and bladder carcinogenesis. *Advances in Experimental Medicine and Biology*, 462, 449-67. PMID: 10599447.
108. **Benbrook, D. M.**, Subramanian, S., Gale, J. B., Liu, S., Brown, C. W., Boehm, M. F., Berlin, K. D. (1998). Synthesis and characterization of heteroarotinoids demonstrate structure specificity relationships. *Journal of Medicinal Chemistry*, 41(19), 3753-7. PMID: 9733501. DOI: 10.1021/jm980308p
109. **Benbrook, D. M.**, Madler, M. M.*, Spruce, L. W., Birckbichler, P. J., Nelson, E. C., Subramanian, S., Weerasekare, G. M., Gale, J. B., Patterson, Jr, M. K., Wang, B., Wang, W., Lu, S.*, Rowland, T. C.*, DiSivestro, P.*, Lindamood, 3rd, C., Hill, D. L., Berlin, K. D. (1997). Biologically active heteroarotinoids exhibiting anticancer activity and decreased toxicity. *Journal of Medicinal Chemistry*, 40(22), 3567-83. PMID: 9357524. DOI: 10.1021/jm970196m
110. Miller, A. M., Sahl, W. J., Brown, S. A., Young, S. K., Quinlan, C. M., Patel, P. R., **Benbrook, D. M.**, Naylor, M. F. (1997). The role of human papillomavirus in the development of pyogenic granulomas. *International Journal of Dermatology*, 36(9), 673-6. PMID: 9352408.
111. **Benbrook, D. M.**, Lu, S.*, Flanagan, C.*, Shen-Gunther, J.*, Angros, L. H., Lightfoot, S. A. (1997). Biological assay for activity and molecular mechanism of retinoids in cervical tumor cells. *Gynecologic Oncology*, 66(1), 114-21. PMID: 9234931. DOI: 10.1006/gyno.1997.4736
112. **Benbrook, D. M.**, Shen-Gunther, J.*, Nuñez, E. R.*, Dynlacht, J. R.* (1997). Differential retinoic acid radiosensitization of cervical carcinoma cell lines. *Clinical Cancer Research*, 3(6), 939-45. PMID: 9815769.
113. Johnson, G. A., Mannel, R. S., Khalifa, M., Walker, J. L., Wren, M., Min, K. W., **Benbrook, D. M.** (1997). Epidermal growth factor receptor in vulvar malignancies and its relationship to metastasis and patient survival. *Gynecologic Oncology*, 65(3), 425-9. PMID: 9190969. DOI: 10.1006/gyno.1997.4660
114. **Benbrook, D. M.**, Rogers, R. S.*, Medlin, M. A.*, Dunn, S. T. (1995). Immunohistochemical analysis of proliferation and differentiation in organotypic cultures of cervical tumor cell lines. *Tissue & Cell*, 27(3), 269-74. PMID: 7645007.
115. Apfel, R., **Benbrook, D. M.**, Lernhardt, E., Ortiz, M. A., Salbert, G., Pfahl, M. (1994). A novel orphan receptor specific for a subset of thyroid hormone-responsive elements and its interaction with the retinoid/thyroid hormone receptor subfamily. *Molecular and Cellular Biology*, 14(10), 7025-35. PMID: 7935418.
116. **Benbrook, D. M.**, Jones, N. C. (1994). Different binding specificities and transactivation of variant CRE's by CREB complexes. *Nucleic Acids Research*, 22(8), 1463-9. PMID: 8190638.
117. **Benbrook, D. M.**, Jones, N. C. (1990). Heterodimer formation between CREB and JUN proteins. *Oncogene*, 5(3), 295-302. PMID: 2138276.
118. **Benbrook, D. M.**, Lernhardt, E., Pfahl, M. (1988). A new retinoic acid receptor identified from a hepatocellular carcinoma. *Nature*, 333(6174), 669-72. PMID: 2836738. DOI: 10.1038/333669a0

119. Pfahl, M., **Benbrook, D. M.** (1987). Nucleotide sequence of cDNA encoding a novel human thyroid hormone receptor. *Nucleic Acids Research*, 15(22), 9613. PMID: 3684612.
120. **Benbrook, D. M.**, Pfahl, M. (1987). A novel thyroid hormone receptor encoded by a cDNA clone from a human testis library. *Science (New York, N.Y.)*, 238(4828), 788-91. PMID: 3672126.
121. **Benbrook, D. M.**, Miller, R. V. (1986). Effects of norfloxacin on DNA metabolism in *Pseudomonas aeruginosa*. *Antimicrobial Agents and Chemotherapy*, 29(1), 1-6. PMID: 3015000.

Book Chapters

1. **Benbrook, D. M.**, Chambon, P., Rochette-Egly, C., Asson-Batres, M. M. (2014). History of Retinoic Acid Receptors. *The Biochemistry of Retinoic Acid Receptors: Structure, Activation, and Function at the Molecular Level* (vol. 70, pp. 1-20). Springer. PMID: 24962878.
2. **Benbrook, D. M.** (2006). Organotypic cultures represent tumor microenvironment for drug testing. In Tornell, J., Noble, D. (Eds.), *Drug Discovery Today, Disease Models* (2nd ed., vol. 3, pp. 143-148). Elsevier. DOI: 10.1016/j.ddmod.2006.05.005
3. Alberts, D. A., Barakat, R. R., Daly, M., Method, M. W., **Benbrook, D. M.** (2004). Prevention of Gynecologic Malignancies. In Gershenson, D. M., McGuire, W. P., Gore, M., Quinn, M. A., Thomas, G. (Eds.), *Gynecologic Cancer: Controversies in Management*. Philadelphia, PA: Gynecologic Cancer: Controversies in Management. Elsevier, Churchill, Livingston. DOI: 10.1016/B978-0-443-07142-3.50070-1
4. **Benbrook, D. M.**, Tonetti, D. A., Miller, R. V. (1989). DNA gyrase of *Pseudomonas aeruginosa*: Inhibition by quinolones. In Fernandez, P. B. (Ed.), *Proceedings International Telesymposium on Quinolones* (pp. 171-186). J.R. Prous Science Publishers.
5. Pfahl, M., Payne, J., **Benbrook, D. M.**, Wu, K. C. (1988). *Differential activation of a hormone responsive element in various cell lines* (pp. 161-168). Steroid Hormone Action.

Commentary

1. Leslie, K. K., Thiel, K. W., **Benbrook, D. M.**, Mutch, D. (2020). The Dawning of the Age of Personalized Medicine in Gynecologic Oncology. *Special Edition: The Current and Future Status of Personalized Medicine for Gynecologic Cancers: Current Status* (vol. 12, pp. 3135). Basel: Cancers. PMID: 33120871. DOI: <https://www.mdpi.com/2072-6694/12/11/3135>

Published Abstracts

1. Vaughn, K., Lausen, J., Bruns, M., **Benbrook, D. M.**, Hannafon, B. N. (2020). *A novel drug inhibits exosome content loading and secretion in ovarian cancer cells*. (1-1 ed., vol. 34). The FASEB Journal.

Book Reviews

1. **Benbrook, D. M.** (2014). In Ho, J. Y. (Ed.), *Biotechnology and Biopharmaceuticals: Transforming Proteins and Genes Into Drugs, 2nd Edition* (2nd ed., vol. 60, pp. 331-332). Wiley-Blackwell: Clinical Infectious Diseases. DOI: 10.1093/cid/ciu792
2. **Benbrook, D. M.**, Wilkerson, J. C. (2003). *Nature Reviews Cancer* (8th ed., vol. 289, pp. 1049-1050). JAMA. DOI: 10.1001/jama.289.8.1049

Other

1. Ramraj, S. K.* , **Benbrook, D. M.** (2018). *Synergistic combination of mortalin-targeting and p53 reactivator drugs for ovarian cancer*. Seattle, WA: 12th Biennial Ovarian Cancer Research Symposium.
2. Nugent, E.* , **Benbrook, D. M.**, Long, A.* , Moxley, K. M.* , Wild, R., McMeekin, D. S. (2013). Biomarkers associated with metabolic syndrome, endometrioid adenocarcinoma (EC) of the uterus, and disease prognosis. *Gynecologic Oncology* (1st ed., vol. 130, pp. e86-e87).
3. Slaughter, K., Thai, T. C., Penarozza, S., **Benbrook, D. M.**, Thavathiru, D. M.* , Ding, K., Nelson, T., McMeekin, D. S. (2013). Measurements of adiposity as predictive biomarkers for response to first-line bevacizumab-based chemotherapy in epithelial ovarian cancer. *Gynecologic Oncology* (1st ed., vol. 130, pp. e86-e87). *Gynecologic Oncology*.
4. Moxley, K. M.* , **Benbrook, D. M.**, Moore, K.* , Zuna, R. E. (2013). *The role of single-nucleotide polymorphisms in the ERCC1 gene in predicting the sensitivity of epithelial ovarian carcinoma to platinum-based chemotherapy and overall patient survival* (2nd ed., vol. 130, pp. 377-382). *Gynecologic Oncology*. PMID: 23632208. DOI: 10.1016/j.ygyno.2013.04.054
5. Nugent, E.* , Long, A.* , Mathews, C.* , Bishop, E.* , Moxley, K. M.* , **Benbrook, D. M.**, Wild, R., McMeekin, D. (2012). Biomarkers associated with metabolic syndrome, endometrioid adenocarcinoma (EC) of the uterus, and disease prognosis. *Gynecologic Oncology* (1st ed., vol. 127, pp. S7-S8). *Gynecologic Oncology*. DOI: 10.1016/j.gyno.2012.01.021
6. **Benbrook, D. M.**, Bishop, E.* , Nugent, E.* , Lightfoot, S., Elangovan, T.* , Long, A.* , Zhao, D. (2012). *Modeling effects of diabetes and obesity co-morbidities in endometrial cancer development and progression* (Suppl 3 ed., vol. 6, pp. 56). *BMC Proceedings*. DOI: 10.1186/1753-6561-6-S3-P56
7. Chenedza, S.* , **Benbrook, D. M.** (2009). *Sensitization of ovarian cancer cell lines to death receptor ligands by the flexible heteroarotinoid (Flex-Het), SHetA2* (3rd ed., vol. 115, pp. 438-442). *Proceedings of the American Association for Cancer Research*. DOI: 10.1016/j.ygyno.2009.09.007
8. Moxley, K. M.* , Dozmorov, I., Lightfoot, S., **Benbrook, D. M.** (2009). Dynamics of DMBA-induced transformation and gene expression in endometrial organotypic cultures. *Proceedings of the American Association for Cancer Research* (9th ed., vol. 69). American Association for Cancer Research Proceedings (AACR).
9. Masamha, P.* , **Benbrook, D. M.** (2009). p21 prevents aberrant cyclin E2 expression from interfering with G1 arrest caused by SHetA2-induced cyclin D1 loss in ovarian cancer cell lines. *Proceedings of the American Association for Cancer Research* (9th ed., vol. 69). American Association for Cancer Research Proceedings (AACR).
10. Masamha, C. P.* , Liu, T.* , **Benbrook, D. M.** (2008). Elucidation of the roles of cyclin D1 and up- and down- stream effectors in the mechanism of SHetA2 induced G1 cell cycle arrest. *The Cell Cycle* (pp. 142). Cold Springs Harbor, New York: The Cell Cycle.
11. Ju, T. Z., Lenneau, G. S., Gautam, T., Wang, Y. C., Xia, B. Y., Stowell, S. R., Willard, M. T., Wang, W. Y., Xia, J. Y., Zuna, R. E., Laszik, Z., **Benbrook, D. M.**, Hanigan, M. H., Cummings, R. D. (2008). Human Cancer and Gene Mutations in O-Glycosylation Pathway. *Anticancer Research Journal* (5C ed., vol. 28, pp. 3337). *Anticancer Research Journal*.
12. Chenedza, S.* , **Benbrook, D. M.** (2007). Effects of SHetA2 on IKappaB and NF-KappaB in Ovarian Cancer. *Molecular Cancer Therapeutics* (12th ed., vol. 6, pp. 3442S). *Molecular Cancer*

Therapeutics.

13. Masamha, C. P.* , Liu, T.* , **Benbrook, D. M.** (2007). SHetA2 targets cyclin D1 for proteasomal degradation through a GSK3 β -independent mechanism leading to G1 cell cycle arrest. *AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics* (12th ed., vol. 6, pp. 3372S). Molecular Cancer Therapeutics.
14. Myers, T.* , **Benbrook, D. M.** (2007). Thymidine phosphorylase is a molecular target of SHetA2 antiangiogenesis activity. *Proceedings of the American Association for Cancer Research* (48th ed., pp. 4615). American Association for Cancer Research Proceedings (AACR).
15. Ju, T., Lenneau, G. S., Gautam, T., Wang, Y., Xia, B., Stowell, S. R., Willard, M. T., **Benbrook, D. M.**, Hannigan, M. H., Cummings, R. D. (2007). Human Tumor Antigens Arising from Mutations in Cosmc. *Proceedings of the American Association for Cancer Research* (9th ed., vol. 67, pp. 406). American Association for Cancer Research Proceedings (AACR).
16. Ju, T. Z., Lenneau, G., Gautam, T., Wang, Y. C., **Benbrook, D. M.**, Hannigan, M. H., Cummings, R. D. (2006). Expression of Tn and SialylTn antigens in human tumor cell lines raised from mutation in molecular chaperone cosmc. *Glycobiology* (11th ed., vol. 16, pp. 1113). Glycobiology.
17. Lightfoot, S., Chenedza, S.* , Naylor, M., **Benbrook, D. M.** (2006). Inhibition of thymidine phosphorylase (TP), thrombospondin 4 (TSP4) and angiogenesis by flexible heteroartotinoids (Flex-Het), SHetA2. *Proceedings of the American Association for Cancer Research* (vol. 47, pp. 57). American Association for Cancer Research Proceedings (AACR).
18. **Benbrook, D. M.**, Lightfoot, S., Ranger-Moore, J. (2006). Karyometric analysis of inhibition of DMBA carcinogenesis by flexible heteroartotinoids (Flex-Het) SHetA2 in an endometrial organotypic model. *Proceedings of the American Association for Cancer Research* (47th ed., pp. 917). American Association for Cancer Research Proceedings (AACR).
19. Dearnley, D. D.* , Hannafon, B.* , Ding, W. Q., Lind, S., Cook, S., **Benbrook, D. M.** (2005). Regulation of Gene Expression and Vascular Capillary Formation by a Novel Anticancer Compound, SHetA2. *Proceedings of the American Association for Cancer Research* (46th ed.). American Association for Cancer Research Proceedings (AACR).
20. Kelly, W. J., Gill, L. W.* , Hannafon, B.* , **Benbrook, D. M.** (2005). SHetA2 induces mitochondrial swelling, superoxide formation and apoptosis in human cancer cells. *Abstracts of Papers for the American Chemical Society* (22nd ed., pp. U492 (Part 1)). Abstracts of Papers for the American Chemical Society.
21. **Benbrook, D. M.**, Lightfoot, S. L. (2004). Reactive Oxygen Species (ROS) are involved in the mechanism of SHetA2-induced apoptosis but not differentiation in ovarian cancer organotypic cultures. *Proceedings of the American Association for Cancer Research* (45th ed.). American Association for Cancer Research Proceedings (AACR).
22. De Bault, L. E., Lu, S.* , Angros, L. H., **Benbrook, D. M.** (2004). Retinoic acid effects on the expression of EGFreceptor mRNA and its protein in cervical cancer cells in vitro. *Journal of Histochemistry & Cytochemistry* (52nd ed., pp. S36). Journal of Histochemistry & Cytochemistry.
23. Lightfoot, S. L., **Benbrook, D. M.** (2004). Effects of steroids and retinoids in an organotypic model of endometrial carcinogenesis. *Proceedings of the American Association for Cancer Research* (vol. 45). American Association for Cancer Research Proceedings (AACR).
24. **Benbrook, D. M.**, Kamelle, S.* , Joyce, K., Guruswamy, S.* , Tillmanns, T.* , Gould, N.* , Rutledge, T.* (2002). Evaluation of Human Papillomavirus and p53 transcriptional activation in the

mechanism of 9-cisretinoic acid radiosensitization of squamous gynecologic cancer cell lines. *Proceedings of the American Association for Cancer Research* (43rd ed., pp. 433). American Association for Cancer Research Proceedings (AACR).

25. Guruswamy, S.*, **Benbrook, D. M.** (2002). The Roles of p53, retinoid receptors, and DNA damager response genes in the mechanism of retinoid sensitization of OVCAR-3 to cisplatin. *Proceedings of the American Association for Cancer Research* (43rd ed.). American Association for Cancer Research Proceedings (AACR).
26. **Benbrook, D. M.**, Sienko, A. (2001). A hormonally responsive organotypic model of cycling endometrium. *Proceedings of the American Association for Cancer Research* (vol. 42, pp. 547). American Association for Cancer Research Proceedings (AACR).
27. Guruswamy, S.*, Berlin, K. D., **Benbrook, D. M.** (2001). Chemosensitization of two ovarian carcinoma cell lines to cisplatin by heteroarotinoids. *Proceedings of the American Association for Cancer Research* (vol. 42, pp. 953-954). American Association for Cancer Research Proceedings (AACR).
28. Ju, K. H., **Benbrook, D. M.**, Berlin, K. D., Hong, W. K., Lotan, R. (2001). Induction of apoptosis in head and neck squamous cell carcinoma cell (HNSCC) lines by selected heteroarotinoids. *Proceedings of the American Association for Cancer Research* (vol. 42, pp. 548-549). American Association for Cancer Research Proceedings (AACR).
29. Berlin, K. D., Brown, C. W., **Benbrook, D. M.** (2001). Modified heteroarotinoids-anticancer activity. *Abstracts of Papers for the American Chemical Society* (221st ed., pp. U54). Abstracts of Papers for the American Chemical Society.
30. Lu, S.*, **Benbrook, D. M.** (2000). Anti-AP-1 activity of retinoids may not be a contribution to their growth inhibition activity in some tumor cell lines. *Proceedings of the American Association for Cancer Research* (41st ed., pp. 851). American Association for Cancer Research Proceedings (AACR).
31. Patrick, S. D., Waugh, K., Subramanian, S., Simms-Kelley, M. D., **Benbrook, D. M.**, Berlin, K. D., Nelson, E. C. (2000). Synthetic retinoids induce differentiation in F9 cells. *The FASEB Journal* (4th ed., vol. 14, pp. A245). The FASEB Journal.
32. Simms-Kelley, M. D., Subramanian, S., Madler, M. M., Patrick, S. D., Klucik, J., Browth, C. E., Liu, S., Lemire, T. D., **Benbrook, D. M.**, Birckbichler, P. J., Berlin, K. D., Nelson, E. C. (1999). Heteroarotinoids promote growth in vitamin A-deficient rats. *The FASEB Journal* (5th ed., vol. 13, pp. A896). The FASEB Journal.
33. Liu, S., Berlin, K. D., Madler, M. M., **Benbrook, D. M.**, Nelson, E. C. (1999). Synthesis and structure-activity relationships of nitrogen heteroarotinoids. *Abstracts of Papers for the American Chemical Society* (vol. 217, pp. U1169). Abstracts of Papers for the American Chemical Society.
34. Lu, S.*, Dhar, A.*, Ivey, R. T.*, Berlin, K. D., **Benbrook, D. M.** (1998). Heteroarotinoid structure affects receptor specificity and growth inhibitory activities. *Proceedings of the American Association for Cancer Research* (107th ed., vol. 39, pp. abstract #723). American Association for Cancer Research Proceedings (AACR).
35. Simms-Kelley, M. D., Subramanian, S., Spruce, L. W., Madler, M. M., Patrick, S. D., Grummer, R., Lemire, T. D., **Benbrook, D. M.**, Birckbichler, P. J., Berlin, K. D., Nelson, E. C. (1998). Growth promoting activity of heteroarotinoids in vitamin A deficient rats. *The FASEB Journal* (5th ed., vol. 12, pp. A840). The FASEB Journal.

36. Lu, S.*, Flanagan, C. W.*, Shen-Gunther, J.*, **Benbrook, D. M.** (1997). Biological assay for activity and molecular mechanism of retinoids in cervical tumor cells. *Gynecologic Oncology* (2nd ed., vol. 64, pp. 312). Gynecologic Oncology.
37. Flanagan, C.*, Fishburne, V. H.*, DiSilvestro, P.*, Nuñez, E. R.*, **Benbrook, D. M.** (1997). Mechanism of retinoid and cartenoid growth inhibition of a cervical tumor cell line. *Gynecologic Oncology* (2nd ed., vol. 64, pp. 357). Gynecologic Oncology.
38. Qian, X., **Benbrook, D. M.**, Berlin, K. D., Cushman, J. C., Madler, M. M., Patrick, S. D., Simms, M. D., Nelson, E. S. (1996). Comparative effects of a diaryl heteroarotinoid and all-trans-retinoic acid on induction of differentiation. *The FASEB Journal* (10th ed., pp. 4390). The FASEB Journal.
39. Nuñez, E. R.*, **Benbrook, D. M.**, Berlin, K. D., Nelson, E. C. (1995). A heteroarotinoid affects growth and transactivation of a retinoic acid response element in cervical carcinoma cell lines. *The FASEB Journal* ((3 , part 1) ed., vol. 9, pp. 985). The FASEB Journal.

Intellectual Property

Patents

1. Garcia-Contreras, L., Hatipoglu, S. M., **Benbrook, D. M.** "Nanocrystal Microparticles of Poorly Soluble Drugs and Methods of Production and Use Thereof," US 11,534,3397 B2, United States. (Submitted: October 4, 2017, Application: February 9, 2021, Approved: December 27, 2022).
2. Sorokin, A., **Benbrook, D. M.** "Treatment of Hypertension and Vascular Diseases," WO 2022/182753 A1, Patent Cooperation Treaty. (Application: February 23, 2022).
3. **Benbrook, D. M.**, Ramraj, S. "Combination Cancer Therapies," US 2022/0047546 A1, United States. (Application: February 17, 2022).
4. Sorokin, A., **Benbrook, D. M.** "Treatment of Hypertension and Vascular Diseases," MCW 650053.00777, United States. (Submitted: February 12, 2021, Application: February 23, 2021).
5. **Benbrook, D. M.** "CHROMAN- AND TETRAHYDROQUINOLINE-DERIVED HETEROAROTINOIDS AS AGENTS TO TREAT HUMAN OVARIAN CANCER," United States. (Submitted: 2018).
6. **Benbrook, D. M.**, Ramraj, S. "Drug Combinations with Synergistic Activity Against Cancer and Methods of Use," 62730345, United States. (Submitted: 2018).
7. **Benbrook, D. M.**, Ramraj, S. "Treatment of Cancer with Synergistic Combinations of p53-Targeted Drugs," United States. (Application: 2018).
8. **Benbrook, D. M.**, Ramraj, S. K. "Combination Cancer Therapies," 62/730,345, United States. (Application: September 12, 2018).
9. Garcia-Contreras, L., Hatipoglu, S. M., **Benbrook, D. M.** "Nanocrystal Microparticles of Poorly Soluble Drugs and Methods of Use," US 62/583,755, United States. (Application: November 9, 2017).
10. **Benbrook, D. M.** "Protection of Healthy Cells and Treatment of Diseases by Binding Heat Shock Proteins," 61/603,394, United States. (Application: February 27, 2012).
11. **Benbrook, D. M.**, Guruswamy, S., Turman, M. A. "Treatment and inhibition of disease conditions

using flexible heteroarotinooids," US 7,612,107 B2, United States. (Approved: November 3, 2009).

12. **Benbrook, D. M.**, Turman, M. A., Guruswamy, S. "Treatment and Inhibition of Disease Conditions (Angiogenesis) Using Flexible Heteroarotinooids," 12/608,468, United States. (Application: October 29, 2009).
13. Berlin, K. D., **Benbrook, D. M.**, Nelson, E. C. "Heteroarotinooid containing urea or thiourea linker," US 6,586,460 B1, United States. (Approved: July 1, 2003).

PRESENTATIONS

Invited

* indicates mentee

National/International

1. **Benbrook, D. M.**, "Targeting Metastases in Optimizing Ovarian Cancer Maintenance", 2023 Meeting of the International Ovarian Cancer Research Consortium in conjunction with the International Society of Precision Cancer Medicine, International Ovarian Cancer Research Consortium in conjunction with the International Society of Precision Cancer Medicine, Oklahoma City, OK, Oral Presentation. June 12, 2023.
2. **Benbrook, D. M.**, "Investigational New Drug that treats cancer without toxicity by targeting cancer addiction to", 7th Cancer World Congress, Cancer World Congress, Palermo, Sicily, Italy, Oral Presentation. May 31, 2023.
3. **Benbrook, D. M.**, "Ovarian Cancer Chemoprevention", I-SCORE: Investigators' and Site Coordinators' Opportunity for Research Excellence, National Cancer Institute Department of Cancer Prevention, Hybrid NCI Rockville, MD and WebEx, Oral Presentation. March 31, 2023.
4. **Benbrook, D. M.**, "Overcoming Challenges of developing a new investigational drug in an academic setting", End2Cancer, Stephenson Cancer Center, Oklahoma City, Oral Presentation. December 2, 2022.
5. **Benbrook, D. M.**, "What causes cervical cancer and how can it be prevented and treated?", Celebration of International HPV Awareness Day and International Women's Day, Indian Council of Medical Research/National Institute of Cancer Prevention and Research, Virtual, Keynote/Plenary Address. March 8, 2022.
6. **Benbrook, D. M.**, "Ovarian Cancer Chemoprevention: Feasibility and Promise", Vincent Center for Reproductive Biology Virtual Seminar Series, Massachusetts General Hospital, Boston, MA, Lecture. March 2, 2021.
7. Chandra, V., Rai, R., **Benbrook, D. M.**, "Preclinical Development of SHetA2 for Endometrial Cancer Therapy", NEW BIOLOGY DRIVING RESEARCH AND TREATMENT, American Association for Cancer Research, Virtual, Oral Presentation. November 9, 2020.
8. **Benbrook, D. M.**, "Development of a cancer drug that disrupts oncogenic heat shock protein A/client protein interactions", Adam Mickiewicz University, Poznan, Poland, Lecture. May 6, 2020.
9. **Benbrook, D. M.**, "Development of a Drug to Prevent and Treat Gynecologic Cancers", Grand Rounds, Medical College of Wisconsin, Milwaukee, WI, Lecture. October 4, 2019.
10. **Benbrook, D. M.**, "Collaborations Between Clinicians and Scientists to Impact Patient Care", Annual Research Symposium, Arkansas College of Osteopathic Medicine, Fort Smith, AR,

Keynote/Plenary Address. May 16, 2019.

11. **Benbrook, D. M.**, "Development of an Oklahoma Made Drug", 2019 John C. Krantz Jr. Memorial Lectureship, University of Maryland, Keynote/Plenary Address. April 16, 2019.
12. **Benbrook, D. M.**, "Targeting mortalin in ovarian cancer chemoprevention", 2nd Annual Meeting of the International Ovarian Cancer Consortium and the Symposium on Tumor Microenvironment and Therapeutic Resistance, Stephenson Cancer Center, Oklahoma City, OK, Lecture. August 17, 2015.
13. **Benbrook, D. M.**, "Integration of autophagy and apoptosis in the tumor microenvironment and downstream of mortalin/client protein disruption", Eppley Seminar Series, University of Nebraska, Omaha, NE, Lecture. September 5, 2014.
14. **Benbrook, D. M.**, "Autophagy and immunology in ovarian cancer", MD Anderson Cancer Center/Stephenson Cancer Center (MDACC/SCC) Collaboration, Oklahoma City, OK, Lecture. August 28, 2014.
15. **Benbrook, D. M.**, "Drug-conjugated nanoparticles reveal mechanism of SHetA2 drug activity", 2nd International BAU Drug Design Congress, Istanbul, Turkey, Lecture. April 15, 2014.
16. **Benbrook, D. M.**, "How cancer cells use ER stress and autophagy to eat stroma", Annual Meeting of the International Ovarian Cancer Consortium: Tumor Microenvironment and Drug Discovery, Stephenson Cancer Center, Oklahoma City, OK, Lecture. February 10, 2014.
17. **Benbrook, D. M.**, "Development of a cancer drug: From tubes to tissues to treatments", Texas Tech University Department of Cell Biology and Biochemistry, Lubbock, TX, Lecture. September 24, 2013.
18. **Benbrook, D. M.**, "Cancer prevention", Women's Enrichment Fellowship Talk Show, Forward in Faith Ministries International, Farmers Branch, TX, Lecture. March 16, 2013.
19. **Benbrook, D. M.**, "Stress response in ovarian cancer resistance", MD Anderson Cancer Center and Stephenson Cancer Center Collaborative Retreat, MD Anderson Cancer Center, Houston, TX, Lecture. September 29, 2012.
20. **Benbrook, D. M.**, "Collaboration in drug discovery and translation to clinical trials", 14th Annual Rall Symposium for Undergraduate Research, North Central College, Naperville, IL, Lecture. May 17, 2011.
21. **Benbrook, D. M.**, "Before you can shoot, you need to know what the target is", Symposium on drug design and molecular pharmacology, University of Southern California, Los Angeles, CA, Oral Presentation. May 17, 2011.
22. **Benbrook, D. M.**, "Development of a Flex-Het drug and biomarkers for chemoprevention clinical trial", International Cancer Research Symposium 2010: Defining & Translating Science Behind Disease, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, Kerala, India, Lecture. December 10, 2010.
23. **Benbrook, D. M.**, "Development of Flex-Het drugs for prevention and treatment of cancer: From basic laboratory science to clinical trials", University of Cape Town, Cape Town, South Africa, Lecture. June 23, 2010.
24. **Benbrook, D. M.**, "Translation of biological systems driving experimental carcinogenesis and chemoprevention to clinical application", University of Louisiana Shreveport Cancer Center,

Shreveport, LA, Lecture. April 30, 2009.

25. **Benbrook, D. M.**, "Systems biology of Flex-Het drugs and cancer biomarkers in experimental models and clinical trials", Notre Dame, Notre Dame, IN, Lecture. May 13, 2008.
26. **Benbrook, D. M.**, "Signal transduction mechanisms of Flex-Het therapeutic and chemoprevention activity", University of Illinois at Chicago, Chicago, IL, Lecture. March 18, 2008.
27. **Benbrook, D. M.**, "Translating Flex-Het drug and biomarker research to clinical application", Gynecologic Oncology Grand Rounds, MD Anderson Cancer Center, Houston, TX, Lecture. November 7, 2007.
28. **Benbrook, D. M.**, "Flex-Het regulation of gene expression, angiogenesis and apoptosis", Conference on Retinoids, Federation for the American Association of Experimental Biology (FASEB), Indian Wells, CA, Lecture. 2006.
29. **Benbrook, D. M.**, "Molecular mechanisms of apoptosis and angiogenesis regulation by Flex-Het drugs", University of Maryland, Baltimore, MD, Lecture. December 11, 2006.
30. **Benbrook, D. M.**, "Angiogenesis targeting in ovarian cancer", 7th Annual International Conference on Ovarian Cancer, MD Anderson Cancer Center, Houston, TX, Lecture. November 30, 2006.
31. **Benbrook, D. M.**, "Angiogenesis biomarkers in GOG thalidomide trials", GOG Semi-Annual Meeting, Gynecologic Oncology Group (GOG), San Diego, CA, Lecture. January 21, 2006.
32. **Benbrook, D. M.**, "Mitochondria and gene expression in Flex-Het induction of apoptosis in cancer versus normal cells", Winship Cancer Center, Emory University, Atlanta, GA, Lecture. July 15, 2005.
33. **Benbrook, D. M.**, "Mechanism of differentiation of apoptosis induction in cancer cells by a retinoid receptor-independent heteroarotinoid, SHetA2", Summer Research Conference on Retinoids, Federation of the American Association of Experimental Biology (FASEB), Callaway Gardens, GA, Lecture. June 12, 2004.
34. **Benbrook, D. M.**, "Preclinical development of SHetA2 for cancer", Huntsman Cancer Center, Ovarian Cancer Research Group, Salt Lake City, UT, Lecture. October 10, 2003.
35. **Benbrook, D. M.**, "SHetA2 regulation of growth, differentiation and apoptosis in cancer cells and tumors without evidence of toxicity", National Cancer Access to Intervention and Development (RAID) Program, National Cancer Institute, Bethesda, MD, Lecture. April 1, 2003.
36. **Benbrook, D. M.**, "Molecular biology of endometrial cancer", Controversies in the Management of Gynecologic Malignancies Conference 3, Washington, DC, Lecture. December 5, 2002.
37. **Benbrook, D. M.**, "Refining retinoids with heteroatoms", Proctor & Gamble, Cincinnati, OH, Lecture. March 14, 2002.
38. **Benbrook, D. M.**, "Development of retinoids for chemoprevention", Dip. Sc. Farmaceutiche, Ferrara, Italy, Lecture. June 21, 2001.
39. **Benbrook, D. M.**, "Retinoids, apoptosis and cancer", Policlinico P. Giaccone, Palermo, Italy, Lecture. June 7, 2001.
40. **Benbrook, D. M.**, "Molecular mechanisms of retinoid drugs", Shanghai Institute of Biochemistry, Shanghai, China, Lecture. October 2000.

41. **Benbrook, D. M.**, "Molecular mechanisms of retinoids against gynecologic cancers", Special Meeting on Retinoids, Federation of the American Association of Experimental Biology (FASEB), Copper Mountain, CO, Lecture. June 2000.
42. **Benbrook, D. M.**, "Translational research to develop retinoids for gynecological cancers", Louisiana State University Department of Cellular Biology, Shreveport, LA, Lecture. September 1998.
43. **Benbrook, D. M.**, "Translational research to develop retinoids for gynecological cancers", University of Ottawa Department of Cellular and Molecular Medicine, Ottawa, Ontario, Lecture. September 1998.
44. **Benbrook, D. M.**, "Potential and molecular markers for 4HPR in chemoprevention of ovarian cancer", GOG Semi-Annual Meeting, Gynecologic Oncology Group, Toronto, Ontario, Lecture. July 1998.
45. **Benbrook, D. M.**, "Prevention and treatment of cervical cancer with synthetic retinoids", Drug Dynamic Institute, University of Texas, Austin, TX, Lecture. July 1997.

Local/Regional

1. **Benbrook, D. M.**, "Ovarian Cancer", Speaker Night, Lambda Delta Psi Sorority, Inc., Norman, OK, Oral Presentation. September 23, 2022.
2. **Benbrook, D. M.**, "Developing an anti-cancer drug from concept through clinical trial in Oklahoma", Biology and Chemistry Seminar Series, Northeastern University, Broken Arrow, OK, Lecture. October 29, 2021.
3. **Benbrook, D. M.**, "Challenges and Opportunities in Cancer Prevention Trials", Hematology Oncology Grand Rounds, University of Oklahoma Health Sciences Center, Virtual Zoom Meeting, Lecture. January 8, 2021.
4. **Benbrook, D. M.**, "Development of a cancer drug that disrupts oncogenic heat shock protein A/client protein interactions", Departmental Seminar, Stephenson School of Biomedical Engineering, Norman, Oklahoma, Lecture. April 10, 2020.
5. **Benbrook, D. M.**, "Development of a cancer drug that disrupts oncogenic heat shock protein A/client protein interactions.", Stephenson School of Biomedical Engineering (SBME) at the University of Oklahoma, Norman, OK, Lecture. April 10, 2020.
6. **Benbrook, D. M.**, "Research at the Stephenson Cancer Center", Peggy and Charlie Stephenson Family Event, Peggy and Charlie Stephenson Family, Southern Hills Country Club, Tulsa, OK, Lecture. October 16, 2019.
7. **Benbrook, D. M.**, "How we are trying to prevent & kill cancer without harming you", Gynecologic Cancers Survivors' Workshop, Stephenson Cancer Center, Oklahoma City, OK, Lecture. September 16, 2017.
8. **Benbrook, D. M.**, "Bringing an Oklahoma-made drug to clinical trial", Annual Stephenson Cancer Center Symposium, University of Oklahoma Health Sciences Center, Oklahoma City, OK, Lecture. January 27, 2017.
9. **Benbrook, D. M.**, "Identifying and validating molecular targets for development of cancer prevention and treatment drugs", OB/GYN Grand Rounds, University of Oklahoma Health

Sciences Center, Oklahoma City, OK, Lecture. September 9, 2016.

10. **Benbrook, D. M.**, OKC Chamber of Commerce Annual Breakfast, Oklahoma City, OK, Speaker and Panel Member. September 7, 2016.
11. **Benbrook, D. M.**, "An ounce of prevention costs more than a pound of cure", Hematology Oncology Grand Rounds, Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK, Lecture. August 19, 2016.
12. **Benbrook, D. M.**, "Why an ounce of prevention costs more than a pound of cure", Annual Stephenson Cancer Center Board of Advocates Meeting, Stephenson Cancer Center, Oklahoma City, OK, Lecture. August 12, 2016.
13. **Benbrook, D. M.**, "Finding and fighting the origins of cancer", Central Travel Club, Oklahoma City, OK, Lecture. April 15, 2016.
14. **Benbrook, D. M.**, "Ovarian Cancer Prevention", HOPE Ovarian Cancer Survival Group, Stephenson Cancer Center, Oklahoma City, OK, Lecture. April 4, 2016.
15. **Benbrook, D. M.**, "Finding and fighting the origins of cancer", Physiology Seminar Series, University of Oklahoma Health Sciences Center, Oklahoma City, OK, Lecture. February 25, 2016.
16. **Benbrook, D. M.**, "Ovarian cancer", National Ovarian Cancer Philanthropy Event, OU Student Organization, Lambda Delta Psi, Norman, OK, Lecture. September 17, 2015.
17. **Benbrook, D. M.**, "A journey from vitamin A to mortalin in a quest to prevent cancer", Institute for Natural Products Applications & Research Technologies (INPART) Seminar, University of Oklahoma, Norman, OK, Lecture. April 16, 2015.
18. **Benbrook, D. M.**, "Phase 0 trial of SHetA2 for ovarian cancer chemoprevention", Gynecologic Cancers Program Meeting, Stephenson Cancer Center, Oklahoma City, OK, Lecture. May 28, 2014.
19. **Benbrook, D. M.**, "Bringing our small molecule drug over the pharmaceutical wall into clinical trial", University of Oklahoma Department of Pharmaceutical Sciences, Oklahoma City, OK, Lecture. January 28, 2014.
20. **Benbrook, D. M.**, "Mechanism of SHetA2 differential effects on cancer over normal cells", Experimental Therapeutics Program Monthly Meeting, Stephenson Cancer Center, Oklahoma City, OK, Lecture. December 12, 2013.
21. **Benbrook, D. M.**, "Phase 0 trial of SHetA2", Women's Cancer Program Monthly Meeting, Stephenson Cancer Center, Oklahoma City, OK, Lecture. October 26, 2013.
22. **Benbrook, D. M.**, "Curing cancer with chemistry", Chemistry Club Meeting, University of Central Oklahoma, Edmond, OK, Lecture. March 7, 2013.
23. **Benbrook, D. M.**, "Translating mechanistic and pharmacokinetic studies into S-Het-A2 drug clinical trials", Monthly Research Seminar Series, Stephenson Cancer Center, Oklahoma City, OK, Lecture. February 1, 2013.
24. **Benbrook, D. M.**, "Leveraging cell stress response pathways in drug discovery", Tumor Microenvironment and Drug Discovery Conference, Stephenson Cancer Center, Oklahoma City, OK, Lecture. December 3, 2012.

25. **Benbrook, D. M.**, "Heat shock proteins and stress response pathways in cancer drug development", Oklahoma State University Department of Biochemistry, Stillwater, OK, Lecture. October 12, 2012.
26. **Benbrook, D. M.**, "Development of a cancer prevention pill", Ovarian Cancer Support Group, Bartlesville, OK, Lecture. October 22, 2011.
27. **Benbrook, D. M.**, "How to know which targets to hit in the fight against cancer", Departments of Biochemistry & Molecular Biology and Cell Biology Seminar Series, University of Oklahoma Health Sciences Center, Oklahoma City, OK, Lecture. June 15, 2011.
28. **Benbrook, D. M.**, "Progress report on development of SHetA2 for chemoprevention", HOPE Ovarian Cancer Survivor Group, University of Oklahoma Health Sciences Center, Oklahoma City, OK, Lecture. April 3, 2010.
29. **Benbrook, D. M.**, "Preclinical development of SHetA2", Oklahoma State University College of Veterinary Sciences, Stillwater, OK, Oral Presentation. February 10, 2010.
30. **Benbrook, D. M.**, "Preclinical Development of SHetA2", Oklahoma State University, College of Veterinary Sciences, Stillwater, OK, Lecture. February 4, 2010.
31. **Benbrook, D. M.**, "Systems biology and translation of an organotypic model of carcinogenesis and chemoprevention", University of Oklahoma Department of Physiology, Oklahoma City, OK, Lecture. September 11, 2008.
32. **Benbrook, D. M.**, "Translating Flex-Het drug and biomarker research to clinical application", College of Pharmacy Research Seminar, University of Oklahoma Health Sciences Center, Oklahoma City, OK, Lecture. November 8, 2007.
33. **Benbrook, D. M.**, "Reversal of abnormal differentiation in cancer and polycystic kidney disease by Flex-Hets", Pathology Grand Rounds, University of Oklahoma Health Sciences Center, Oklahoma City, OK, Lecture. October 1, 2007.
34. **Benbrook, D. M.**, "Developing drugs and biomarkers for cancer", Biochemistry and Cell Biology Seminar Series, University of Oklahoma Health Sciences Center, Oklahoma City, OK, Oral Presentation. May 10, 2006.
35. **Benbrook, D. M.**, "Glycoproteins in cervical cancer metastases", OU Cancer Cell Biology Program, University of Oklahoma Health Sciences Center, Oklahoma City, OK, Lecture. November 8, 2005.
36. **Benbrook, D. M.**, "How to make a chemical into a drug", Chemistry Club, Southwestern Oklahoma State University, Weatherford, OK, Lecture. March 10, 2005.
37. **Benbrook, D. M.**, "Flex-Hets", Meet the Scientist, i2E, Oklahoma City, OK, Lecture. January 26, 2005.
38. **Benbrook, D. M.**, "Development of drugs that target mitochondria", Oklahoma State University Department of Microbiology, Stillwater, OK, Lecture. January 10, 2005.
39. **Benbrook, D. M.**, "Preclinical development of Flex-Hets", Section of Endocrinology Grand Rounds, University of Oklahoma Department of Medicine, Oklahoma City, OK, Lecture. December 16, 2004.

40. **Benbrook, D. M.**, "Preclinical development of SHetA2 for cancer", Department of Medicine Grand Rounds, University of Oklahoma Health, Oklahoma City, OK, Lecture. August 23, 2004.
41. **Benbrook, D. M.**, "How to get an NCI grant", Grant Writing Workshop, OU Cancer Center, Oklahoma City, OK, Lecture. September 5, 2003.
42. **Benbrook, D. M.**, "Development of heteroarotinoids for chemoprevention", Encore Site Visit, Free Radical Biology Section, Oklahoma Medical Research Foundation (OMRF), Oklahoma City, OK, Lecture. May 19, 2003.
43. **Benbrook, D. M.**, "Translational research and the Dawn Hope Tissue Bank", Aventis Site Visit, University of Oklahoma, Section of Gynecologic Oncology, Department of Obstetrics and Gynecology, Oklahoma City, OK, Lecture. May 12, 2003.
44. **Benbrook, D. M.**, "Development of chemoprevention drugs that regulate growth, apoptosis and differentiation in cancer cells without toxicity", Breast Cancer Program of the OU Cancer Center Meeting, University of Oklahoma Health Sciences Center, Oklahoma City, OK, Lecture. May 6, 2003.
45. **Benbrook, D. M.**, "Carcinogenesis and chemoprevention of gynecologic cancers", University of Oklahoma Department of Biochemistry and Molecular Biology, Oklahoma City, OK, Lecture. April 30, 2003.
46. **Benbrook, D. M.**, "Understanding cancer and developing new prevention and treatment strategies", Women's Health Center Research Meeting, University of Oklahoma Health Sciences Center, Oklahoma City, OK, Lecture. February 21, 2003.
47. **Benbrook, D. M.**, "Biomarkers, histology & stem cells in endometrial cycling & cancer", Gynecologic Oncology Program, OU Cancer Center, Oklahoma City, OK, Lecture. February 19, 2003.
48. **Benbrook, D. M.**, "Organotypic models of carcinogenesis", Cancer Group, Oklahoma Medical Research Foundation, Oklahoma City, OK, Lecture. December 13, 2002.
49. **Benbrook, D. M.**, "Tumor suppressor genes and DNA tumor viruses", Annual Spring Meeting, Texas Section of the American Association for Clinical Chemistry, Norman, OK, Lecture. April 2001.
50. **Benbrook, D. M.**, "Retinoids, not just for acne anymore", Oklahoma Medical Research Foundation, Oklahoma City, OK, Lecture. September 2000.
51. **Benbrook, D. M.**, "Molecular advances in cancer therapy", Academy of Medicine, Oklahoma City, OK, Lecture. March 2000.
52. **Benbrook, D. M.**, "Molecular biological techniques", OB/GYN Grand Rounds, University of Oklahoma Department of OB/GYN, Oklahoma City, OK, Lecture. February 2000.
53. **Benbrook, D. M.**, "Organotypic culture models of gynecological cancer and disease", OB/GYN Grand Rounds, University of Oklahoma Department of OB/GYN, Oklahoma City, OK, Lecture. March 1999.
54. **Benbrook, D. M.**, "Anti-AP1 activity of retinoids: Correlation with growth inhibition and radiosensitization", Steroid Hormone Receptor Group, Oklahoma City, OK, Lecture. February 1999.

55. **Benbrook, D. M.**, "Translational research to develop retinoids for gynecological cancers", Oklahoma Medical Research Foundation, Oklahoma City, OK, Lecture. October 1998.
56. **Benbrook, D. M.**, "Translational research to develop retinoids for gynecological cancers", University of Oklahoma Department of Biochemistry and Molecular Biology, Oklahoma City, OK, Lecture. September 1998.
57. **Benbrook, D. M.**, "The food you eat can change you", The Science Forum, Oklahoma Medical Research Foundation, Oklahoma City, OK, Lecture. November 1997.
58. **Benbrook, D. M.**, "Cancer genetics", Women's Health Symposium, Oklahoma City, OK, Lecture. October 1997.
59. **Benbrook, D. M.**, "Oncogenes and tumor suppressor genes", Cancer Conference, Integris Baptist Medical Center, Oklahoma City, OK, Lecture. June 1997.
60. **Benbrook, D. M.**, "Oncogenes and tumor suppressor genes", University of Oklahoma OB/GYN Grand Rounds, Oklahoma City, OK, Lecture. May 1997.
61. **Benbrook, D. M.**, "Translational research: Studying the relationship between nutrition and cancer", University of Oklahoma OB/GYN Grand Rounds, Oklahoma City, OK, Lecture. November 1995.
62. **Benbrook, D. M.**, "Drug discovery and design", Premed Club, University of Oklahoma Undergraduate School, Norman, OK, Lecture. 1994.
63. **Benbrook, D. M.**, "Radiation and retinoid effects on cervical cancer", University of Oklahoma Department of Pathology, Oklahoma City, OK, Lecture. 1994.
64. **Benbrook, D. M.**, "Effects of retinoids on organotypically grown tumors", Oklahoma State University Department of Biochemistry and Molecular Biology, Stillwater, OK, Lecture. 1993.
65. **Benbrook, D. M.**, "Retinoid effects on organotypically grown cervical tumor tissue", University of Oklahoma Department of Anatomy, Oklahoma City, OK, Lecture. 1993.
66. **Benbrook, D. M.**, "The influence of diet and retinoic acid on cancer", Science Forum, Combined NIH Training Grants Meeting, Oklahoma Medical Research Foundation, Lecture. 1993.
67. **Benbrook, D. M.**, "Interaction of CREB and Jun transcription factors", Oklahoma State University Department of Microbiology, Stillwater, OK, Lecture. September 1991.
68. **Benbrook, D. M.**, "Interaction of CREB and Jun transcription factors", University of Oklahoma Department of Biochemistry and Molecular Biology, Oklahoma City, OK, Lecture. September 1991.

Accepted

* indicates mentee

National/International

1. Mortan, L.*, **Benbrook, D. M.**, "Mechanisms of Drugs in Ovarian Cancer and Prevention of Invasion and Metastasis", AACR Annual Meeting, American Association for Cancer Research, San Diego, CA, Poster. April 5, 2024.

2. Garland, J. *, Hussain, S. *, **Benbrook, D. M.**, "Modulation of HR_HP V Viral Protein E7 by SHetA2 in Cervical Cancer", AACR Annual Meeting, American Association for Cancer Research, San Diego, CA, Poster. April 5, 2024.
3. Bohn, J. *, Mortan, L. *, **Benbrook, D. M.**, "Elevated integrin subunit $\beta 3$ in recurrent compared to newly-diagnosed ovarian cancer patient ascites is a promising new target to prevent recurrence", SGO Annual Meeting, Society of Gynecologic Oncology, San Diego, CA, Poster. March 16, 2024.
4. Duinink, G., Mortan, L., **Benbrook, D. M.**, "Preclinical investigation of a novel investigational new drug, SHetA2, for treatment of vulvar cancer", SGO Annual Meeting, Society of Gynecologic Oncology, San Diego, CA, Poster. March 16, 2024.
5. Miller, B., Imig, J., Schupbach, P., Woo, S., **Benbrook, D. M.**, Sorokin, A., "SHetA2 Interference with p66Shc signaling prevents renal vascular dysfunction in rat model of hypertension-induced nephropathy", 22nd International Vascular Biology Meeting (October 13-17, 2022), International Vascular Biology Organization, San Francisco Bay Area, Poster. October 2022.
6. Borden, L. E. *, Javaidan, P. *, Kennedy, A. *, Xu, C., Sjoelund, V., **Benbrook, D. M.**, "Identification of Molecular Targets and Pathways for Improving Endometrial Cancer Racial Disparities", IGCS Annual Global Meeting 2022, International Gynecologic Cancer Society, New York, NY, USA, Poster. September 29, 2022.
7. **Benbrook, D. M.**, ra*, Chandra, V. *, Kennedy, A. *, Moore, K., "Preclinical Synergistic Mechanisms of Investigational New Drug SHetA2", IGCS Annual Global Meeting 2022, International Gynecologic Cancer Society, New York, NY, USA, Poster. September 29, 2022.
8. Isingizwe, Z. *, **Benbrook, D. M.**, "Thrombocytosis Contributes to Increased Ex-Vivo Agonist-Induced Platelet Aggregation in Ovarian Cancer Patients", IGCS Annual Global Meeting 2022, International Gynecologic Cancer Society, New York, NY, USA, Poster. September 29, 2022.
9. Isingizwe, Z. R. *, **Benbrook, D. M.**, "Implication of integrins in eptifibatide interference with platelet stimulation of ovarian cancer", Experimental Biology 2022, Experimental Biology, Philadelphia, Pennsylvania, Poster. April 3, 2022.
10. Isingizwe, Z. *, **Benbrook, D. M.**, "Potential of Pharmaceutical Intervention In Platelets And Cancer Positive Feedback Loop", Virtual 2021 ASPET Annual Meeting, American Society of Pharmacology and Experimental Therapeutics, Virtual, Poster. April 2021.
11. Rai, R. *, Chandra, V., **Benbrook, D. M.**, "The mechanism of the drug, SHetA2, in cervical cancer cells involves growth inhibition, mitochondria damage and release of AIF to cause caspase-independent cell death", American Association of Cancer Research Annual Meeting, American Association of Cancer Research, Virtual, Poster. April 2021.
12. Isingizwe, Z. *, **Benbrook, D. M.**, "Potential of Pharmaceutical Intervention in Platelets and Cancer Positive Feedback Loop", Experimental Biology 2021, Virtual, Poster. April 27, 2021.
13. **Benbrook, D. M.**, Kennedy, A. *, "SHetA2 Increases the Activity of Palbociclib in Cervical Cancer in vitro and in vivo", Experimental Biology 2021, Virtual, Poster. April 27, 2021.
14. Chandra, V. *, Rai, R. *, **Benbrook, D. M.**, "Preclinical Development of SHetA2 for Endometrial Cancer Therapy", Endometrial Cancer: New Biology Driving Research and Treatment, American Association for Cancer Research, Virtual, Oral Presentation. November 2020.

15. Vaughn, K., Gillen, J., Lausen, J., Parker, M., Bruns, M., **Benbrook, D. M.**, Hannafon, B. N., "A Novel Drug Blocks Exosome Secretion and Promotes Endo-Lysosomal Degradation of Forming Exosomes in Ovarian Cancer Cells.", Pathobiology for Investigators, Students, and Academicians (PISA), American Society of Investigative Pathology, Virtual, Poster. November 2020.
16. Chandra, V.* , Rai, R.* , Hatipoglu, M. K., Garcia-Contreras, L., **Benbrook, D. M.**, "Chemoprevention and regression of estrogen-induced atypical endometrial hyperplasia by oral SHetA2 in a rat model", American Association for Cancer Research Virtual Special Conference: Endometrial Cancer: New Biology Driving Research and Treatment, American Association of Cancer Research, Virtual, Poster. November 2020.
17. Chandra, V., Lightfoot, S., Hatipoglu, M. K., Garcia-Contreras, L., **Benbrook, D. M.**, "Chemoprevention and Regression of Estrogen-Induced Atypical Endometrial Hyperplasia by oral SHetA2 in a Rat Model", Endometrial Cancer: New Biology Driving Research and Treatment, American Association for Cancer Research, Virtual, Poster. November 2020.
18. Kennedy, A., Rai, R.* , Isingizwe, Z.* , Lightfoot, S., **Benbrook, D. M.***, "SHetA2 Increases the Activity of Palbociclib in Cervical Cancer In Vitro and In Vivo", Pathology for Investigators, Students, & Academics Conference, American Society of Investigational Pathology, Virtual, Poster. November 2020.
19. Rai, R.* , Chandra, V., **Benbrook, D. M.**, "SHetA2-mediated mitochondrial dysfunction induces caspase-independent cell death in cervical cancer cell.", 11th World Congress on Targeting Mitochondria 2020, World Mitochondria Association, Virtual, Poster. October 2020.
20. **Benbrook, D. M.**, "Development of a model of dihomo-gamma-linolenic acid interference with platelet promotion of ovarian cancer", AACR Virtual Meeting II, American Association for Cancer Research, Poster. June 2020.
21. Isingizwe, Z.* , **Benbrook, D. M.**, "Development Of A Model Of DihomoGamma-Linolenic Acid Interference With Platelet Promotion Of Ovarian Cancer", AACR 2020 Virtual Meeting, American Association for Cancer Research, Virtual, Poster. June 2020.
22. Chandra, V.* , Rai, R.* , Hussain, S., Garcia-Contreras, L., Hatipoglu, M., **Benbrook, D. M.**, "Development of a rat model of atypical endometrial hyperplasia and a vaginal suppository formulation of SHetA2 for chemoprevention studies", AACR Virtual Meeting II, American Association for Cancer Research, Poster. June 2020.
23. Kennedy, A.* , Rai, R.* , **Benbrook, D. M.**, "SHetA2 increases the activity of palbociclib in cervical cancer in vitro and in vivo", AACR Virtual Meeting II, American Association for Cancer Research, Poster. June 2020.
24. Vaughn, K., Hannafon, B. N.* , **Benbrook, D. M.**, "A novel drug inhibits exosome content loading and secretion in ovarian cancer cells", Experimental Biology 2020, American Society for Investigative Pathology, San Diego, CA, Poster. April 5, 2020.
25. Essel, K. G.* , **Benbrook, D. M.**, Rai, R.* , Chandra, V.* , "Sulforaphane as a Potential Therapeutic for Endometrial Cancer", Annual Meeting on Women's Cancer, Society of Gynecologic Oncology, Toronto, Canada, Poster. March 28, 2020.
26. **Essel, K. G.* , Benbrook, D. M.**, Rai, R.* , Chandra, V., "Sulforaphane as a potential therapeutic for endometrial cancer.", Western Association of Gynecologic Oncologists 2019 Annual Meeting, Huntington Beach, CA, Poster. June 2019.

27. **Benbrook, D. M.**, "Serum vitamin D levels and treatment-related morbidity in ovarian, primary peritoneal, and Fallopian tube cancer: A prospective study", Society of Gynecologic Oncologists Annual Meeting, SGO, Honolulu, HI, Abstract. March 19, 2019.
28. Carlson, B. W., Jones, K. R., Carlson, J. R., Craft, M., **Benbrook, D. M.**, Coleman-Jackson, R., Hershey, L. A., "Cerebral Oxigenation and Sleep Disordered Breathing in Adults and Mild Cognetive Impairment", 2018 Annual Scientific Meeting of the Gerontological Society of America, Gerontological Society of America, Boston, MA, Abstract. November 2018.
29. Ramraj, S. K., **Benbrook, D. M.**, "Synergistic combination of mortalin-targeting and p53 reactivator drugs for ovarian cancer", 12th Biennial Ovarian Cancer Research Symposium, University of Washington, Seattle, WA, Abstract. September 15, 2018.
30. Docker, L. E., Ward, J. M., Vesely, S. K., Thavathiru, E., **Benbrook, D. M.**, Moore, K., Holman, L. L., "Vitamin D, Leptin, Vitamin D Receptor (VDR) Single Nucleotide Polymorphism (SNP) and Treatment-Related Morbidity in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer", Western Association for Gynecologic Oncologists Annual Meeting, WAGO, Park City, UT, Abstract. June 2018.
31. Watts, F. M., Berlin, K. D., **Benbrook, D. M.**, Bunce, R. A., 26th Meeting of the International Society of Heterocyclic Chemists - ISHC, International Society of Heterocyclic Chemists - ISHC, Regensburg, Germany, Oral Presentation. September 2017.
32. Chandra, V., Long, A., Masamha, C. P., **Benbrook, D. M.**, "Mitophagy induction and interference with cancer-specific apoptosis in SHetA2-treated cells", 108th American Associaiton for Cancer Research (AACR) Annual Meeting, American Association for Cancer Research (AACR), Washington, DC, Oral Presentation. April 2017.
33. Thavathiru, E., Chandra, V., Rai, R., **Benbrook, D. M.**, "Mortalin precursor as potential marker for chemopreventionwith SHetA2", 108th American Associaiton for Cancer Research (AACR) Annual Meeting, American Association for Cancer Research (AACR), Washington, DC, Oral Presentation. April 2017.
34. Ramraj, S. K., Pelikan, R., Chandra, V., **Benbrook, D. M.**, "SHetA2 targets mortalin-p53 interaction in differential induction of apoptosis in ovarian cancer over normal cells", 108th American Associaiton for Cancer Research (AACR) Annual Meeting, American Association for Cancer Research (AACR), Washington, DC, Oral Presentation. April 2017.
35. Watts, F. M., Berlin, K. D., **Benbrook, D. M.**, Bunce, R. A., "Synthesis of Oxygen Analogues of a Promising Anticancer Drug", The 62nd Annual Oklahoma Pentasectional Meeting of the American Chemical Society, American Chemical Society, Cameron University, Lawton, OK, Oral Presentation. March 25, 2017.
36. Razaq, W., Tanaka, T., Carlson, B., Wenger, M., Friedman, J., **Benbrook, D. M.**, Craft, M., "Diagnosing cognitive impairment ("Chemo brain") in breast cancer survivors", San Antonio Breast Cancer Symposium, Cancer Therapy & Research Center and American Association for Cancer Research (CTRC-AACR), San Antonio, TX, Abstract. December 2016.
37. Hatipoglu, M. K., Mahjabeen, S., **Benbrook, D. M.**, Garcia-Contreras, L., "Development and Validation of Reverse Phase HPLC Method for SHetA2 in Gynecological Tissue for Treatment of Cervical Dysplasia", American Association for Pharmaceutical Scientists 2016 Meeting, American Association for Pharmaceutical Scientists (AAPS), Denver, CO, Abstract. November 2016.
38. Mahjabeen, S., Chandra, V., Hatipoglu, M. K., **Benbrook, D. M.**, Garcia-Contreras, L.,

- "Formulation of SHetA2 in a Vaginal Suppository for Chemoprevention Against Cervical Dysplasia", American Association for Pharmaceutical Scientists 2016 Meeting, American Association for Pharmaceutical Scientists (AAPS), Denver, CO, Abstract. November 2016.
39. Pouland, T., Bunce, R., Berlin, K. D., **Benbrook, D. M.**, "Structure Activity Relationship of Analogs of a Cancer-Selective Small Molecule, OK-1", International Ovarian Cancer Research Symposium, Stephenson Cancer Center, Oklahoma City, OK, Abstract. August 2016.
 40. Carlson, B. W., Wenger, M. J., Craft, M. A., Crudden, G., DeStefano, L., Deardeuff, K., Curran, K. A., Daji, S., Byerly, R., Mooney, E., **Benbrook, D. M.**, Carlson, J. R., Hershey, L. A., "Cerebral Oxygenation during Afternoon Naps and Memory Consolidation in Older Adults with Mild Cognitive Impairment", 2016 Annual Scientific Meeting of the Associated Professional Sleep Societies (APSS), Associated Professional Sleep Societies (APSS), Denver, CO, Podium Presentation. June 2016.
 41. Craft, M. A., Carlson, B. W., **Benbrook, D. M.**, Friedman, J. R., Razaq, W., Wenger, M. J., Curran, K. A., Crudden, G. M., "Descriptive study of cognitive disturbances in older breast cancer survivors", 2016 Midwest Nursing Research Society Conference, Midwest Nursing Research Society Foundation, Milwaukee, WI, Abstract. March 2016.
 42. Craft, M., Carlson, B., Wenger, M., Friedman, J., **Benbrook, D. M.**, Razaq, W., Carlson, J., Curran, K. A., Mooney, E., Byerly, R., Daji, S., Crudden, G., "Descriptive study of perceived persistent declines in memory in older breast cancer survivors", International Ovarian Cancer Research Symposium, Stephenson Cancer Center, Oklahoma City, OK, Abstract. January 2016.
 43. Craft, M., Wenger, M., Carlson, J., Razaq, W., **Benbrook, D. M.**, Curran, K. A., Crudden, G., Carlson, B., "Descriptive study of cognitive disturbances in older adult breast cancer survivors", Sigma Theta Tau 43rd Biennial Conference, Sigma Theta Tau International Honor Society of Nursing, Las Vegas, NV, Podium Presentation. November 2015.
 44. Ibrahim, M., **Benbrook, D. M.**, Garcia-Contreras, L., "Optimization of Inhalable SHetA2 Microparticles for Tuberculosis Treatment", 2015 American Association of Pharmaceutical Sciences (AAPS) Annual Meeting & Exposition, American Association of Pharmaceutical Sciences (AAPS), Orlando, FL, Abstract. October 2015.
 45. Sharma, A., Thavathiru, E., **Benbrook, D. M.**, Woo, S., "Physiologically-Based Pharmacokinetic Models for SHetA2 in Orthotopic Murine Model of Ovarian Cancer (Awarded 2016 AAiPS Research Award in PPDM section)", 2015 American Association of Pharmaceutical Sciences (AAPS) Annual Meeting & Exposition, American Association of Pharmaceutical Sciences (AAPS), Orlando, FL, Abstract. October 2015.
 46. Ibrahim, M., **Benbrook, D. M.**, Garcia-Contreras, L., "Development of a Powder-Filled Capsule Formulation for SHetA2, a Novel Anticancer Drug", 2014 American Association of Pharmaceutical Sciences (AAPS) Annual Meeting & Exposition, American Association of Pharmaceutical Sciences (AAPS), San Diego, CA, Poster. November 2014.
 47. Jackson, C. C., **Benbrook, D. M.**, Farris, R., Butler, J. L., Ding, K., Smith, K. M., "Factors Affecting Differential Incidence of Adenocarcinoma of the Cervix", Society of Colposcopy and Cervical Pathology Biennial Meeting, Society of Colposcopy and Cervical Pathology, Scottsdale, AZ, Oral Presentation. April 2014.
 48. Sharma, A., **Benbrook, D. M.**, Woo, S., "First-in-Human Dose Determination for a Phase 0 Study of SHetA2, a Novel Anticancer Agent Using the Interspecies Scaling", 2013 AAPS Annual Meeting and Exposition, American Association of Pharmaceutical Scientists (AAPS), San Antonio, TX, Abstract. 2013.

49. Ibrahim, M., **Benbrook, D. M.**, Garcia-Contreras, L., "Formulation and Characterization of SHetA2 Capsules for Phase 0 Clinical Trials", 2013 AAPS Annual Meeting and Exposition, American Association of Pharmaceutical Scientists (AAPS), San Antonio, TX, Abstract. 2013.
50. Lightfoot, S., Zhao, D., Thavathiru, E., **Benbrook, D. M.**, "SHetA2 decreases mitoses and growth, and alters pathology of MNU-induced rat mammary tumors", 104th AACR Annual Meeting, American Association for Cancer Research, Washington, DC, Abstract. April 2013.
51. Zhakharov, A. D., Kabirov, K. K., Nickolic, D., Chen, L., Mankovskaya, I., van Breemen, R. B., **Benbrook, D. M.**, Kapetanovic, I. M., Lyubimov, A. V., "Analysis of a new chemo preventative agent SHetA2 and its metabolites in Beagle dog liver", 103rd AACR Annual Meeting, American Association for Cancer Research (AACR), Chicago, IL, Oral Presentation. 2012.
52. **Benbrook, D. M.**, Bishop, E., Nugent, E., Lightfoot, S., Elangovan, T., Long, A., Zhao, D., "Modeling effects of diabetes and obesity co-morbidities in endometrial cancer development and progression", 2012 Metabolism, Diet & Disease Meeting, BMC, Washington, DC, Abstract. May 2012.
53. Hurteau, J., McGuire, W., Darcy, K., Pearl, M. L., Ivanov, L., Tewari, K., Mannel, R. S., Zanotti, K. M., **Benbrook, D. M.**, "A Randomized Phase III Trial of Tamoxifen versus Thalidomide in Women with Biochemical-Recurrent Only Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma with an Evaluation of Serum Vascular Endothelial Growth Factor: A Gynecologic Oncology Group Study", 41st Annual SGO Meeting, Society of Gynecologic Oncology (SGO), San Francisco, CA, Abstract. March 2010.
54. Moxley, K. M., **Benbrook, D. M.**, Moore, K., Zuna, R. E., "The role of single-nucleotide polymorphisms in the ERCC1 gene in predicting the sensitivity of epithelial ovarian carcinoma to platinum-based chemotherapy and overall patient survival", 41st Annual SGO Meeting, Society of Gynecologic Oncology (SGO), San Francisco, CA, Abstract. March 2010.
55. Moxley, K. M., Dozmorov, I., Lightfoot, S., **Benbrook, D. M.**, "Dynamics of DMBA-induced transformation and gene expression in endometrial organotypic cultures", 100th AACR Annual Meeting, American Association for Cancer Research (AACR), Denver, CO, Abstract. April 2009.
56. Masamha, P., **Benbrook, D. M.**, "p21 prevents aberrant cyclin E2 expression from interfering with G1 arrest caused by SHetA2-induced cyclin D1 loss in ovarian cancer cell lines", 100th AACR Annual Meeting, American Association for Cancer Research (AACR), Denver, CO, Abstract. April 2009.
57. Chenedza, S., **Benbrook, D. M.**, "Sensitization of ovarian cancer cell lines to death receptor ligands by the flexible heteroarotinoid (Flex-Het), SHetA2", 100th AACR Annual Meeting, American Association for Cancer Research (AACR), Denver, CO, Abstract. April 2009.
58. McDaniel, S., **Benbrook, D. M.**, "Deciphering Structural Features Important for Heteroarotinoid Growth Inhibition Activity in Normal and Cancerous Ovarian Cells", 2008 Historically Black Colleges and Universities Undergraduate Program (HBCU-UP) National Conference, American Association for the Advancement of Science (AAAS), Atlanta, GA, Poster. October 2008.
59. Chenedza, S., **Benbrook, D. M.**, "Inhibition of NF- κ B Activity By SHetA2 Overcomes Tumor Necrosis Factor-Alpha Resistance in Ovarian Cancer Cells", Third Annual NIH National Graduate Student Research Festival, National Institute of Health (NIH), Bethesda, MD, Poster. September 2008.
60. Chenedza, S., **Benbrook, D. M.**, "Effects of SHetA2 on I κ B α and NF- κ B in Ovarian Cancer",

NFkappaB Keystone Symposia, Keystone Symposia on Molecular and Cellular Biology, Banff, Alberta, Canada, Abstract. December 2007.

61. Ju, T., Lenneau, G. S., Gautam, T., Wang, Y., Xia, B., Stowell, S. R., Willard, M. T., **Benbrook, D. M.**, Hannigan, M. H., Cummings, R. D., "Human Tumor Antigens Arising from Mutations in Cosmc", 98th Annual American Association for Cancer Research Meeting, American Association for Cancer Research (AACR), Los Angeles, CA, Abstract. 2007.
62. Myers, T., **Benbrook, D. M.**, "Thymidine phosphorylase is a molecular target of SHetA2 antiangiogenesis activit", 98th Annual American Association for Cancer Research Meeting, American Association for Cancer Research (AACR), Los Angeles, CA, Abstract. 2007.
63. Liu, T., Masamha, C. P., Chenedza, S., **Benbrook, D. M.**, "Regulation of apoptosis, cell cycle progression and differentiation by SHetA2 in renal cancer cells is associated with alterations in Bcl-2, Cyclin D1 and E-Cadherin proteins", AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, AACR, NCI, EORTC, San Francisco, CA, Abstract. October 2007.
64. Chenedza, S., Liu, T., **Benbrook, D. M.**, "SHetA2 Effects on Thymidine Phosphorylase and NF- κ B activity", AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, AACR, NCI, EORTC, San Francisco, CA, Abstract. October 2007.
65. Masamha, C. P., Liu, T., **Benbrook, D. M.**, "SHetA2 Targets cyclin D1 for proteasomal degradation through a GSK3 β -independent mechanism leading to G1 cell cycle arrest", AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, AACR, NCI, EORTC, San Francisco, CA, Abstract. October 2007.
66. Myers, T., **Benbrook, D. M.**, "Thymidine phosphorylase is a molecular target of SHetA2 antiangiogenesis activit", 2nd Annual Angiogenesis Research & Therapeutics, Angiogenesis Research & Therapeutics, Philadelphia, PA, Oral Presentation. February 2007.
67. Lightfoot, S., Chenedza, S., Naylor, M., **Benbrook, D. M.**, "Inhibition of thymidine phosphorylase (TP), thrombospondin 4 (TSP4) and angiogenesis by flexible heteroarotinoids (Flex-Het), SHetA2", 97th AACR Annual Meeting, American Association for Cancer Research (AACR), Washington, DC, Abstract. 2006.
68. **Benbrook, D. M.**, Lightfoot, S., Ranger-Moore, J., "Karyometric analysis of inhibition of DMBA carcinogenesis by flexible heteroarotinoids (Flex-Het) SHetA2 in an endometrial organotypic model", 97th AACR Annual Meeting, American Association for Cancer Research (AACR), Washington, DC, Abstract. 2006.
69. Dearnley, D. D., Hannafon, B., Ding, W. Q., Lind, S., Cook, S., **Benbrook, D. M.**, "Regulation of Gene Expression and Vascular Capillary Formation by a Novel Anticancer Compound, SHetA2", 96th AACR Annual Meeting, American Association for Cancer Research (AACR), Anaheim, CA, Abstract. 2005.
70. Kelly, W. J., Gill, L. W., Hannafon, B., **Benbrook, D. M.**, "SHetA2 induces mitochondrial swelling, superoxide formation and apoptosis in human cancer cells", American Chemical Society Annual Meeting, American Chemical Society, Abstract. 2005.
71. Hannafon, B. N., Dearnley, D. D., **Benbrook, D. M.**, "Gene Expression of the Angiogenic Factor Thrombospondin 4 can be inhibited by SHetA2 in Ovarian Cancer Cells", Fifth International Conference on Ovarian Cancer, MD Anderson Cancer Center, Houston, Texas. December 2004.
72. Dearnley, D. D., Hannafon, B. N., **Benbrook, D. M.**, "A Novel Chemotherapeutic Agent, SHetA2,

Inhibits Expression of Platelet Derived Endothelial Cell Growth Factor (PD-ECGF) in Ovarian Cancer and Angiogenesis In Vitro", Fifth International Conference on Ovarian Cancer, MD Anderson Cancer Center, Houston, Texas, Oral Presentation. December 2004.

73. Lightfoot, S. L., **Benbrook, D. M.**, "Effects of steroids and retinoids in an organotypic model of endometrial carcinogenesis", 95th Annual American Association of Cancer Research Meeting, American Association of Cancer Research, Orlando, FL, Abstract. 2004.
74. **Benbrook, D. M.**, Lightfoot, S. L., "Reactive Oxygen Species (ROS) are involved in the mechanism of SHetA2-induced apoptosis but not differentiation in ovarian cancer organotypic cultures", 95th Annual American Association of Cancer Research Meeting, American Association of Cancer Research, Orlando, FL, Abstract. 2004.
75. Liu, Z., Covey, J., **Benbrook, D. M.**, Chan, K., "Pharmacokinetic and Metabolism Study of SHetA2 (NSC 683864), an dNew Heteroarotinoid Antitumor Agent in the Reat", American Association for Pharmaceutical Scientists 2004 Meeting, American Association for Pharmaceutical Scientists (AAPS), Baltimore, MD, Oral Presentation. November 2004.
76. **Benbrook, D. M.**, "Both receptor-active and receptor-independent retinoids regulate of growth, differentiation and apoptosis without toxicity in an ovarian cancer xenograft model", 94th Annual American Association of Cancer Research, American Association of Cancer Research (AACR), Washington, DC, Abstract. 2003.
77. Arendse, C. E., Brennan, M., **Benbrook, D. M.**, Hendricks, D. T., "Characterisation of heteroarotinoids as potential agents in the treatment of oesophageal cancer", IUBMB conference, Internation Union of Biochemistry and Molecular Biology (IUBMB), Toronto, Ontario, Canada, Oral Presentation. July 2003.
78. **Benbrook, D. M.**, Kamelle, S., Joyce, K., Guruswamy, S., Tillmanns, T., Gould, N., Rutledge, T., "Evaluation of Human Papillomavirus and p53 transcriptional activation in the mechanism of 9-cisretinoic acid radiosensitization of squamous gynecologic cancer cells", 93rd Annual American Associaiton for Cancer Research Meeting, American Association for Cancer Research, San Francisco, CA, Abstract. 2002.
79. Guruswamy, S., **Benbrook, D. M.**, "The roles of p53, retinoid receptors, and DNA damager response genes in the mechanism of retinoid sensitization of OVCAR-3 to cisplatin", 93rd Annual American Associaiton for Cancer Research Meeting, American Association for Cancer Research, San Francisco, CA, Abstract. 2002.
80. DuPont, N., **Benbrook, D. M.**, "The Clinical Significance of MUC-1 Expression in Ovarian Cancer", American College of Obstetricians and Gynecologists (ACOG) District VII Meeting, American College of Obstetricians and Gynecologists (ACOG), New Orleans, LA, Oral Presentation. October 11, 2002.
81. **Benbrook, D. M.**, "Relations of differentiation, apoptosis and MUC1 in retinoid growth inhibition of ovarian cancer", Summer Research Conference, Federation of the American Association of Experimental Biology (FASEB), Tucson, AZ, Lecture. June 24, 2002.
82. DuPont, N., **Benbrook, D. M.**, "MUC-1 as an indicator of cellular differentiation in ovarain cancer", American College of Obstetricians and Gynecologists (ACOG) District VII Meeting, American College of Obstetricians and Gynecologists (ACOG), Tulsa, OK, Oral Presentation. September 25, 2001.
83. Berlin, K. D., Brown, C. W., **Benbrook, D. M.**, "Modified heteroarotinoids-anticancer activity", American Chemical Society Annual Meeting, American Chemical Society, Abstract. April 1, 2001.

84. **Benbrook, D. M.**, Sienko, A., "A hormonally responsive organotypic model of cycling endometrium", 92nd AACR Annual Meeting, American Association of Cancer Research, New Orleans, LA, Abstract. March 2001.
85. Guruswamy, S., Berlin, K. D., **Benbrook, D. M.**, "Chemosensitization of two ovarian carcinoma cell lines to cisplatin by heteroarotinoids", 92nd AACR Annual Meeting, American Association of Cancer Research, New Orleans, LA, Abstract. March 2001.
86. Ju, K. H., **Benbrook, D. M.**, Berlin, K. D., Hong, W. K., Lotan, R., "Induction of apoptosis in head and neck squamous cell carcinoma cell (HNSCC) lines by selected heteroarotinoids", 92nd AACR Annual Meeting, American Association of Cancer Research, New Orleans, LA, Abstract. March 2001.
87. Kamelle, S. A., Sienko, A., **Benbrook, D. M.**, "An in vitro model of normal endometrium using organotypic culture: The first step in producing a model to study endometrial carcinogenesis", Society of Gynecologic Oncology Annual Meeting 2000, Society of Gynecologic Oncology (SGO), Oral Presentation. 2000.
88. Spencer, C., **Benbrook, D. M.**, "Retinoids induce apoptosis in ovarian organotypic cultures", American Society of Clinical Oncologists 2000 Annual Meeting, American Society of Clinical Oncologists (ASCO), Oral Presentation. 2000.
89. Patrick, S. D., Waugh, K., Subramanian, S., Simms-Kelley, M. D., **Benbrook, D. M.**, Berlin, K. D., Nelson, E. C., "Synthetic retinoids induce differentiation in F9 cells", FASEB, FASEB, Oral Presentation. 2000.
90. Simoni, D., Roberti, M., Rondanin, R., Rossi, M., Baruchello, R., Grimaudo, S., Tolomeo, M., Arindam, D., **Benbrook, D. M.**, "A New Class of HeterocyclicContaining Arotinoids Endowed with Potent Differentiating and Apoptotic Activity", XVIth International Symposium on Medicinal Chemistry, International Symposium on Medicinal Chemistry, Bologna, Italy, Oral Presentation. September 2000.
91. Kamelle, S., Sienko, A., Berlin, K. D., **Benbrook, D. M.**, "Retinoid inhibition of ovarian cancer xenograft growth", Western Association of Gynecologic Oncologists 2000 Annual Meeting, Western Association of Gynecologic Oncologists (WAGO), Monterrey, CA, Oral Presentation. May 2000.
92. Hassan, **Benbrook, D. M.**, Lightfoot, S. A., Lerner, M. R., Brackett, D. J., Chowdhury, P. S., Pastan, I., "SS1(DSFV)-PE38, A recombinant anti-mesothelin immunotoxin targets human gynecologic tumors overexpressing mesothelin", The 36th Annual American Society of Clinical Oncology Meeting, American Society of Clinical Oncology (ASCO), New Orleans, LA, Oral Presentation. May 2000.
93. Lu, S., **Benbrook, D. M.**, "Anti-AP-1 activity of retinoids may not be a contribution to their growth inhibition activity in some tumor cell lines", 91st American Association for Cancer Research Annual Meeting, American Association for Cancer Research (AACR), San Francisco, CA, Abstract. April 2000.
94. Guruswamy, S., **Benbrook, D. M.**, "Retinoids induce differentiation and apoptosis in ovarian adenocarcinoma organotypic culture", 91st American Association for Cancer Research Annual Meeting, American Association for Cancer Research (AACR), San Francisco, CA, Oral Presentation. April 2000.
95. Dhar, A., Berlin, K. D., **Benbrook, D. M.**, "Structural Features of Synthetic Retinoids Confer

Receptor Selectivity and Refined Biological Activities", 91st American Association for Cancer Research Annual Meeting, American Association for Cancer Research (AACR), San Francisco, CA, Oral Presentation. April 2000.

96. Patrick, S. D., Waugh, K., Subramanian, S., Simms-Kelley, M. D., **Benbrook, D. M.**, Berlin, K. D., Nelson, E. C., "Synthetic retinoids induce differentiation in F9 cells", Federation of American Society of Experimental Biology Meeting (FASEB), Federation of American Society of Experimental Biology (FASEB), Bethesda, MD, Abstract. March 15, 2000.
97. Kamelle, S., Sienko, A., **Benbrook, D. M.**, "In vitro representation of endometrium using organotypic culture: A future model for the study of endometrial carcinogenesis", Society of Gynecologic Oncologists 31st Annual Meeting, Society of Gynecologic Oncologists (SGO), San Diego, CA, Abstract. February 2000.
98. Spencer, C., **Benbrook, D. M.**, "Retinoids induce apoptosis in ovarian organotypic cultures", Western Association for Gynecologic Oncologists 1999 Annual Meeting, Western Association of Gynecology Oncologists (WAGO), Victoria, British Columbia, Canada, Abstract. June 1999.
99. Dhar, A., Berlin, K. D., Madler, M. M., Ivey, R. T., Birckbichler, P. J., Lu, S., Zacheis, D., **Benbrook, D. M.**, "Flexible Nitrogen Heteroarotinoids: Receptor specificity and Therapeutic Potential in Epithelial Cancers", 90th American Association for Cancer Research Annual Meeting, American Association for Cancer Research (AACR), Philadelphia, PA, Abstract. April 1999.
100. Lu, S., Dhar, A., Ivey, R. T., Berlin, K. D., **Benbrook, D. M.**, "Heteroarotinoid structure affects receptor specificity and growth inhibitory activities", 89th Annual American Association for Cancer Research Meeting, American Association for Cancer Research, New Orleans, LA, Abstract. 1998.
101. Zacheis, D., Houck, J. R., Berlin, K. D., **Benbrook, D. M.**, "Inhibition of the growth of head and neck squamous cell carcinoma by heteroarotinoids", Fifth Research Workshop on the Biology, Prevention, and Treatment of Head and Neck Cancer, Head & Neck Cancer Research, McLean, VA, Abstract. 1998.
102. Ivey, R. T., Brown, D., Berlin, K. D., **Benbrook, D. M.**, "Retinoid response of two ovarian carcinoma cell lines", 89th Annual American Association for Cancer Research Meeting, American Association for Cancer Research, Abstract. 1998.
103. **Benbrook, D. M.**, Berlin, K. D., Birckbichler, P. J., "Correlation of transactivation with growth inhibition and transglutaminase induction by heteroarotinoids", 88th Annual Meeting of the American Association for Cancer Research, American Association for Cancer Research, Abstract. 1997.
104. DiSilvestro, P., Flanagan, C., Angros, L., **Benbrook, D. M.**, "Decrease in Ki-67 and epidermal growth factor receptor expression correlates with retinoic acid induced growth inhibition in a cervical cancer cell line", 88th Annual Meeting of the American Association for Cancer Research, American Association for Cancer Research, Abstract. 1997.
105. **Benbrook, D. M.**, Nuñez, E. R., "Differences in radiosensitization and cell cycle progression of cervical carcinoma cell lines", 88th Annual Meeting of the American Association for Cancer Research, American Association for Cancer Research, Abstract. 1997.
106. **Benbrook, D. M.**, Lu, S., "Retinoid regulation of endogenous receptors, growth and EGF-R in a cervical carcinoma cell line", 88th Annual Meeting of the American Association for Cancer Research, American Association for Cancer Research, Abstract. 1997.
107. Nuñez, E. R., Jordan, T. L., **Benbrook, D. M.**, "13-Cis acid is a radiosensitizer of SiHa cervical carcinoma cell line", 87th Annual American Association for Cancer Research Meeting, American

Association for Cancer Research, Washington, DC, Abstract. 1996.

108. **Benbrook, D. M.**, Lu, S., Flanagan, C. W., Jordan, T. L., "Retinoids inhibit growth and activate endogenous receptors in a cervical tumor cell line", FASEB Summer Research Conference on Retinoids, Federation of American Societies for Experimental Biology (FASEB), Oral Presentation. 1996.
109. Madler, M., **Benbrook, D. M.**, Birckbichler, P. J., Nelson, E. C., Berlin, K. D., "Biologically active heteroarotinoids", Annual Meeting of the Medicinal Chemistry Division of the American Chemical Society, American Chemical Society, Abstract. August 1996.
110. Waliszewski, P., **Benbrook, D. M.**, Nasim, M., Hurst, R. E., ""Human uroepithelial cells contain retinoid signaling pathways"", American Association for Cancer Research, 86th Annual American Association for Cancer Research, Toronto, Ontario, Canada, Abstract. 1995.
111. **Benbrook, D. M.**, Jordan, T. L., Heldermon, C., Robinson, K., "Evaluation of endogenous retinoic acid receptor function in cervical tumor cells", 6th Annual Research Conference, American Institute for Cancer Research, Washington, DC, Abstract. 1995.
112. Waliszewski, P., **Benbrook, D. M.**, Blaszewski, M. K., Gupta, M., Drews, M., Hurst, R. E., "The retinoic acid signaling pathway in normal and transformed human intestinal epithelial cells", American Association for Cancer Research, 86th Annual American Association for Cancer Research, Toronto, Ontario, Canada, Abstract. 1995.
113. Nuñez, E. R., Heldermon, C., **Benbrook, D. M.**, "Restoration of RAR expression and function in RAR-deficient cervical tumor cell lines has different effects depending on the intercellular environment", American Association for Cancer Research Special Conference "Mechanism of Action of Retinoids, Vitamin D, and Steroid Hormones", American Association for Cancer Research, Oral Presentation. 1995.
114. Nuñez, E. R., **Benbrook, D. M.**, "Retinoic acid receptor expression effects growth and retinoid sensitivity in cervical tumor cell lines", American Association for Cancer Research Conference "Molecular Biology of Cancer: Implications for Prevention and Therapy", American Association for Cancer Research, Oral Presentation. 1995.
115. Mannel, R. S., Khalifa, M., Wren, M., Walker, J. L., Min, K. W., **Benbrook, D. M.**, "Epidermal growth factor receptor in vulvar malignancies and its relationship to metastasis and patient survival", 26th Annual Society of Gynecologic Oncologists' Meeting, Society of Gynecologic Oncologists, Abstract. 1994.
116. **Benbrook, D. M.**, Heldermon, C., Nunez, E. R., Waliszewski, P., "Retinoic acid receptor (RAR) effects in cervical tumor cell lines", Diet and Cancer: Molecular Mechanisms of Interactions, American Institute of Cancer Research, Abstract. 1994.
117. **Benbrook, D. M.**, Heldermon, C., "Retinoic acid receptors bind to HPV16LCR sequence and repress transcription indirectly through AP1 sites", 13th International Papillomavirus Conference, International Papillomavirus Society, Amsterdam, The Netherlands, Abstract. 1994.
118. **Benbrook, D. M.**, Medlin, M., Rogers, R., Ahern-Moore, J., Dunn, S. T., Lord, B., Walker, J. L., ""Retinoid effects on tumor cells in organotypic culture"", American Association for Cancer Research Special Conference "Mechanism of Action of Retinoids, Vitamin D, and Steroid Hormones", American Association for Cancer Research, Oral Presentation. 1993.
119. Rogers, R. S., **Benbrook, D. M.**, Walker, J. L., Lord, B. J., Haas, G. G., ""Silent" carriers of human papillomavirus (HPV) identified in sperm bank donor population", American Fertility Society, 48th

Annual Meeting, American Fertility Society, Abstract. 1992.

120. **Benbrook, D. M.**, Miller, R., "The effects of Norfloxacin on Pseudomonas aeruginosa and its DNA Gyrase", American Society of Microbiology, 84th Annual Meeting, American Society of Microbiology, Oral Presentation. 1984.
121. **Benbrook, D. M.**, Miller, R., "The effects of Norfloxacin, A pyriconecarboxylic acid-derivative, on DNA replication and DNA gyrase activity in Pseudomonas aeruginosa", Federation of American Society of Experimental Biology Meeting, Federation of American Society of Experimental Biology, Abstract. 1982.

Local/Regional

1. Syed, Z., **Benbrook, D. M.**, Krishnan, S., "Ovarian Cancer Biomarker Profiling with Pyrenyl-Nanocarbon Antibody Arrays", Southwest Regional Meeting - American Chemical Society, American Chemical Society, Oklahoma City, Poster. November 15, 2023.
2. Izingizwe, Z. *, **Benbrook, D. M.**, "Eptifibatide Inhibits Cancer Cells Mediated Platelets Aggregation", 46th Graduate Research Education And Technology (GREAT) symposium, University of Oklahoma Health Sciences Center Graduate School, University of Oklahoma Health Sciences Center, Oral Presentation. March 2021.
3. Izingizwe, Z. *, **Benbrook, D. M.**, "Potential of Pharmaceutical Intervention In Platelets And Cancer Positive Feedback Loop", Stephenson Cancer Center Annual Research Symposium, Stephenson Cancer Center, Virtual, Oral Presentation. March 2021.
4. Izingizwe, Z. *, **Benbrook, D. M.**, "Potential of Pharmaceutical Intervention In Platelets And Cancer Positive Feedback Loop", Technical Meeting of the virtual meeting of the Oklahoma Academy of Science, Oklahoma Academy of Science, Virtual, Oral Presentation. November 2020.
5. Izingizwe, Z. *, **Benbrook, D. M.**, "Development Of A Model Of DihomoGamma-Linolenic Acid Interference With Platelet Promotion Of Ovarian Cancer", 2020 Graduate Research Education And Technology (GREAT) symposium, Graduate College, University of Oklahoma Health Sciences Center, Virtual, Oral Presentation. March 2020.
6. **Benbrook, D. M.**, Izingizwe, Z. *, "Development Of A Model Of DihomoGamma-Linolenic Acid Interference With Platelet Promotion Of Ovarian Cancer", Stephenson Cancer Center Annual Research Symposium, Stephenson Cancer Center, Virtual, Oral Presentation. February 2020.
7. Izingizwe, Z. *, **Benbrook, D. M.**, "Dihomo-Gamma-Linolenic Acid Inhibits Ovarian Cancer Cell Growth Through Apoptosis", 44th annual GREAT symposium, Graduate School, University of Oklahoma Health Sciences Center, Oklahoma City, Poster. April 2019.
8. Mahjabeen, S., Sanjida, Chandra, Vishal, Hatipoglu, M. K., **Benbrook, D. M.**, Garcia-Contreras, L., "Formulation of SHetA2 in a Vaginal Suppository for Chemoprevention Against Cervical Dysplasia", 2016 Stephenson Cancer Center Research Symposium, University of Oklahoma Health Sciences Center, Oklahoma City, OK, Abstract. January 29, 2016.
9. Yari, Hooman, Hatipoglu, M. K., **Benbrook, D. M.**, Garcia-Contreras, L., "Formulation of SHetA2 Nanoparticles for the Treatment of Lung Cancer", 2016 Stephenson Cancer Center Research Symposium, University of Oklahoma Health Sciences Center, Oklahoma City, OK, Abstract. January 29, 2016.
10. Sharma, A., Thavathiru, E., Ramraj, S. K., **Benbrook, D. M.**, Woo, S., "Physiologically-Based PHarmacokinetic Models for SHetA2 in Orthotopic Murine Model of Ovarian Cancer (Awarded

2016 AAiPS Research Award in PPDM section)", 2016 Stephenson Cancer Center Research Symposium, University of Oklahoma Health Sciences Center, Oklahoma City, OK, Abstract. January 29, 2016.

11. Ramraj, S. K., Thavathiru, E., Toal, C., Smith, K., Crouse, E., **Benbrook, D. M.**, "Targeting mortalin-p53 interaction in differential induction of apoptosis in cancer over normal cells", 2016 Stephenson Cancer Center Research Symposium, University of Oklahoma Health Sciences Center, Oklahoma City, OK, Abstract. January 29, 2016.
12. Eschiti, V., **Benbrook, D. M.**, Sanford, S., Rhoades, D., Doescher, M., Warson, E., Lauderdale, J., Matzo, M., "Art Interventions for Palliative Care Symptom Management in Comanche Cancer Survivors", Partners in Quality: Evidence-based Practice and Quality Improvement, University of Oklahoma Health Sciences Center, Oklahoma City, OK, Oral Presentation. 2015.
13. Sharma, A., **Benbrook, D. M.**, Woo, S., "Application of interspecies scaling to predict SHetA2 pharmacokinetics in humans", 38th Annual GREAT Symposium, OU Health Science Center, Oklahoma City, OK, Abstract. April 2013.

TEACHING AND INSTRUCTION

Teaching and Course Instruction – OUHSC/SCM

Year(s) of Instruction	Course ID	Course/Lecture Title	Role	Avg. Contact Hrs/Year	Primary Learner Audience
Fall 2022 - Present	PATH 6024	Principals of Pathology: Gynecologic Cancers	Instructor	4	Graduate
Spring 2021 - Present	PHSC 6712	Research and Education Methods: NCI Clinical Issues and Translational Research	Lecturer		Graduate
2021 - Present	BMSC 6100	GPIBs Laboratory Rotations	Instructor	20	Graduate
2014 - Present	CTS 5133	Foundations in Translational Research Course	Course Director and Instructor	30	Junior Faculty
2005 - Present	BMSB 6100	Laboratory Rotations	Lab Instructor	20	Graduate
2012 - 2018	BMSC 6053	CSI and CSII, Cellular Systems, Integration of Cell Death and Survival Pathways	Instructor	4.5	Graduate
Spring 2018	CTS 5133	Foundations in Translational Research: I directed this course and personally developed online curriculum and lectured for 3 of the 3 credit hour class sessions.	Course Director	17	Graduate
Fall 2017	CS 2	Cellular Systems: (CSII-18) Mechanisms Controlling Cell Death in Health and Diseases (CSII-19) Mechanisms Controlling Survival in Health and Diseases (CSII-20) Targeting the Integration of Cell Death and Survival Networks in the Development of Disease Prevention and Treatment Strategies	Lecturer	6	Graduate
Spring 2017	CTS 5133	Foundations in Translational Research: I directed this course and personally developed online curriculum and lectured for 3 of the 3 credit hour class sessions.	Course Director	17	Graduate

Year(s) of Instruction	Course ID	Course/Lecture Title	Role	Avg. Contact Hrs/Year	Primary Learner Audience
Fall 2016	CS 2	Cellular Systems: (CSII-18) Mechanisms Controlling Cell Death in Health and Diseases (CSII-19) Mechanisms Controlling Survival in Health and Diseases (CSII-20) Targeting the Integration of Cell Death and Survival Networks in the Development of Disease Prevention and Treatment Strategies	Lecturer	6	Graduate
Spring 2016	CTS 5133	Foundations in Translational Research: I directed this course and personally developed online curriculum and lectured for 3 of the 3 credit hour class sessions.	Lecturer	17	Graduate
2005 - 2014	BMSC 5221	Cancer Journal Club	Instructor	4	
2011		Cell Death	Instructor	2	
2007 - 2010	CTS	Clinical and Translational Science Award (CTSA) Summer Scholar Program: Clinical and Translation Science (2 hours) The University of Oklahoma Cancer Institute (1 hour)	Instructor		
2007 - 2009		CSI and CSII, Cellular Systems, Apoptosis		1.5	
2005 - 2008	BMSB 6121	Molecular Mechanisms of Disease			
2005 - 2007	RADI 5403, 5413	Clinical Bioinformatics (RADI5403, RADI5413): Assisted in development of this new course in 2005 and lectured in: •Structural Biology (1.5 hrs) •Carcinogenesis, Chemoprevention and Cancer Genetics (1.5 hrs) •Angiogenesis, molecular targets for treatment, diagnosis, monitoring & imaging (1.5 hrs) •Cancer Metastasis and Immunity, treatment, diagnosis, monitoring & imaging (1.5 hrs) • Lunch and Learn (2 hrs)	Lecturer	8	Graduate
2006		Molecular Mechanisms of Cancer	Instructor	1	
2004 - 2006	CELL 6331	Cancer Genetics/Biomarkers	Instructor	1.5	
2004 - 2006		Carcinogenesis and Chemoprevention	Instructor	2	
1993 - 2004		Oncogenes and Tumor Suppressor Genes: Departments of Pathology and Radiological Sciences	Lecturer		
2002 - 2003	BMSC 5221	Cancer Journal Club	Instructor	4	
2002 - 2003		Regulation of Gene Expression	Instructor	4.5	
2001 - 2003		Oncogenes and Tumor Suppressor Genes	Instructor	4	
2000 - 2003		Current Issues in Biomedical Research: Clinical Trials	Instructor	2	
1999 - 2001		Dental Biochemistry: Carcinogenesis	Instructor	1	

Year(s) of Instruction	Course ID	Course/Lecture Title	Role	Avg. Contact Hrs/Year	Primary Learner Audience
2000		Biochemistry 5224: DNA Sequencing and EMSA	Instructor	2	
2000		Biochemistry 5970: Student Research Seminar	Instructor	1	
2000		Biochemistry 6224: 7 week laboratory rotations for Graduate Students	Instructor		
2000		Biochemistry 6234: DNA tumor viruses and Chemical Carcinogenesis	Instructor	4	
2000		Biochemistry 6502: Advanced Topics in Human Molecular Genetics	Instructor	2	
2000		Nucleic Acids: RNA Splicing Mechanisms	Instructor	4	

Graduate or Research Oversight Committee Membership

Date	Mentee Name	Mentee Level/Program	Role/Involvement Type	Mentorship Outcomes
2023 - Present	Estafania Valencia-Rincon	Doctoral Student, Pathology/Medicine, Graduate School/OUHSC	Doctoral Advisory Committee Member - General Exam Committee	
2023 - Present	Yohan Park	Doctoral Student, Pathology/Medicine, University of Oklahoma Health Sciences Center	Doctoral Advisory Committee Member	
2022 - Present	Barbara Mensah Sankofi	Doctoral Student, Pathology/Medicine, OUHSC Graduate College	Doctoral Advisory Committee Member	
2022 - Present	Laura Mortan, BA	Doctoral Student, Pathology/Medicine, Pathology/Graduate School	Doctoral Advisory Committee Chair	
2022 - Present	Richard Bui	Doctoral Student, Pharmaceutical Sciences Department/College of Pharmacy, Pharmaceutical Sciences	Doctoral Advisory Committee Member	
2022 - Present	Santny Shanmugarama	Doctoral Student, Pathology, Graduate College	Doctoral Advisory Committee Member	
2021 - Present	Justin Garland, BS	Doctoral Student, Pathology/Medicine, Pathology/Graduate Student	Doctoral Advisory Committee Chair	
2018 - Present	Amy Kennedy, BA	Doctoral Student, Pathology/Medicine, Pathology/Graduate School	Doctoral Advisory Committee Chair	
2021 - 2022	James Lausen, BA	Doctoral Student, Cell Biology/Medicine, Cell Biology/Graduate School	Doctoral Advisory Committee Member	
2018 - 2022	Zitha Isingizwe, BS	Doctoral Student, Pharmaceutical Sciences/Pharmacy	Doctoral Advisory Committee Chair	
2018 - 2022	Chetan Ahire, BS	Doctoral Student	Doctoral Advisory Committee Member	

Date	Mentee Name	Mentee Level/Program	Role/Involvement Type	Mentorship Outcomes
2020 - 2022	Pouya Javadian, MD	Master's Student, Gynecologic Oncology/Ob/Gyn/Medicine, Clinical and Translational Sciences	Master's Advisory Committee Chair	Thesis on Molecular and Biological Aspects of Endometrial Cancer Racial Disparity.
2021	Justin Garland, BS	Doctoral Student, Cell Biology/Medicine, Cell Biology/Graduate School	Doctoral Advisory Committee Member	
2016 - 2019	Taleah Farasyn, BS	Pharmaceutical Sciences/ College of Pharmacy, Graduate College	Doctoral Advisory Committee Member	
2015 - 2019	Alexandra Crowe, PhD	Doctoral Student, Pharmaceutical Sciences, College of Pharmacy	Doctoral Advisory Committee Member	PhD earned 2017
2015 - 2019	Joshua Corbin, BS	Graduate Student, Pathology/College of Medicine, Graduate College	Doctoral Advisory Committee Member	PhD earned 2019
2015 - 2019	Yifan Xu, BS	Doctoral Student, Pathology Department/College of Medicine, Graduate College	Doctoral Advisory Committee Member	PhD earned 2019
2017 - 2018	John Wood, BS	Graduate Student, Department of Physiology, College of Medicine	Doctoral Advisory Committee Member	
2015 - 2018	Sanjida Mahjabeen, BS	Doctoral Student, Pharmaceutical Sciences/ College of Pharmacy, Graduate College	Doctoral Advisory Committee Member - PhD earned 2018	
2017	Dhawal Raghuvanshi	MD/PhD Student, Pharmaceutical Sciences	Doctoral Advisory Committee Member - Service on other dissertation/thesis committee	PhD transferred 2017
2016 - 2017	Lauren Dockery, MD	Master's Student, Gynecologic Oncology Section/Obstetrics and Gynecology Department, Clinical and Translational Sciences Program/Graduate College	Master's Advisory Committee Member	MS earned 2017
2015 - 2017	Christa DeVette, BS	MD/PhD Student, Microbiology and Immunology Department/College of Medicine, Graduate College	Doctoral Advisory Committee Member	PhD earned 2017
2015 - 2017	Rachel Ruskin, MD	Master's Student, Gynecologic Oncology Section/Obstetrics and Gynecology Department, Clinical and Translational Sciences Program	Master's Advisory Committee Member	
2014 - 2017	Mariam Ibrahim, BS	Doctoral Student, Pharmaceutical Sciences/ College of Pharmacy, Graduate College	Doctoral Advisory Committee Member - PhD earned 2017	
2013 - 2017	Ankur Sharma, BS	Graduate Student, Pharmaceutical Sciences	Doctoral Advisory Committee Member	PhD earned 2017

Date	Mentee Name	Mentee Level/Program	Role/Involvement Type	Mentorship Outcomes
2016	Angelica Harper	MD/PhD Student, Cell Biology	Doctoral Advisory Committee Member	PhD earned 2016
2014 - 2016	Camille Gunderson, MD	Master's Student, Gynecologic Oncology Section/Obstetrics and Gynecology Department, Clinical and Translational Sciences Program/Graduate College	Master's Advisory Committee Chair	MS earned 2016
2013 - 2016	Adam Walter, MD	Master's Student, Gynecologic Oncology Section/Obstetrics and Gynecology Department, Clinical and Translational Sciences Program/Graduate College	Master's Advisory Committee Member - MS earned 2016	
2013 - 2016	Katrina Slaughter, BS	Master's Student, Gynecologic Oncology Section/Obstetrics and Gynecology Department, Clinical and Translational Sciences Program/Graduate College	Master's Advisory Committee Member	MS earned 2016
2015	Andrea Patterson	MD/PhD Student, Microbiology and Immunology	Doctoral Advisory Committee Member	PhD earned 2015
2011 - 2015	Matthew Caleb Martin, BS	Graduate Student, Biochemistry and Cell Biology Department/College of Medicine, Graduate College	Doctoral Advisory Committee Member	PhD earned 2015
2014	Shuai Wang	MD/PhD Student, Pathology	Doctoral Advisory Committee Member - Service on other dissertation/thesis committee	PhD earned 2014
2014	LaToya Perry, MD	Master's Student, Gynecologic Oncology Section/Obstetrics and Gynecology Department, Clinical and Translational Sciences Program/Graduate College	Master's Advisory Committee Chair	MS earned 2014
2013	Feng He	MD/PhD Student, Biochemistry	Doctoral Advisory Committee Member - Service on other dissertation/thesis committee	PhD earned 2013
2013	Ravilha Durgadevi	MD/PhD Student, Pathology	Doctoral Advisory Committee Member - Service on other dissertation/thesis committee	PhD earned 2013
2013	William Berry	MD/PhD Student, Cell Biology	Doctoral Advisory Committee Member - Service on other dissertation/thesis committee	PhD earned 2013
2011	Jason Kesinger	PharmD/MS, Pharmacy	Doctoral Advisory Committee Member - Service on other dissertation/thesis committee	PharmD/MS earned 2011

Date	Mentee Name	Mentee Level/Program	Role/Involvement Type	Mentorship Outcomes
2011	Wei Wu	MD/PhD Student, Cell Biology	Doctoral Advisory Committee Member - Service on other dissertation/thesis committee	PhD earned 2011
2010	Amy Knoll	MD/PhD Student, Cell Biology	Doctoral Advisory Committee Member - Service on other dissertation/thesis committee	PhD earned 2010
2010	Bin Zhang	MD/PhD Student, Cell Biology	Doctoral Advisory Committee Member - Service on other dissertation/thesis committee	PhD earned 2010
2010	Feng Li	MD/PhD Student, Biochemistry	Doctoral Advisory Committee Member - Service on other dissertation/thesis committee	PhD earned 2010
2010	Krysten Farjo	MD/PhD Student, Cell Biology	Doctoral Advisory Committee Member - Service on other dissertation/thesis committee	PhD earned 2010
2010	Madhu Unnikrishanan	MD/PhD Student, Pathology	Doctoral Advisory Committee Member - Service on other dissertation/thesis committee	PhD transferred 2010
2010	Monica Draper	MD/PhD Student, Cell Biology	Doctoral Advisory Committee Member - Service on other dissertation/thesis committee	PhD transferred 2010
2009	Ann Howell	PharmD/MS, Pharmacy	Doctoral Advisory Committee Member - Service on other dissertation/thesis committee	PharmD/MS earned 2009
2008	Liao Xiaoyun	MD/PhD Student, Pathology, University of Hong Kong	Doctoral Advisory Committee Member - Service on other dissertation/thesis committee	PhD earned 2008
2007	Chaitali Tophkhane	MD/PhD Student, Pathology	Doctoral Advisory Committee Member - Service on other dissertation/thesis committee	PhD earned 2007
2007	Mathew Gibson	MD/PhD Student, Cell Biology	Doctoral Advisory Committee Member - Service on other dissertation/thesis committee	PhD earned 2007
2006	Richard Langeras	MD/PhD Student, Biochemistry and Molecular Biology	Doctoral Advisory Committee Member - Service on other dissertation/thesis committee	PhD transferred 2006
2005	Dustin Smith	MD/PhD Student, Biochemistry and Molecular Biology	Doctoral Advisory Committee Member - Service on other dissertation/thesis committee	PhD earned 2005
2003	Stephanie Si Liu	MD/PhD Student, Biochemistry, University of Hong Kong	Doctoral Advisory Committee Member - Service on other dissertation/thesis committee	PhD earned 2003
2002	Suresh Guruswamy, PhD	MD/PhD Student, Biochemistry and Molecular Biology	Doctoral Advisory Committee Chair - Biochemistry 6980: Chair of PhD thesis committee	Currently Academic Faculty
2001	Shennan Lu, PhD	MD/PhD Student, Biochemistry and Molecular Biology	Doctoral Advisory Committee Chair - Biochemistry 6980: Chair of PhD thesis committee	Currently NIH Employee
2000	Ahmed Mohamed Mahmoud Abou-Eisha	MD/PhD Student, Cairo University	Master's Advisory Committee Member - Service on other dissertation/thesis committee	PhD earned 2000
1997	Shankar Sachithanandam	MD/PhD Student, Radiological Sciences	Master's Advisory Committee Member - Service on other dissertation/thesis committee	PhD earned 1997
1996	Kim Kyker	Master's Student, Biochemistry and Molecular Biology	Master's Advisory Committee Member - Service on other dissertation/thesis committee	MS earned 1996
1995	Todd Corn	MD/PhD Student, Biochemistry and Molecular Biology	Doctoral Advisory Committee Member - Service on other dissertation/thesis committee	PhD earned 1995

Mentoring and Advising

Date	Mentee Name	Mentee Level/Program	Role/Involvement Type	Mentorship Outcomes
2023 - Present	Que Chance	Graduate Student, Department of Pharmaceutical Sciences/College of Pharmacy, Graduate College	Mentor - Research Degree Option of Pharm. D. Program	
2023 - Present	James Lausen, BA	Doctoral Student, Pathology/Medicine, Pathology/Graduate School	Doctoral Advisory Committee Chair	
2022 - Present	Zitha Isingizwe, PhD	Postgraduate Fellow, Gynecologic Oncology, Stephenson Cancer Center	Postdoctoral Research Supervision	
2022 - Present	Rajani Rai, PhD	Junior Faculty, Gynecologic Oncology/Obstetrics and Gynecology/Medicine, Gynecologic Oncology/Stephenson Cancer Center	Mentor	
2021 - Present	Dongin Kim, PhD	Junior Faculty, Pharmaceutical Sciences Department/College of Pharmacy, University of Oklahoma Health Sciences Center	Mentor	
2021 - Present	Margaret Bournalon, BS	Doctoral Student, Pharmaceutical Sciences/Pharmacy, Pharmaceutical Sciences Graduate College	Doctoral Advisory Committee Member	
2020 - Present	Handan Acar, PhD	Junior Faculty, Biomedical Engineering, OU Norman	Mentor	
2017 - Present	Vishal Chandra, PhD	Junior Faculty, Gynecologic Oncology/Obstetrics and Gynecology/Medicine, Gynecologic Oncology/Stephenson Cancer Center	Mentor	
2023	Showket Hussain, PhD	Visiting Scientist, Gynecologic Oncology/Stephenson Cancer Center, Indian Council of Medical Research (ICMR)	Mentor	
2022 - 2023	Brooke Meelheim, MD	Fellow, Gynecologic Oncology/Obstetrics and Gynecology/Medicine, Gynecologic Oncology/Stephenson Cancer Center	Mentor	

Date	Mentee Name	Mentee Level/Program	Role/Involvement Type	Mentorship Outcomes
2016 - 2022	Rajani Rai, PhD	Postgraduate Fellow, Gynecologic Oncology, Stephenson Cancer Center	Mentor - Guide experimental design; interpretation, presentation and publication of results; teaching skills and grant writing. Taught about drug development and cervical cancer.	Co-PI on a PREVENT grant and corresponding task order.
2021 - 2022	Lindsay Borden, MD	Fellow, Gynecologic Oncology/Obstetrics and Gynecology/Medicine, Gynecologic Oncology/Stephenson Cancer Center	Mentor	
2018 - 2020	Sugantha Priya Elayapillai, PhD	Postgraduate Fellow, Gyn/Onc SCC	Mentor	Two publications.
2015 - 2020	Satish Ramraj, PhD	Postgraduate Fellow, Gynecologic Oncology, Stephenson Cancer Center	Mentor - Guide experimental design; interpretation, presentation and publication of results; teaching skills and grant writing. Taught about drug development, p53 and ovarian cancer.	Rivkin Center Postdoctoral Fellowship. Two articles published. Presented national and local posters. Taught in one graduate student class. Promoted to Assistant Professor of Research
2017 - 2018	Kathleen Essel, MD	Postgraduate Fellow, Gynecologic Oncology, Stephenson Cancer Center	Mentor - Mentored experimental design and interpretation of results. Trained to submit IACUC applications and interpret mass spec data using bioinformatic approaches. Taught about drug development.	First authored peer-reviewed publication
2014 - 2017	Alexander Quaas, MD	Master's Student, Obstetrics and Gynecology, Clinical and Translational Sciences Program/Graduate College	Master's Advisory Committee Member	
2015 - 2017	Vishal Chandra, PhD	Postgraduate Fellow, Gynecologic Oncology, Stephenson Cancer Center	Mentor - Guide experimental design; interpretation, presentation and publication of results; teaching skills and grant writing. Taught about drug development, ovarian cancer, autophagy and p53.	Promoted to Assistant Professor of Research in October 2017.
2017	Hanna Schaeffer	Undergraduate Student, Native American Research Center for Health (NARCH), Summer Research Scholar	Mentor - Studied the role of a CCL2 single nucleotide polymorphism (SNP) in regulation of the CCL2 protein expression and ovarian cancer survival. Taught about the science behind the project and ovarian cancer.	Evaluated CCL2 SNP status and protein expression in patient samples. Tested the CCL2 SNP effect on protein expression in a tissue culture model. Presented the results at a research symposium.
2016 - 2017	Joy Oshomuvwe	Oklahoma School of Math and Science	High School Student/Teacher Research Project Mentoring	Full fellowship to the University of Chicago
2016 - 2017	Timothy Pouland, BS	MD/PhD Student, Pharmaceutical Sciences, Department of Pharmaceutical Sciences/ College of Pharmacy	Doctoral Advisory Committee Chair - Training in Drug Discovery methods, experimental design and interpretation of results. Teaching about cancer and molecular biology. Mentoring career goals.	Performed drug modeling and evaluated compound potency and efficacy against cancer cells. Completed graduate school courses. Presented results at the Stephenson Cancer Center Annual Symposium

Date	Mentee Name	Mentee Level/Program	Role/Involvement Type	Mentorship Outcomes
2016	Abigail Jebaraj	Medical Student, CTS Summer Research Training Program (SRTP)	Medical Student Research Projects Mentoring	
2016	Coralee Toal	Medical Student, CTS Summer Research Training Program (SRTP)	Medical Student Research Projects Mentoring	
2016	Amy Bosley	Summer Undergraduate Research Experience (SURE)	Undergraduate Student Research Project Mentoring	
2016	Cassadie Holybee	IDEA Network for Biomedical Research Excellence (INBRE)	Undergraduate Student Research Project Mentoring	
2016	Julie Nguyen	Stephenson Cancer Center C.U.R.E. Summer Program	Undergraduate Student Research Project Mentoring	
2014	Pham Trung	Medical Student, Medical Student Academic Year Shadow	Medical Student Research Projects Mentoring	
2013	Andrew Long, PhD	Postdoctoral Fellow, Biochemistry and Molecular Biology	Doctoral Advisory Committee Chair	Currently Postdoc. Fellow
2010 - 2013	Franklin Hays, MD	Biochemistry, Assistant Professor	Clinical Faculty Mentoring	
2007 - 2013	Wei-Qun Ding, MD	Pathology, Assistant Professor	Clinical Faculty Mentoring	
2007 - 2012	Kathleen Moore, MD	Gynecologic Oncology, Assistant Professor	Clinical Faculty Mentoring	
2011	Xiaolei Liu	Graduate Student, Biomedical Sciences Research Rotation	Graduate Research Project Mentoring	
2010 - 2011	Erin Bishop, MD	Gynecologic Oncology	Mentor - Clinical Fellow Research Mentored (40% Currently in Academia)	
2010	Nasim Maryam Niroumand	Medical Student, Medical Student Summer Research Project	Medical Student Research Projects Mentoring	
2006 - 2010	Chioniso Patience Masamha, PhD	Postdoctoral Fellow, Biochemistry and Molecular Biology	Doctoral Advisory Committee Chair	Currently Assistant Professor, Butler University
2009	Shylet Chenedza, PhD	MD/PhD Student, Biochemistry and Molecular Biology	Doctoral Advisory Committee Chair	Currently Academic Faculty
2009	Christina Highley	Medical Student, Clinical and Translational Summer Scholar	Medical Student Research Projects Mentoring	
2009	Mira Georgey	Medical Student, Clinical and Translational Summer Scholar	Medical Student Research Projects Mentoring	
2008 - 2009	Kathleen Moxley, MD	Gynecologic Oncology	Mentor - Clinical Fellow Research Mentored (40% Currently in Academia)	
2005 - 2009	Tongzu Liu, MD, PhD	Postdoctoral Fellow	Postdoctoral Research Supervision - Postdoctoral Fellow in Dr. Benbrook's Lab Currently in Faculty at Wuhan University, Wuhan, China	
2008	Frank Han	Oklahoma School of Math and Science, Fall Semester	High School Student/Teacher Research Project Mentoring	

Date	Mentee Name	Mentee Level/Program	Role/Involvement Type	Mentorship Outcomes
2008	Margaret Wang	Oklahoma School of Math and Science, Fall Semester	High School Student/Teacher Research Project Mentoring	
2008	Larissa Hines	Medical Student, Clinical and Translational Summer Scholar	Medical Student Research Projects Mentoring	
2008	Sheree McDaniel	Langston's Integrated Network College (LINC)	Undergraduate Student Research Project Mentoring	
2007 - 2008	Feng He	Graduate Student, Biochemistry Research Rotation	Graduate Research Project Mentoring	
2007 - 2008	Erin Tuller, MD	Gynecologic Oncology	Mentor - Clinical Fellow Research Mentored (40% Currently in Academia)	
2007	Alysha Ann Rauhauser	Graduate Student, University of Central Oklahoma	Graduate Research Project Mentoring	
2007	Yanfang Pan	Graduate Student, Biochemistry Research Rotation	Graduate Research Project Mentoring	
2007	Oba Hughes	Oklahoma Biomedical Research Infrastructure Network	Undergraduate Student Research Project Mentoring	
2006 - 2007	Tashana Myers, MD	Gynecologic Oncology	Mentor - Clinical Fellow Research Mentored (40% Currently in Academia)	
2006	Laura Russell	Graduate Student, Biomedical Sciences Research Rotation	Graduate Research Project Mentoring	
2006	Patience Masamha	Graduate Student, Biomedical Sciences Research Rotation	Graduate Research Project Mentoring	
2006	William Berry	Graduate Student, Biomedical Sciences Research Rotation	Graduate Research Project Mentoring	
2006	Lauren Ritterhouse	MD/PhD Student, MD/PhD Program Research Rotation	Medical Student Research Projects Mentoring	
2005 - 2006	Granger Lanneau, MD	Gynecologic Oncology	Mentor - Clinical Fellow Research Mentored (40% Currently in Academia)	
2005 - 2006	Johnny Hyde, MD	Gynecologic Oncology	Mentor - Clinical Fellow Research Mentored (40% Currently in Academia)	
2005 - 2006	Ann Nelson	Oklahoma Biomedical Research Infrastructure Network	Undergraduate Student Research Project Mentoring	
2003 - 2006	Karl Hanson, MD	Reproductive Endocrinology, Assistant Professor	Clinical Faculty Mentoring	
2005	Shylet Chenedza	Graduate Student, Biomedical Sciences Research Rotation	Graduate Research Project Mentoring	
2005	Margaret P. O'Connell	Medical Student, Medical Student Summer Research Project	Medical Student Research Projects Mentoring	
2005	Chasity Jackson	Undergraduate Biomedical Education Program (UBEP)	Undergraduate Student Research Project Mentoring	

Date	Mentee Name	Mentee Level/Program	Role/Involvement Type	Mentorship Outcomes
2004 - 2005	Mark Naylor, MD	Dermatology, Member OMRF	Clinical Faculty Mentoring	
2004 - 2005	Daynelle Dearnley, MD	Gynecologic Oncology	Mentor - Clinical Fellow Research Mentored (40% Currently in Academia)	
2004 - 2005	Lance Gill	Oklahoma Biomedical Research Infrastructure Network	Undergraduate Student Research Project Mentoring	
2004	Barbara Jeske	Summer Undergraduate Research Experience (SURE)	Undergraduate Student Research Project Mentoring	
2003 - 2004	Abbas Shoberi, MD	Urogynecology, Assistant Professor	Clinical Faculty Mentoring	
2002 - 2004	Camille Falkner, MD	Gynecologic Oncology	Mentor - Clinical Fellow Research Mentored (40% Currently in Academia)	
2003	Anne Murray	Graduate Student, Biomedical Sciences Research Rotation	Graduate Research Project Mentoring	
2003	Bahara Ebadifar	Graduate Student, Biomedical Sciences Research Rotation	Graduate Research Project Mentoring	
2003	Julie Scott	Graduate Student, Biomedical Sciences Research Rotation	Graduate Research Project Mentoring	
2003	Kelsie Brooks	Science Fair Project, Regional Winner	High School Student/Teacher Research Project Mentoring	
2003	Amy Noll, BS	Summer Pre-graduate Student	Undergraduate Student Research Project Mentoring	
2003	Ashley Hopkins	Summer Undergraduate Research Experience (SURE)	Undergraduate Student Research Project Mentoring	
2003	Jen'nea Ose, BS	Biomedical Research Infrastructure Network (BRIN)	Undergraduate Student Research Project Mentoring	
1999 - 2003	Nefertiti DuPont, MD	Resident, Obstetrics and Gynecology	Resident Research Projects Mentoring	
2001 - 2002	Natalie Gould, MD	Gynecologic Oncology	Mentor - Clinical Fellow Research Mentored (40% Currently in Academia)	
2001 - 2002	Teresa Rutledge, MD	Gynecologic Oncology	Mentor - Clinical Fellow Research Mentored (40% Currently in Academia)	
2001 - 2002	Shennan Lu, PhD	Postdoctoral Fellow	Postdoctoral Research Supervision	Postdoctoral Fellow in Dr. Benbrook's Lab, 2001-2002 Currently NIH Employee
1999 - 2002	Raffit Hassan, MD	Hematology Oncology, Assistant Professor	Clinical Faculty Mentoring	Senior Investigator National Cancer Institute, Thoracic and Gastrointestinal Malignancies Branch
2001	Kayla Brooks	Science Fair Project, Regional Winner	High School Student/Teacher Research Project Mentoring	
2000 - 2001	Dennis Scribner, MD	Gynecologic Oncology	Mentor - Clinical Fellow Research Mentored (40% Currently in Academia)	
2000 - 2001	Todd Tillmanns, MD	Gynecologic Oncology	Mentor - Clinical Fellow Research Mentored (40% Currently in Academia)	

Date	Mentee Name	Mentee Level/Program	Role/Involvement Type	Mentorship Outcomes
1999 - 2000	Avi Khafif, MD	Orthynolaryngology	Mentor - Clinical Fellow Research Mentored (40% Currently in Academia)	
1999 - 2000	Scott Kamelle, MD	Gynecologic Oncology	Mentor - Clinical Fellow Research Mentored (40% Currently in Academia)	
1997 - 2000	Arindam Dhar, PhD	Postdoctoral Fellow	Postdoctoral Research Supervision	Postdoctoral Fellow in Dr. Benbrook's Lab, 1997 - 2000 Fellow, Interagency Oncology Task Force, NCI/FDA, 2005-2008 Cancer Research Training Associate, NCI, 2000-2005 GaxoSmithKlein, Phase I Trial Director, 2008-present
1998 - 1999	Michael Gold, MD	Gynecologic Oncology	Mentor - Clinical Fellow Research Mentored (40% Currently in Academia)	
1998 - 1999	Carla Spencer, MD	Resident, Obstetrics and Gynecology	Resident Research Projects Mentoring	
1998	Marylin Webster	Medical Student, Medical Student Summer Research Project	Medical Student Research Projects Mentoring	
1997 - 1998	Todd Ivey, MD	Gynecologic Oncology	Mentor - Clinical Fellow Research Mentored (40% Currently in Academia)	
1997 - 1998	Dana Stone, MD	Resident, Obstetrics and Gynecology	Resident Research Projects Mentoring	
1997	Suresh Guruswamy	Graduate Student, Biochemistry	Graduate Research Project Mentoring	
1997	Xiaohong Zhong	Graduate Student, Biochemistry	Graduate Research Project Mentoring	
1997	Virginia Fishburne	Medical Student, Medical Student Summer Research Project	Medical Student Research Projects Mentoring	
1996 - 1997	Jane Shen-Gunther, MD	Gynecologic Oncology	Mentor - Clinical Fellow Research Mentored (40% Currently in Academia)	
1996 - 1997	Paul DiSilvestro, MD	Gynecologic Oncology	Mentor - Clinical Fellow Research Mentored (40% Currently in Academia)	
1996	Hai Ying Qui	Graduate Student, Biochemistry	Graduate Research Project Mentoring	
1996	Shennan Lu	Graduate Student, Biochemistry	Graduate Research Project Mentoring	
1996	Ebony Allen	Summer Minority Program	High School Student/Teacher Research Project Mentoring	
1996	Jacqueline Maliwat	Summer Minority Program	High School Student/Teacher Research Project Mentoring	
1995 - 1996	Cole Flanagan, MD	Gynecologic Oncology	Mentor - Clinical Fellow Research Mentored (40% Currently in Academia)	
1995 - 1996	Janet Larsen, MD	Maternal Fetal Medicine	Mentor - Clinical Fellow Research Mentored (40% Currently in Academia)	
1995 - 1996	Tim Zacheis, MD	Orthynolaryngology	Mentor - Clinical Fellow Research Mentored (40% Currently in Academia)	

Date	Mentee Name	Mentee Level/Program	Role/Involvement Type	Mentorship Outcomes
1994 - 1995	Evelyn Rosas Nuñez, MD	Gynecologic Oncology	Mentor - Clinical Fellow Research Mentored (40% Currently in Academia)	
1994 - 1995	Rick Erickson, MD	Orthynolaryngology	Mentor - Clinical Fellow Research Mentored (40% Currently in Academia)	
1994	Terry Kay Epperson	Graduate Student, Biochemistry	Graduate Research Project Mentoring	
1994	Regina Harper	High School Student, Summer Academy	High School Student/Teacher Research Project Mentoring	
1993	Kent Rodgers	Graduate Student, Biochemistry	Graduate Research Project Mentoring	
1993	Kelly Jester	High School Student, Summer Academy	High School Student/Teacher Research Project Mentoring	
1993	Mary Ruth Boone	Minority Program, High School Teacher, Summer	High School Student/Teacher Research Project Mentoring	
1993	Cassandra Onofre	Medical Student, Medical Student Summer Research Project	Medical Student Research Projects Mentoring	
1992	Coy Heldermon	Graduate Student, Biochemistry	Graduate Research Project Mentoring	
1992	Anjan Shah	High School Student, Summer Academy	High School Student/Teacher Research Project Mentoring	
1992	Anjan Shah	School of Math and Science, Winter Semester	High School Student/Teacher Research Project Mentoring	
1992	Lulla Moore Wilson	Minority Program, High School Teacher, Summer	High School Student/Teacher Research Project Mentoring	
1992	Rod Rogers	Medical Student, Medical Student Research Project	Medical Student Research Projects Mentoring	

ORGANIZATIONAL SERVICE

Organizational Administration and Leadership

Campus/University

Director, Gynecologic Cancer Group, Stephenson Cancer Center, 2021 - Present

Speaker, Presbyterian Health Foundation White Coat Ceremony, University of Oklahoma Health Sciences Center, April 11, 2023

Spotlight Speaker, "A Time to Celebrate, A Time to Lead" Gala, University of Oklahoma, October 14, 2022

Co-Leader, Gynecologic Cancer Program, Stephenson Cancer Center, 2016 - 2021

Co-Leader, Womens Cancer Program, Stephenson Cancer Center, 2010 - 2014

Co-Director, "Med into Grad" PhD Specialization Program, OU Clinical and Translational Science Award (CTSA), 2009

Chair, Research and Graduate Student Affairs Committee, University of Oklahoma, 2006 - 2009

Co-Chair, Scientific Advisory Committee, Stephenson Cancer Center, 2006 - 2009

Chair, Data Safety and Monitoring Board, Laser and TLR-Agonist Immunotherapy: A Novel Autologous Melanoma Vaccine Strategy, 2005 - 2009

Chancellor, Clinical and Translational Science Society (CTSS), OU Clinical and Translational Science Award (CTSA), 2007 - 2008

Chair, Internal Review Committee of the Epidemiology Graduate Program, University of Oklahoma, 2006

Vice Chair, Institutional Biosafety Committee (IBC), University of Oklahoma, 1995 - 2006

Co-Chair, Translational Working Group, Clinical & Translational Science Awards (CTSA), University of Oklahoma, 2005

College

Speaker, Evening of Excellence, College of Medicine Alumni Association, March 30, 2023 - Present

Department

Member, Promotions Committee, Obstetrics & Gynecology, 2003 - Present

Chair, Promotions Committee, Obstetrics & Gynecology, 2007 - 2015

Organizational Committee Service

Campus/University

Member, Faculty Search Committee in Imaging and Cancer Research, Stephenson School of Bioengineering, University of Oklahoma, October 19, 2023 - Present

Member, Investigator-Initiated Trials Funding Committee, Stephenson Cancer Center, 2022 - Present

Member, OK Center for Therapeutic Sciences PHF Pilot Grant Review Committee, Oklahoma, 2022 - Present

Member, Vice President of Research Search Committee, University of Oklahoma Health Sciences Center, August 2021 - Present

Member, Executive Director and Chief Innovation and Corporate Officer Search Committee, Office of Innovation and Corporate Relations, University of Oklahoma, 2021 - Present

Member, Internal Advisory Board for S10 Grant Zeiss AuxioScan, University of Oklahoma, 2021 - Present

Member, Review Committee for GeroOncology Pilot Grants., GeroOncology, 2021 - Present

Member, Review Committee for Harold Hamm Diabetes Center/Stephenson Cancer Center Pilot Grants, Review Committee for Harold Hamm Diabetes Center/Stephenson Cancer Center, 2021 - Present

Member, Selection Committee for Assistant Professor (Consecutive Term) position at SCC, Stephenson Cancer Center, August 2020 - Present

Member, Education and Faculty Development Committee, Stephenson Cancer Center, August 2019 - Present

Member, Executive Committee, CTS Master's Program, College of Public Health/Graduate College, 2008 - Present

Member, Faculty Appeals Board, University of Oklahoma Health Sciences Center, 2018 - 2026

Commercial Subject, There's Only One Commercial, OU, December 6, 2022 - 2022

Member, OUHSC Research Strategic Plan Strategies and Tactics Development, University of Oklahoma, February 11, 2022 - March 3, 2022

Member, Stephenson Cancer Center Steering Committee, Stephenson Cancer Center, 2017 - 2020

Member, Scientific Review Committee, Stephenson Cancer Center, University of Oklahoma, 2002 - 2018

Member, OUCI Biospecimen Core Operations Committee, OU Cancer Institute, 2006 - 2014

Member, CTS Masters Program Executive Committee, Clinical and Translational Sciences Program, 2006 - 2008

Member, Search Committee of Deputy Director of the Basic and Translational Cancer Research Center, University of Oklahoma, 2007

Member, Clinical & Translational Science Awards (CTSA) Degree and Curriculum Committee, University of Oklahoma, 2006

Member, Faculty Advisory Committee for the Core Laboratories, University of Oklahoma, 2006

Member, Search Committee for Cancer Genetics Endowed Chair, University of Oklahoma, 2005 - 2006

Member, Search Committee for Children's Medical Research Institute Endowed Chair, University of Oklahoma, 2005 - 2006

Member, Outstanding Thesis/Dissertation Committee, University of Oklahoma, 2000 - 2001

College

Member, Promotion and Tenure Committee, College of Medicine/University of Oklahoma Health Sciences Center, June 16, 2023 - Present

Member, Medical School Curriculum, Molecular and Cellular Systems, Committee, College of Medicine, 2007 - 2008

Member, Recruitment Committee, Pharmaceutical Sciences Department Chair, University of Oklahoma, College of Pharmacy, 2007

Department

Member, Graduate Student Awards Committee, Biochemistry Department, 2007 - 2013

Member, Faculty Search Committee, Biochemistry Department, 2008 - 2010

Member, Student Admissions & Recruitment Committee, Biochemistry Department, 2004 - 2007

Member, Dental/Pharmacy Course Curriculum Committee, Biochemistry Department, 2003 - 2004

Member, Student Admissions & Advisory Committee, Biochemistry Department, 2002 - 2003

Member, General Examination Committee, Biochemistry Department, 2001 - 2002

Member, Student Advisory Committee, Biochemistry Department, 2001 - 2002

Member, Student Recruitment Committee, Biochemistry Department, 2000 - 2001

Member, Adjunct Faculty Review and Evaluation Committee, Biochemistry Department, 1997 - 2000

Member, Graduate Program Curriculum/Review Committee, Biochemistry Department, 1995 - 1997

PROFESSIONAL SERVICE

National/International

Member, Translational Research Committee, NRG Oncology, Philadelphia, PA, November 20, 2023 - Present

Advisor, Lurie Cancer Center Targeted External Advisory Board, Northwestern Cancer Center, Chicago, IL, USA, January 2023 - Present

Member, Advisory Board, Acquired Resistance Therapy Network (ARTNet), United States, 2022 - Present

Reviewer, National Priorities Research Program (NPRP), Qatar National Research Fund (QNRF), Virtual, 2021 - Present

Reviewer, SONATA BIS, National Science Centre /Narodowe Centrum Nauki - NCN, Poland, December 2019 - Present

Reviewer, OPUS, National Science Centre/Narodowe Centrum Nauki - NCN, Poland, October 2019 - Present

Member, Translational Science GYN Committee, NRG Oncology, July 1, 2019 - Present

Reviewer, Oak Ridge Associated Universities (ORAU) Center for Excellence Award Reviews, ORAU, 2007 - Present

Referee, Italian Research Council, Italian Research Council, 2002 - Present

NCI Reviewer SPORE, EDNR, SBIR, AREA, Onc Fellowships, SBIR/STTR, 1999 - Present

Member, Biology Sciences Research Council UK, 2002 - 2028

Member, Subcommittee A: Cancer Centers, National Cancer Institute, US, 2019 - 2025

Co-Leader GYN Target Group, Cancer Prevention Clinical Trial Network (CP-CTNet), The MW Chemoprevention Network, USA, September 3, 2020 - July 31, 2025

Member, Planning Committee, Specialized Program in Organ Research Excellence (SPORE), NCI, NIH, Shady Grove, MD, 2023 - 2024

Member, Subcommittee A Cancer Centers, National Cancer Institute, July 1, 2019 - June 30, 2023

Member, Subcommittee A Cancer Centers, National Cancer Institute, July 1, 2019 - June 30, 2023

Keynote Speaker, Annual Cancer Disparities and Health Equities Symposium, University of Chicago, Chicago, IL, US, October 20, 2022

Member, Ovarian Cancer Research Program Pilot – 3 Panel, Department of Defence, USA, September 15, 2020 - September 16, 2020

Member, GAO Focus Group with Merit Review Panelists, US Government Accountability Office (GAO), September 6, 2019

Reviewer, Clinical and Translational Exploratory/Developmental Studies meeting, NIH/National Cancer Institute, 2018

Reviewer, Ad-Hoc, Drug Discovery and Metabolic Pharmacology Study Section, NIH, Center for Scientific Review, 2018

Reviewer, Genetic Basis of Disease Grant Review Committee, King Abdulaziz City for Science and Technology (KACST), 2018

Reviewer, Health and Medical Research Fund (HMRF), Food and Health Bureau (FHB) of the Government of Hong Kong SAR, 2018

Reviewer, Ad-Hoc, NIH Oncological Science Fellowship F09B Study Section, NIH/National Cancer Institute, 2018

Reviewer, PreCancer Atlas (PCA) Research Centers (U2C) Review Committee, NIH/National Cancer Institute, 2018

Reviewer, PRIN 2017, MIUR (the Italian Ministry for Education, University and Research), 2018

Reviewer, NCI Outstanding Investigator Awards, National Cancer Institute, 2017

Chair, NIH/NCI Clinical and Translational Omnibus Special Emphasis Panel, National Institutes of Health/National Cancer Institute, 2017

Chair, NCI Program Project Review Committee ZCA1 R{RB-C M1, National Cancer Institute, 2016

Chair, NCI R21/R03 Review Committee ZCA1 SRB-8 (M1), National Cancer Institute, 2016

Reviewer, Bankhead-Coley Cancer Research Program Proposal Review, December 2015

Reviewer, CDMRP Clinical and Experimental Therapeutics - 1 Review Panel, Congressionally Directed Medical Research Programs (CDMRP), October 2015

Member, State of Florida Department of Health and Oak Ridge Associated Universities (ORAU), October 2015

Member, AREA R15 Review Panel, ZRG1 OTC-N (80), Academic Research Enhancement Awards, September 2015

Reviewer, NCI R21/R01 Omnibus ZRG1-OTC-B (80) Study Section, National Cancer Institute, September 2015

Co-Chair, NCI SPORE Review Panel ZCA1 RPRB-C (O1), National Cancer Institute, June 8, 2015 - June 9, 2015

Reviewer, Hong Kong, Health and Medical Research Fund (HMRF), May 2015

Member, CDC Special Emphasis Panel on Global Health Research, Center for Disease Control, April 1, 2015

Member, Review Panel for NCI Innovative Molecular Analysis Technologies (IMAT) Program, National Cancer Institute, March 17, 2015

Chair, NCI SPORE Review Panel ZCA1 RPRB-C M1 P, February 3, 2015 - February 4, 2015

Chair, AREA R15 Grant Review Panel. 2015/01 Council ZRG1 OTC-N 80, Academic Research Enhancement Awards, January 29, 2015

Reviewer, CDMRP/DOD Reviewer Ovarian Cancer Academy - Dean/Assistant Dean (OCA-D) Awards, Congressionally Directed Medical Research Programs/Department of Defense, 2014

Chair, Drug Discovery and Molecular Pharmacology (DMP) Special Emphasis Panel, Drug Discovery and Molecular Pharmacology (DMP), 2014

Reviewer, NCI Review Panel of Cancer Detection, Diagnosis and Treatment Technologies for Global Health, National Cancer Institute, 2014

Reviewer, NCI Reviewer for Innovative Molecular Analysis Technologies Program (IMAT), National Cancer Institute, 2014

Chair, NCI SPORE Programs, National Cancer Institute, 2014

Chair, AREA R15: Oncological Sciences Application Review Panel, ZRG1 OTC-X (80) A, Academic Research Enhancement Awards, May 2014

Chair, Cancer Therapeutics Area Grant Applications Review Panel, National Institutes of Health, Center of Scientific Review, 2013

Expert Scientific Witness, Patent Infringement Case, Haynes and Boone, LLP, Dallas, TX, United States of America, 2012 - 2013

Reviewer, Drug Discovery and Molecular Pharmacology (DMP) Study Section, Drug Discovery and Molecular Pharmacology (DMP), 2009 - 2013

Reviewer, World Cancer Research Fund International, World Cancer Research Fund International, 2010 - 2011

Chair, SBIR/STTR SEP Reviews, 2007 - 2010

Chair, Session on Functional genomics, proteomics and signalomics in cancer at the International Cancer Research Symposium 2010: Defining & Translating Science Behind Disease, Thiruvananthapuram, Kerala, India, December 21, 2010

Chair, Cancer Diagnostics and Therapeutics SBIR/STTR AED Review, Cancer Diagnostics and Therapeutics, 2009

Reviewer, External Advisory Board, New Mexico Cancer Center, 2009

Reviewer, Mock Study Session in Grant Writing Workshop for Clinicians, AACR Professional Advancement Series Section, American Association for Cancer Research (AACR), 2009

Chair, Review Committee of NIH SBIR Topics 238, 237 and 270, National Institutes of Health, 2009

Reviewer, Drug Discovery and Molecular Pharmacology (DMP) Study Section, Drug Discovery and Molecular Pharmacology (DMP), 2008 - 2009

Reviewer, NCI Oncology Fellowship and AREA grants, NIH CSR, VED, National Cancer Institutes, 2005 - 2009

Member, Experimental Medicine & Cancer Prevention Committees, Gynecologic Oncology Group, 1992 - 2009

Chair, NCI oncology Fellowship and AREA grants, NIH CSR, VED, National Cancer Institutes, June 2008 - August 2009

Participant, NCI Clinical Development of Small Molecules Workshop, National Cancer Institute, Bethesda, MD, 2008

Chair, Review Committee of NIH SBIR Topics 242 and 243, National Institutes of Health, 2008

Chair, Developmental Therapeutics Subcommittee of the GOG CEM Committee, Gynecologic Oncology Group (GOG), 2006 - 2008

Reviewer, Ad-Hoc, Drug Discovery and Metabolic Pathology (DMP) Study Section, NIH CSR, 2006 - 2008

Member, NCI ZRG1 Cancer Biomarkers Study Section (CBSS), National Cancer Institute, 2004 - 2008

Member, Chemoprevention Committee, Gynecologic Oncology Group (GOG), 2000 - 2008

Member, Experimental Medicine Committee (CEM), Gynecologic Oncology Group (GOG), 1992 - 2008

Member, Improving Public Health Practice through Translation Research, (R18), Center for Disease Control (CDC), 2007

Chair, Review Committee of NIH SBIR Topics 238 and 239, National Institutes of Health, 2007

Reviewer, U.S. Civilian Research & Development Foundation (CRDF) Cooperative Grants Program (CGP) Competition, U.S. Civilian Research & Development Foundation (CRDF), 2007

Reviewer, Phillip Morris External Research Program, Phillip Morris, 2003 - 2007

Referee, Biotechnology and Biological Sciences Research Council, Biotechnology and Biological Sciences Research Council (BBSRC), Swindon, United Kingdom, 2006

Reviewer, Drug Discovery and Molecular Pharmacology (DMP) Study Section, Drug Discovery and Molecular Pharmacology (DMP), 2006

Reviewer, Mock Study Session in Grant Writing Workshop for Clinicians, AACR Professional Advancement Series Section, American Association for Cancer Research (AACR), 2006

Reviewer, Ad-Hoc, NCI Chemoprevention Committee, Subcommittee E, Cancer Epidemiology, Prevention and Control, National Cancer Institute, 2006

Reviewer, NCI SBIR grants (ZCA1 SRRB-U (C1)), National Cancer Institute, 2006

Session Chair, Retinoids and Cancer, FASEB Retinoid Meeting, FASEB, 2006

Reviewer, University Grants Committee, University of Hong Kong, Hong Kong, China, 2006

Substitute Chair and Reviewer, SPORE in Ovarian-GYN Cancer, Specialized Programs of Research Excellence (SPORE), 2005

Co-Chair, Translation Research Session of the Ovarian Cancer State of the Art Meeting, CTEP and GOG, 2005

Chair, NCI Chemoprevention Committee, Subcommittee E, Cancer Epidemiology, Prevention and Control, National Cancer Institute, 2003 - 2005

Member, NCI Chemoprevention Committee, Subcommittee E, Cancer Epidemiology, Prevention and Control, National Cancer Institute, 2000 - 2005

Substitute Chair and Reviewer, Early Detection Research Network, Clinical Epidemiology and Validation Centers, Early Detection Research Network, 2004

Reviewer, Department of Defense Ovarian Cancer Grants, Department of Defense, 2002 - 2004

Reviewer, Eppley NCI - Designated Cancer Center Site Visit, National Cancer Institute, January 2004

Reviewer, Grant Reviewer, Cancer Research UK, United Kingdom, 2002

Nominee, National Advisory Committee, Department of Veterans Affairs' Medical Research Branch, 2002

Consultant, Procter & Gamble, 1999 - 2002

Reviewer, Clinical Nutrition Research Units, National Cancer Institute, December 2001

Cancer Genetics Trainer, American Society of Clinical Oncologists (ASCO), Cancer Genetics Trainer, ASCO, 2000

Reviewer, Chemoprevention in Genetically-Identified High-Risk Groups: Interactive Research and Development Projects, National Cancer Institute, 2000

Reviewer, Molecular Target Drug Discovery, National Cancer Institute, 2000

Chair, State Legislative Committee, American Association for Cancer Research, 2000

Reviewer, The Early Detection Network - Clinical Epidemiologic Centers, National Cancer Institute, 2000

Reviewer, Ad-Hoc, Department of Veterans Affairs' Medical Research Branch ad hoc grant reviewer, Department of Veterans Affairs' Medical Research Branch, 1992 - 2000

Co-Chair, Chemoprevention Workshop, Gynecologic Cancer Translational Research Retreat II, Chantilly, VA, US, May 5, 2000 - May 7, 2000

Temporary Member, Scientific Review Group, Subcommittee E, Cancer Epidemiology, Prevention and Control, National Cancer Institute, April 2000

Reviewer, Chemoprevention Committee Site Visit, National Cancer Institute, January 2000

Reviewer, Chemoprevention Committee Site Visit, National Cancer Institute, June 1999

Local/Regional

Member, Roundtable Discussion on Advances in Integrative Oncology, Flourish Pharmacy, Edmond, OK, USA, October 18, 2022 - Present

Member, Review Committee Oklahoma Shared Clinical and Translational Resources Pilot Grants, Oklahoma Shared Clinical and Translational Resources, Oklahoma City, OK, USA, 2021 - Present

Editor, Editorial Board, Journal Reviewer

BBA - Molecular and Cell Biology

Editorial Board Member, Cancers

Editorial Board Member, Cancers, 2020 - Present

Editor, Cancers, 2020 - Present

Editor-in-Chief, Biologics: Targets & Therapy, 2008 - Present

Editorial Board Member, Journal of Cell Death, 2008 - Present

Editorial Board Member, Open Access Journal of Clinical Trials, 2008 - Present

Editorial Board Member, Biochemical Journal and Biochemical Society Transactions, 2007 - Present

Editorial Board Member, Bioinformatics and Biology Insights, 2007 - Present

Editorial Board Member, Open Medicinal Chemistry Journal, 2007 - Present

Editorial Board Member, Open Reproductive Science Journal, 2007 - Present

Editorial Board Member, Current Medicinal Chemistry, 2006 - Present

Editorial Board Member, Cancer Research, 2010 - 2012

Editorial Board Member, Cancer Epidemiology, Biomarkers & Prevention, 2002 - 2009

Advisory Board Member, Native Americans in Biological Sciences Advisory Board (NABS), Oklahoma State University, 2005 - 2007

Ad-Hoc Reviewer:

American Journal of Obstetrics and Gynecology

American Journal of Pathology

American Journal of Reproductive Immunology

Analytica Chimica Acta

Analytical Methods

Anticancer Agents in Medicinal Chemistry
BBA - Molecular Cell Research
BBA-Gene Regulatory Mechanisms
Biochemical Journal
Biochimie
Bioengineered
Bioinformatics and Biology
Biomarkers & Prevention
Biomed Central Cancer
Bioorganic and Medicinal Chemistry
Bioscience Reports
Blood
BMC Cancer
British Journal of Cancer
Cancer
Cancer Biology
Cancer Cell
Cancer Chemoprevention and Pharmacology
Cancer Cytopathology
Cancer Epidemiology
Cancer Investigation
Cancer Letters
Cancer Prevention Research
Cancer Research
Cell Death And Disease
Cellular & Molecular Biology Letters
Chemistry Central Journal
Clinical Cancer Research
Clinical Ovarian Cancer
CRC Press
Current Cancer Therapy Reviews
Current Medicinal Chemistry
European Journal of Cancer
Experimental Cell Research
Expert Opinion on Therapeutic Patents
FASEB Journal
Fertility and Sterility
Gene
Gynecologic and Obstetrics Investigations
Gynecologic Oncology
International Journal of Biochemistry and Cell Biology
International Journal of Cancer
International Journal of Molecular Sciences
Journal of Biochemistry
Journal of Biological Chemistry
Journal of Cancer Research and Therapeutics
Journal of Cell Death
Journal of Geriatric Oncology
Journal of Neurochemistry
Journal of Nutritional Biochemistry
Journal of Oncology
Journal of Ovarian Research
Journal of Reproductive Medicine
Journal of Surgical Oncology
Journal of the National Cancer Institute
Metallomics

Mini Reviews in Medicinal Chemistry	
Mitochondrion	
Molecular and Cellular Endocrinology	
Molecular and Cellular Endocrinology	
Molecular Biosystems	
Molecular Cancer Therapeutics	
Molecular Carcinogenesis	
Molecules	
Nature	
Nutrition and Cancer	
Oncogene	
Oncotarget	
Oncotarget Pharmaceutical Research	
Oncotargets and Therapy	
Open Medicinal Chemistry Journal	
Oxidative Medicine and Cellular Longevity	
PLOSOne	
Targets and Therapy	
The American Journal of Obstetrics and Gynecology	
Artificial Cells, Nanomedicine and Biotechnology	2023 - Present
Artificial Cells, Nanomedicine and Biotechnology	2023 - Present
Cancer Research Communications	2023 - Present
European Journal of Cell Biology	2023 - Present
Future Medicinal Chemistry	2023 - Present
Future Virology	2023 - Present
Biochemistry and Cell Biology	2022 - Present
Cancer Research Communications	2022 - Present
Frontiers in Oncology	2022 - Present
Molecular Medicine Reports	2022 - Present
RSC Advances	2021 - Present
Cardiovascular Diagnosis and Therapy	2023
Future Oncology	2023
Journal of Radiology and Oncology	2023
Precision Oncology	2023
Annals of Palliative Medicine	2022
Biomedical Reports	2022

PERSONAL COMMUNITY SERVICE

Speaker, Description of Cancer Research at the Stephenson Cancer Center, Peggy and Charles Stephenson Family, Tulsa, United States, October 16, 2019

Speaker, Cancer Research Fundraiser, Ford AV, Denver, CO, September 17, 2017

Speaker, Gynecologic Cancers Survivor Workshop, Stephenson Cancer Center, Oklahoma City, OK, USA, September 16, 2017

Speaker, How We Are Trying to Prevent & Kill Cancer Without Harming You, Gynecologic Cancer's Survivors Workshop, Stephenson Cancer Center, Oklahoma City, OK, September 16, 2017

Speaker, Panel Member, OKC Chamber of Commerce Annual Breakfast,, Oklahoma City, OK, September 7, 2016

Speaker, Why an Ounce of Prevention Costs More than a Pound of Cure, Annual Stephenson Cancer Center Board of Advocates Meeting,, Oklahoma City, OK, August 12, 2016

Speaker, Finding and Fighting the Origins of Cancer, Central Travel Club, Oklahoma City, OK, April 15, 2016

Speaker, Ovarian Cancer Prevention, OPE Ovarian Cancer Survival Group, Stephenson Cancer Center, Oklahoma City, OK, April 4, 2016

Speaker, Ovarian Cancer, National Ovarian Cancer Philanthropy Event organized by OU Student Organization, Lambda Delta Psi, University of Oklahoma, Norman, OK, September 17, 2015

Speaker, How to make a chemical into a drug, Chemistry Club, Southwestern Oklahoma State University, Weatherford, OK, March 10, 2015

Speaker, Panel Member, Women's Enrichment Fellowship Talk Show, Forward in Faith Ministries International,, Farmers Branch, TX, March 16, 2013

Speaker, Curing Cancer with Chemistry, Chemistry Club, University of Central Oklahoma, Edmond, OK, March 7, 2013

Speaker, Development of a Cancer Prevention Pill, Ovarian Cancer Support Group, Bartlesville, OK, October 22, 2011

Speaker, Collaboration in Drug Discovery and Translation to Clinical Trials, The 14th annual Rall Symposium for Undergraduate Research, Naperville, IL, May 17, 2011

Speaker, Progress Report on Development of SHetA2 for Chemoprevention, HOPE Ovarian Cancer Survivor Group, Stephenson Cancer Center, Oklahoma City, OK, April 3, 2010

Speaker, Cancer Genetics, Womens Health Symposium, Oklahoma City, OK, USA, 1997

Speaker, Oncogenes and Tumor Suppressor Genes, INTEGRIS Baptist Medical Center, Oklahoma City, OK, 1997

Speaker, Drug Discovery and Design, University of Oklahoma Undergraduate School, Norman, OK, 1994

MEDIA CONTRIBUTIONS

National/ International

Interviewed Expert, Stephenson Cancer Center News Release about OK-1 Clinical Trial, OK-1 Media Briefing Report, OK-1 Clinical Trial, Aired on KOKH Fox 25 News, KFOR News, KOCO Eyewitness News, KWTW News 9, KJRH (Tulsa), KOKI (Tulsa), KOTV (Tulsa), KTUL (Tulsa).
Published in Journal Record, KGOU-online, Oklahoman, Yahoo News, SpotOnOklahoma, Ellatinoamerican.
OU Internal Communication, The Hub, The Pulse, June 23, 2022

Regional/Local

Interviewed Expert, KOCO News 5, Doctors working on drug that could prevent cervical cancer, Targeting HPV in a Cervical Cancer Clinical Trial

Doctors at OU Medical Center's Stephenson Cancer Center are working on medicine that could help prevent cervical center.

<http://www.koco.com/news/doctors-working-on-drug-that-could-prevent-cervical-cancer/40242428>, June 27, 2016

Interviewed Expert, Fox25 News, Researchers develop drug that targets HPV at OU Medical Center, Targeting HPV in a Cervical Cancer Clinical Trial

<http://okcfox.com/news/local/researchers-develop-drug-that-targets-hpv-at-ou-medical-center>, June 22, 2016

Interviewed Expert, Oklahoma's News 4, Stephenson Cancer Center gets 2.2 million grant to fund cervical cancer prevention, Ovarian Cancer Chemoprevention and Targeting HPV in a Cervical Cancer Clinical Trial

<http://kfor.com/2016/06/22/stephenson-cancer-center-gets-2-2-million-grant-to-fund-cervical-cancer-prevention/>, June 22, 2016

Interviewed Expert, Stephenson Cancer Center News, New \$2.2 Million NIH Grant Targets Cervical Cancer Prevention, Targeting HPV in a Cervical Cancer Clinical Trial

<http://stephensoncancercenter.org/News/Article/TabId/6745/ArtMID/17400/ArticleID/839/New-22-Million-NIH-Grant-Targets-Cervical-Cancer-Prevention.aspx>, June 22, 2016

Interviewed Expert, University Hospitals Trust News: Media and releases, Oklahoma Drug May Halt Cervical Cancer, Targeting HPV in a Cervical Cancer Clinical Trial

<http://www.uhatok.com/news/video-news-releases/757-cervical-vnr>, June 22, 2016

Interviewed Expert, The Journal Record, OU researcher receives funding for drug to stop cervical cancer, Targeting HPV in a Cervical Cancer Clinical Trial

<http://journalrecord.com/2016/06/22/ou-researcher-receives-funding-for-drug-to-stop-cervical-cancer-health-care/>, June 22, 2016

Interviewed Expert, The Oklahoman, \$2.2 million grant will fund trials for locally developed cervical cancer drug, Targeting HPV in a Cervical Cancer Clinical Trial and Ovarian Cancer Chemoprevention

<http://www.oklahoman.com/login?referer=/2.2-million-grant-will-fund-trials-for-locally-developed-cervical-cancer-drug/article/5505833>, June 22, 2016

Interviewed Expert, The Edmond Sun, OU researcher's drug targets ovarian cancer prevention, Ovarian Cancer Chemoprevention

http://www.edmondsun.com/news/education/ou-researcher-s-drug-targets-ovarian-cancer-prevention/article_7a6ea6b6-3d54-11e5-9b3e-db076858d268.html, August 7, 2015

Interviewed Expert, Oklahoma's News 4, Oklahoma doctor testing supplement that may prevent ovarian cancer, Ovarian Cancer Chemoprevention

<http://kfor.com/2015/08/06/oklahoma-doctor-testing-supplement-that-may-prevent-ovarian-cancer/>, August 6, 2015

Interviewed Expert, Stephenson Cancer Center News, OU Researcher's Drug Targets Ovarian Cancer Prevention, Ovarian Cancer Chemoprevention

<http://stephensoncancercenter.org/News/Article/TabId/6745/ArtMID/17400/ArticleID/164/OU-Researcher%E2%80%99s-Drug-Targets-Ovarian-Cancer-Prevention.aspx>, August 6, 2015

Interviewed Expert, University Hospitals Trust News: Media and releases, OU Researcher's Drug Targets Ovarian Cancer Prevention, Ovarian Cancer Chemoprevention

<http://www.uhatok.com/news/video-news-releases/672-ovarian-cancer-drug>, August 6, 2015

Guest, Various Outlets (in additional information), OU Medicine Minute, 82. "OU Medicine Minute", 04/08/09 06:06:15AM Oklahoma City (KWTW) 01:00 News 9 This Morning; 04/08/09 05:17:19PM Oklahoma City (KWTW) 01:00 News 9 @ 5pm; 04/09/09 04:43:56PM Oklahoma City (KWTW) 01:00 News 9 @ 4pm; 04/10/09 12:04:09PM Oklahoma City (KWTW) 01:00 News 9 @ Noon; 04/10/09 06:03:24PM Oklahoma City (KWTW) 01:00 News 9 @ 6pm; 04/11/09 06:12:05AM Oklahoma City (KWTW) 01:00 News 9 Saturday Morning; 04/12/09 10:06:14PM Oklahoma City (KWTW) 01:00 News 9 @ 10pm Sunday, 2009

Author, The Oklahoman, Developing a Pill for Cancer Prevention, 2008

Author, The Tulsa World, Developing a Pill for Cancer Prevention, 2008

Author, News Channel 9 (KWTW), Developing a Pill for Cancer Prevention, 2008

Interviewed Expert, KTLR AM890, Community Talk Radio with Robing Decken-Kite, Research, September 30, 2008

Interviewed Expert, Oklahoma Sunday Magazine, aired by Citadel Radio on various stations, including KATTFM, KYIS-FM, WWLS-FM & AM, and KKWD, August 24, 2008

Author, Edmond Sun, Developing a Pill for Cancer Prevention, February 11, 2008

Author, Tulsa World Editorial, Developing a Pill for Cancer Prevention, February 3, 2008

Author, OETA, Developing a Pill for Cancer Prevention, February 1, 2008

Author, News Channel 4 (KFOR), Developing a Pill for Cancer Prevention, January 31, 2008

Guest, KCCU, KLCU, KYCU, KTOK, KRMG AND KMCU Oklahoma and Texas (AM and FM), Oklahoma Innovations Radio Show, Drug Development in Oklahoma, January 5, 2005 - January 6, 2005

Author, Graphics illustrating adenoviral p53 gene therapy for ovarian cancer, "Health Check" presented on News Channel 4, February 2000

Guest, News Channel 4, Health Check, Adenoviral p53 Gene Therapy for Ovarian Cancer, February 2000

PROFESSIONAL MEMBERSHIPS

International Gynecologic Cancer Society (IGCS)	April 28, 2022 - Present
American Association for Cancer Research (AACR)	January 1, 1994 - Present
NRG Oncology (NRG)	January 1, 1992 - Present

PROFESSIONAL GROWTH AND DEVELOPMENT

Formal Course Work

BMSC 5011: Interdisciplinary Special Topics Experimental Design and Applied Statistics, University Of Oklahoma Health Sciences Center, 1 Credit Hours, May 2017 - June 2017

Seminars, Workshops, and Other Training

Clinical Development of Small Molecules, National Cancer Institute, USA, January 15, 2008

Phase 0 Trials in Oncologic Drug Development, National Cancer Institute, USA, September 5, 2007